Welcome to the American Diabetes Association’s hybrid 84th Scientific Sessions in sunny Orlando.

As the world’s largest meeting on diabetes, the Scientific Sessions is both a leading educational gathering and a unique opportunity to network with colleagues from over 115 countries. We couldn’t be more excited to reconnect and accelerate progress towards preventing and curing diabetes and improving the lives of all people affected by diabetes.

This guide includes maps and the day-at-a-glance schedule. For full program details, use the online planner/mobile app. The 84th Scientific Sessions app is compatible with iOS and Android devices.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.—</td>
<td>Welcome to the 84th ADA Scientific Sessions—Keynote Address by Robert M. Califf, MD and Panel Discussion</td>
<td>West Hall B3-4 (General Session)</td>
</tr>
<tr>
<td>11:30 a.m.—</td>
<td>&quot;Pathway to Stop Diabetes&quot; (INCLUDES LIVESTREAM)</td>
<td>West Hall B3-4 (General Session)</td>
</tr>
<tr>
<td>12:45 p.m.—</td>
<td>ORAL PRESENTATIONS AC-OR06-1 Multigran Ultra 1 in Lipid Metabolism</td>
<td>Room: W308</td>
</tr>
<tr>
<td>1:45 p.m.—</td>
<td>ORAL PRESENTATIONS BM-OR05-2 Exploring the Impact of Food/Food Additives on Insulin Sensitivity and Postprandial Glucose (With ADA Presidents’ Select Abstract Presentation)</td>
<td>Room: W315</td>
</tr>
<tr>
<td>11:00 a.m.—</td>
<td>ORAL PRESENTATIONS BM-OR06-1 Tools for Health Care Professionals That Assist in Personalizing Care</td>
<td>Room: W316</td>
</tr>
<tr>
<td>12:30 p.m.—</td>
<td>ORAL PRESENTATIONS BM-OR07-1 Back to the Basics (Sciences) of Exercise and Diabetes</td>
<td>Room: W304 E-H</td>
</tr>
<tr>
<td>2:00 p.m.—</td>
<td>ORAL PRESENTATIONS BM-OR01-1 Emerging Molecular Mechanisms of ASCVD Progression in Cardiometabolic Disease (With Edwin Bierman Award Lecture) (INCLUDES LIVESTREAM)</td>
<td>Room: W307</td>
</tr>
<tr>
<td>3:00 p.m.—</td>
<td>ORAL PRESENTATIONS BM-OR02-1 Exploring Dimensions of Diversity in Diabetes Distress (With Richard R. Rubin Award Lecture) (INCLUDES LIVESTREAM)</td>
<td>Room: W318 (Valencia Ballroom)</td>
</tr>
<tr>
<td>3:30 p.m.—</td>
<td>ORAL PRESENTATIONS CT-OR01-2.5 Practicable Methods to Improve Metabolic Parameters</td>
<td>Room: W311</td>
</tr>
<tr>
<td>2:00 p.m.—</td>
<td>ORAL PRESENTATIONS CT-OR01-2.5 Ways to Improve Insulin Sensitivity and Postprandial Glucose</td>
<td>Room: W307</td>
</tr>
<tr>
<td>3:30 p.m.—</td>
<td>ORAL PRESENTATIONS CT-OR01-2.5 New Technology—The Inpatient Setting (INCLUDES LIVESTREAM)</td>
<td>Room: W314</td>
</tr>
<tr>
<td>2:00 p.m.—</td>
<td>ORAL PRESENTATIONS CT-OR01-2.5 New Technology—What’s Next? (With ADA Presidents’ Select Abstract Presentation)</td>
<td>Room: W311</td>
</tr>
</tbody>
</table>
FRIDAY, JUNE 21, 2024  DAY-AT-A-GLANCE SCHEDULE
American Diabetes Association® 84th Scientific Sessions

Registration Hours: 8:00 a.m.-6:30 p.m.
Shop ADA Hours: 9:00 a.m.-6:30 p.m.
Exhibit Hall Hours: 9:00 a.m.-6:30 p.m.

American Diabetes Association Networking Reception  Exhibit Hall (West A1-A3)
American Diabetes Association Networking Reception  Exhibit Hall (West A1-A3)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 p.m.-</td>
<td>SYMPOSIUM AC-SY01.5: Systemic Medications for Diabetic Retinopathy—Protective and Risk Factors Room: W208</td>
</tr>
<tr>
<td>5:30 p.m.-</td>
<td>ORAL PRESENTATIONS BM-OR05-1: New Biomarkers to Inform Lipid Therapies in Diabetes (With ADA Presidents' Select Abstract Presentation) Room: W306</td>
</tr>
<tr>
<td>8:30 p.m.-</td>
<td>ROOM: W208</td>
</tr>
</tbody>
</table>

**American Diabetes Association® 84th Scientific Sessions**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**

**Day-at-a-Glance Schedule**

**Registration Hours:** 8:00 a.m.-6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 9:00 a.m.-6:30 p.m.

**American Diabetes Association Networking Reception**

**Exhibit Hall (West A1-A3)**
### Day-at-a-Glance Schedule

#### American Diabetes Association® 84th Scientific Sessions

**SATURDAY, JUNE 22, 2024**

#### Registration Hours:
- 7:00 a.m.-6:30 p.m.

#### Shop ADA Hours:
- 9:00 a.m.-6:30 p.m.

#### Exhibit Hall Hours:
- 10:00 a.m.-6:00 p.m.

**Registration Hours:**
- 7:00 a.m.-6:30 p.m.

**Shop ADA Hours:**
- 9:00 a.m.-6:30 p.m.

**Exhibit Hall Hours:**
- 10:00 a.m.-6:00 p.m.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30 a.m.</td>
<td><strong>SYMPOSIUM</strong> AC-SY10-1.5  SELECT Trial—New Looks at Glycemia, Inflammation, and Heart Failure (INCLUDES LIVESTREAM) Room: W115B (Valencia Ballroom)</td>
<td>West Hall B3-4 (General Session)</td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> BM-SY15-1.5  Type 2 Diabetes and Exercise—Where Do We Stand? Room: W314</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> BM-SY14-1.5  NIDDK Early Career Investigator Symposium—Leveraging Social Support to Improve Diabetes Self-Management and Health Outcomes—Innovative Methods and Interventions Room: W211</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> BM-SY15-1.5  ADA Education Recognition Program (ERP)—Diversifying Diabetes Self-Management Education and Support (DSMES) Delivery Models Room: W304 A-O</td>
<td></td>
</tr>
<tr>
<td>9:45 a.m.-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 a.m.</td>
<td><strong>SYMPOSIUM</strong> CT-SY23-1.5  Navigating the Early Phases of Pediatric Type 1 Diabetes Room: W310</td>
<td>West Hall B3-4 (General Session)</td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> CT-SY27-1.5  ADA Diabetes Care Symposium—The Final Frontier—Implementing the Learning from Implementation Science Room: W306</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> CT-SY28-1.5  The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Multiple Daily Insulin Injections in Adults with Type 1 Diabetes—Results of the INHALE-3 Randomized Trial (INCLUDES LIVESTREAM) Room: W320 (Chapin Theater)</td>
<td></td>
</tr>
</tbody>
</table>

---

**ADA Chief Executive Officer Remarks; President, Health Care & Education Address; and Outstanding Educator in Diabetes Award Lecture**

- **Includes Livestream**
- West Hall B3-4 (General Session)

---

**ADA Chief Executive Officer Remarks; President, Health Care & Education Address; and Outstanding Educator in Diabetes Award Lecture**

- **Includes Livestream**
- West Hall B3-4 (General Session)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 11:30 a.m.–  | **PROFESSIONAL INTEREST GROUP AC-IG02-1**  
Discussion on Foot Care—Lower Extremity Complications  
Room: W206  
EPOSTER THEATER  
ePoster01  
(*) Diabetic Kidney Disease—From Genetic Pathways to Social Determinants  
Room: Exhibit Hall (West A1-A3)  
ePoster Theater A | W206                                           |
| 12:30 p.m.–  | **PROFESSIONAL INTEREST GROUP BM-IG02-1**  
Discussion on Exercise Physiology—Synchronizing Circadian Rhythms and Exercise  
Room: W204 A-D  
**PROFESSIONAL INTEREST GROUP BM-IG03-1**  
Discussion on Nutritional Sciences and Metabolism—The Science of Ultra-processed Foods and Impacts on Metabolic Diseases  
Room: W204 E-H  
**PROFESSIONAL INTEREST GROUP BM-IG05-1**  
Discussion on Women’s Intergenerational Network of the ADA (WIN ADA)—How to Say “No” So You Can Say “Yes”—Optimizing Time Management  
Room: W208 | W204 A-D  
W204 E-H  
W208                                           |

12:30 p.m.–1:30 p.m.  
**General Poster Session**—Poster Hall (West Hall A4-B2, Second Level)  
Session Break (Take this opportunity to visit the Exhibit and Poster Halls)
<table>
<thead>
<tr>
<th>1:30 p.m.–3:00 p.m.</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ORAL PRESENTATIONS</strong></td>
<td>AC-OR02-1.5 Cell and Molecular Approaches to Diabetes-Related Foot Complications (With Roger Pecoraro Award Lecture) (INCLUDES LIVESTREAM)</td>
<td>Room: W206</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
<td>BM-OR01-1.5 Social Drivers of Health and Advancement towards Social Justice</td>
</tr>
<tr>
<td><strong>ORAL PRESENTATIONS</strong></td>
<td>AC-OR03-1.5 Hypoglycemia in the Real World—Who’s Really at Risk?</td>
<td>Room: W206</td>
<td><strong>DEBATE</strong></td>
<td>CT-OR01-1.5 Innovation or Access in Diabetes Technology—What Should Be Our Global Priority?</td>
</tr>
<tr>
<td><strong>ORAL PRESENTATIONS</strong></td>
<td>AC-OR04-1.5 Clinical Biomarkers of ASCVD Risk Progression in Diabetes Mellitus and Metabolic Disease</td>
<td>Room: W206</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
<td>CT-OR02-1.5 Using Teams and Technology to Improve Outcomes</td>
</tr>
<tr>
<td><strong>EPOSTER THEATER</strong></td>
<td>ePoster06 (*) From Macrovascular to Microvascular</td>
<td>Room: Exhibit Hall (West A1-A3) ePoster Theater B</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
<td>CT-OR03-1.5 Novel Insights into Pathophysiology, Diagnosis, and Outcomes in GDM</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td>CT-SY03-1.5 ADA Primary Care Council—What Does a Person with Diabetes Need from Their Primary Care Team? (INCLUDES LIVESTREAM)</td>
<td>Room: W320 (Chapin Theater)</td>
<td><strong>SYMPOSIUM</strong></td>
<td>CT-SY04-1.5 Type 2 Diabetes and Related Trait GWAS Variant Effects through Omics Profiles (With ADA President’s Select Abstract Presentation)</td>
</tr>
<tr>
<td><strong>EPOSTER THEATER</strong></td>
<td>ePoster05 (*) Learning Across Diabetes</td>
<td>Room: Exhibit Hall (West A1-A3) ePoster Theater A</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
<td>IBC-OR05-1.5 The “Barrier Reef”—Overcoming Hurdles to Beta-Cell Replacement Therapies</td>
</tr>
<tr>
<td><strong>ORAL PRESENTATIONS</strong></td>
<td>IA-OR02-1.5 Novel Regulators of Insulin Action and Insulin Sensitivity</td>
<td>Room: W414</td>
<td><strong>EPOSTER THEATER</strong></td>
<td>ePoster06 (*) Continuing Education Credit Is Not Awarded for this Session.</td>
</tr>
<tr>
<td>Time</td>
<td>Event Description</td>
<td>Room</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>--------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:15 p.m.–</td>
<td>PANEL AC-PN02-1 From the Cutting Room Floor—Semi-live Surgery for Healing Diabetic Foot Ulcers for the Referring Practitioner</td>
<td>R208</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>SYMPOSIUM BM-SY08-1 Optimizing Outcomes of GLP-1+/GLP Receptor Agonists—How to Help Patients Succeed</td>
<td>W315</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM BM-SY18-1 International Consensus Statement and Movement to End Diabetes Stigma</td>
<td>W211</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DEBATE CT-DB18-1 Diabetes Prevention Program (DPP) vs. GLP-18A—Which Tool Is Best to Battle the Obesity and Diabetes Epidemics?</td>
<td>W304 E-H</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PANEL CT-PN11-1 GLP-1 +/- GIP Receptor Agonists in the Perioperative Setting—To Stop or Not to Stop?</td>
<td>W415C</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-SY13-1 How I Feel Matters, Too—The Psychosocial Aspects of Automated Insulin Delivery</td>
<td>W415B</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-SY16-1 Updates in Autonomic Neuropathy</td>
<td>W308</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM BM-SY01-1.5 The evolution of Diabetes Behavioral Care (INCLUDES LIVESTREAM)</td>
<td>W207</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MAIN EVENT CT-ME40-1.5 Innovation Challenge (INCLUDES LIVESTREAM) Note: Continuing Education Credit Is Not Awarded for this Session</td>
<td>W307</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS CT-OR09-1.5 Leveling Up Incretin-Based Therapy in Type 2 Diabetes (INCLUDES LIVESTREAM)</td>
<td>W314</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-OR09-1.5 Deter/Private Experience in Type 2 Diabetes (INCLUDES LIVESTREAM)</td>
<td>W314</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-OR09-1.5 Heterogeneity of Diabetes—Pathophysiology to Global Considerations (INCLUDES LIVESTREAM)</td>
<td>W314</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DEBATE IA-DB01-1 Boosting Energy Expenditure in Obesity—Debating the Potential of Thermogenic Adipose Tissue and Skeletal Muscle Bioenergetics as Antibesity Targets in Humans</td>
<td>W304 A-D</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PANEL IA-PN02-1.5 Technical Challenges and Solutions in Metabolomics (INCLUDES LIVESTREAM)</td>
<td>W304 A-D</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS IP-OR08-1.5 Towards Targeted Weight-Loss Therapy—New Considerations for GLP-1RA or Surgery</td>
<td>W304 A-D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30 p.m.–</td>
<td>SYMPOSIUM BM-SY01-1.5 The evolution of Diabetes Behavioral Care (INCLUDES LIVESTREAM)</td>
<td>W207</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 p.m.</td>
<td>MAIN EVENT CT-ME40-1.5 Innovation Challenge (INCLUDES LIVESTREAM) Note: Continuing Education Credit Is Not Awarded for this Session</td>
<td>W307</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS CT-OR09-1.5 Leveling Up Incretin-Based Therapy in Type 2 Diabetes (INCLUDES LIVESTREAM)</td>
<td>W314</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-OR09-1.5 Deter/Private Experience in Type 2 Diabetes (INCLUDES LIVESTREAM)</td>
<td>W314</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-OR09-1.5 Heterogeneity of Diabetes—Pathophysiology to Global Considerations (INCLUDES LIVESTREAM)</td>
<td>W314</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DEBATE IA-DB01-1 Boosting Energy Expenditure in Obesity—Debating the Potential of Thermogenic Adipose Tissue and Skeletal Muscle Bioenergetics as Antibesity Targets in Humans</td>
<td>W304 A-D</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PANEL IA-PN02-1.5 Technical Challenges and Solutions in Metabolomics (INCLUDES LIVESTREAM)</td>
<td>W304 A-D</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS IP-OR08-1.5 Towards Targeted Weight-Loss Therapy—New Considerations for GLP-1RA or Surgery</td>
<td>W304 A-D</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SATURDAY, JUNE 22, 2024**

**DAY-AT-A-GLANCE SCHEDULE**

**American Diabetes Association® 84th Scientific Sessions**

**Registration Hours:** 7:00 a.m.–6:30 p.m.
**Shop ADA Hours:** 9:00 a.m.–6:30 p.m.
**Exhibit Hall Hours:** 10:00 a.m.–4:00 p.m.
**Poster Hall Hours:** 10:00 a.m.–6:00 p.m.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.</td>
<td><strong>Acute and Chronic Complications</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Diabetes/Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epidemiology/Genetics</td>
<td></td>
</tr>
<tr>
<td>8:00 a.m.</td>
<td><strong>Panel</strong> AC-PN10-1.5: A Multidisciplinary Approach—Challenging Cases from the Cardiovascular Clinic</td>
<td>Room: W207</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium BM-SY15-1.5: A Multidisciplinary Approach to the Cardiovascular Clinic</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Loneliness is a Real Heartbreaker (INCLUDES LIVESTREAM)</td>
<td>Room: W107</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium CT-PN10-1.5: Noninsulin Treatment for Type 1 Diabetes</strong></td>
<td>Room: W311</td>
</tr>
<tr>
<td></td>
<td>Metformin Reexamined—Pleiotropic Effects in Mother and Offspring in Humans and Animal Models</td>
<td>Room: W107</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium CT-SY15-1.5: Metformin Reexamined—Pleiotropic Effects in Mother and Offspring in Humans and Animal Models</strong></td>
<td>Room: W107</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium CT-SY24-1.5: Joint ADA/ISPAD Symposium on Pediatric Diabetes</strong></td>
<td>Room: W105</td>
</tr>
<tr>
<td></td>
<td>Diabetes Insights and Innovations</td>
<td>Room: W105C (Valencia Ballroom)</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium CT-SY16-1.5: The State of Health Equity and Disability—Supporting Diabetes Technology</strong></td>
<td>Room: W314</td>
</tr>
<tr>
<td></td>
<td>Usage in People Who Are Deaf/Hard of Hearing or Blind/low Vision</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium CT-SY14-1.5: Diabetes and Organ Transplantation—Pathophysiology, Inpatient and Outpatient Management</strong></td>
<td>Room: W316</td>
</tr>
<tr>
<td>9:45 a.m.</td>
<td><strong>Symposium IBC-SY15-1.5: Translating Type 1 Diabetes Risk Alleles to Therapy</strong></td>
<td>Room: W304 A-D</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium IA-SY15-1.5: Metabolite Transport and Molecular Metabolism</strong></td>
<td>Room: W304 E-H</td>
</tr>
<tr>
<td>9:45 a.m.</td>
<td><strong>Symposium IP-SY11-1.5: Severe GLP-1RA Side Effects in Obesity Treatment—Fact or Fiction?</strong></td>
<td>Room: W415B</td>
</tr>
<tr>
<td></td>
<td>(INCLUDES LIVESTREAM)</td>
<td>(Valencia Ballroom)</td>
</tr>
<tr>
<td>9:45 a.m.</td>
<td><strong>Symposium IP-SY12-1.5: ADA Diabetes Journal Symposium—It Is All in Your Head—Central Nervous System Control of Systemic Metabolism</strong></td>
<td>Room: W308</td>
</tr>
<tr>
<td>9:45 a.m.</td>
<td><strong>Symposium IP-SY13-1.5: The Changing Climate of Diabetic Kidney Disease—Environmental Triggers and Vulnerabilities</strong></td>
<td>Room: W206</td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td><strong>SYMPOSIUM IE-PN04-1.5: Noninsulin Treatment for Type 1 Diabetes</strong></td>
<td>Room: W311</td>
</tr>
<tr>
<td>10:45 a.m.</td>
<td><strong>SYMPOSIUM IE-SY13-1.5: Noninsulin Treatment for Type 1 Diabetes</strong></td>
<td>Room: W311</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td><strong>SYMPOSIUM IE-SY24-1.5: Joint ADA/ISPAD Symposium on Pediatric Diabetes</strong></td>
<td>Room: W105</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>President, Medicine &amp; Science Address and National Scientific &amp; Health Care Achievement Awards Presentation</td>
<td>Room: W304 (General Session)</td>
</tr>
<tr>
<td>11:45 a.m.</td>
<td>President, Medicine &amp; Science Address and National Scientific &amp; Health Care Achievement Awards Presentation</td>
<td>Room: W304 (General Session)</td>
</tr>
<tr>
<td>Time</td>
<td>Professional Interest Group (AC-IG01-1)</td>
<td>Discussion on Diabetes and Cardiovascular Disease—Obesity and Diabetes—Innovative Research to Inform Clinical Practice</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Professional Interest Group (BM-IG01-1)</td>
<td>Discussion on Behavioral Medicine and Psychology—including the Excluded in Behavioral Diabetes Research</td>
</tr>
<tr>
<td></td>
<td>Professional Interest Group (CM-IG01-1)</td>
<td>Discussion on Clinical Centers and Programs—Challenges in Management of Diabetes in Older Adults and in Primary Care</td>
</tr>
<tr>
<td></td>
<td>Workshop CT-WS37-1</td>
<td>Improving Care for Deaf People with Diabetes Who Use ASL Interpreters—A Hands-On Workshop</td>
</tr>
<tr>
<td></td>
<td>EPOSTER THEATER ePoster10</td>
<td>(*) Improving Efficacy and Safety of Incretin-Based Therapies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Professional Interest Group (AC-IG03-1)</th>
<th>Discussion on Eye Health—Novel Diabetes Therapies in Diabetic Retinopathy—A Basic Science and Preclinical Perspective</th>
<th>Room: W207</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 p.m.</td>
<td>Professional Interest Group (BM-IG03-1)</td>
<td>Discussion on Diabetes Self-Management Education and Support (DSMES)—It’s Time to Change the Way We Talk about DSMES!</td>
<td>Room: W208</td>
</tr>
<tr>
<td></td>
<td>Professional Interest Group (CM-IG03-1)</td>
<td>Discussion on Clinical Centers and Programs—Challenges in Management of Diabetes in Older Adults and in Primary Care</td>
<td>Room: W304 E-H</td>
</tr>
<tr>
<td></td>
<td>Workshop CT-WS37-1</td>
<td>Improving Care for Deaf People with Diabetes Who Use ASL Interpreters—A Hands-On Workshop</td>
<td>Room: W311</td>
</tr>
<tr>
<td></td>
<td>EPOSTER THEATER ePoster09</td>
<td>(*) Exploring Eating Behaviors and Weight Loss in Youth and Adults with Type 1 and Type 2 Diabetes</td>
<td>Room: Exhibit Hall (West A1-A3) ePoster Theater A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>General Poster Session</th>
<th>General Poster Session—Poster Hall (West Hall A4-B2, Second Level)</th>
<th>Session Break (Take this opportunity to visit the Exhibit and Poster Halls)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 p.m.</td>
<td>EPOSTER THEATER ePoster10</td>
<td>(*) New Progress in Clinical Screening and Interventions for ASCVD Risk Mitigation in Metabolic Disease</td>
<td>Room: Exhibit Hall (West A1-A3) ePoster Theater B</td>
</tr>
<tr>
<td></td>
<td>EPOSTER THEATER ePoster09</td>
<td>(*) Exploring Eating Behaviors and Weight Loss in Youth and Adults with Type 1 and Type 2 Diabetes</td>
<td>Room: Exhibit Hall (West A1-A3) ePoster Theater A</td>
</tr>
</tbody>
</table>

SUNDAY, JUNE 23, 2024 DAY-AT-A-GLANCE SCHEDULE American Diabetes Association® 84th Scientific Sessions

<table>
<thead>
<tr>
<th>Immunology/Insulin Action/Obesity/Integrated Physiology/Islet Biology/Insulin Secretion/Professional Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOSTER THEATER ePoster10 (*) Islet Biology Room: Exhibit Hall (West A1-A3) ePoster Theater B</td>
</tr>
<tr>
<td>PROFESSIONAL DEVELOPMENT PD-02-1 Art of Writing a Winning Grant INCLUDES LIVESTREAM Room: W3107</td>
</tr>
</tbody>
</table>

Register for this session to receive Continuing Education Credit.
<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.–</td>
<td>DEBATE</td>
</tr>
<tr>
<td>3:00 p.m.</td>
<td>BM-0603-1.5 The Role of Artificial Intelligence in Transforming Nutrition and Diabetes Care—Ready for Prime Time or Not Quite?</td>
</tr>
<tr>
<td></td>
<td>BM-0602-1.5 Multifaceted Insights into Behavioral and Psychosocial Care for Youth and Families</td>
</tr>
<tr>
<td></td>
<td>BM-0604-1.5 New Technology—AID Focus</td>
</tr>
<tr>
<td></td>
<td>BM-0605.1 Novel Approaches to Treatment and Characterization of Diabetes in Pregnancy (With Norbert Frinkel Award Lecture) (With ADA Presidents’ Select Abstract Presentation) (Includes LiveStream)</td>
</tr>
<tr>
<td></td>
<td>BM-0604-1.5 Weighing Opportunities of Incretin-Based Therapy in Obesity (With ADA Presidents’ Select Abstract Presentation) (Includes LiveStream)</td>
</tr>
<tr>
<td></td>
<td>BM-0604-1.5 Growing Older with Diabetes</td>
</tr>
<tr>
<td></td>
<td>BM-0605-1.5 Obesity and T2DM—Endgame—Oral Abstracts on Beta-Cell Apoptosis (With ADA Presidents’ Select Abstract Presentation) (Includes LiveStream)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.–</td>
<td>ORAL PRESENTATIONS AC-OR02-1.5 Continuous Glucose Monitoring—Can It Reduce Hypoglycemia Burden? Room: W307</td>
</tr>
<tr>
<td>3:15 p.m.–</td>
<td>ORAL PRESENTATIONS AC-OR02-1.5 Emerging Small Molecule Biomarkers of ASCVD Risk in Metabolic Disease Room: W308</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Clinical Diabetes/Therapeutics</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.–</td>
<td>ORAL PRESENTATIONS CT-0405-1 Clinical Contributions in Type 1 Diabetes and Exercise Room: W314</td>
</tr>
<tr>
<td>3:15 p.m.–</td>
<td>PANEL BM-0403-1 Educating Clinicians in the Latest Inpatient Management Strategies from Both Sides of the Pond Room: W313</td>
</tr>
<tr>
<td>4:15 p.m.–</td>
<td>SYMPOSIUM BM-0601-1 The Future of Diabetes Nutrition Interventions—Innovation in Practice (Includes LiveStream) Room: W413 (Valencia Ballroom)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.–</td>
<td>ORAL PRESENTATIONS BE-0601-1.5 Common and Rare Genetic Variant Associations and Molecular QTL Scans in Type 2 Diabetes Tissues Room: W307</td>
</tr>
<tr>
<td>3:15 p.m.–</td>
<td>EPOSTER THEATER (*) Growing Older with Diabetes Room: Exhibit Hall (West A1-A3) ePoster Theater B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Immunology/ Beta-Cell Replacement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.–</td>
<td>ORAL PRESENTATIONS IA-OR03-1.5 Metabolic Control of Insulin Action and Secretion (Includes LiveStream) Room: W414</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Insulin Action/Molecular Metabolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.–</td>
<td>ORAL PRESENTATIONS BE-0601-1.5 Metabolic Control of Insulin Action and Secretion (Includes LiveStream) Room: W307</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Obesity/Integrated Physiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.–</td>
<td>ORAL PRESENTATIONS IP-0606-1.5 Novel Pathways in Metabolic Regulation Room: W308</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.–</td>
<td>ORAL PRESENTATIONS IE-OR02-1.5 New Insights into Therapeutic Strategies for Obesity and Diabetes Room: W304 E-H</td>
</tr>
<tr>
<td>3:15 p.m.–</td>
<td>ORAL PRESENTATIONS IE-OR03-1.5 Novel Modulators of Adipose Tissue Function and Adiposity Room: W304 A-D</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Professional Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.–</td>
<td>ORAL PRESENTATIONS IE-OR02-1.5 Islet Signal Transduction Room: W306</td>
</tr>
</tbody>
</table>

(*) Continuing Education Credit is Not Awarded for this Session.
<table>
<thead>
<tr>
<th>Time</th>
<th>Area</th>
<th>Event Title</th>
<th>Room/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m.</td>
<td>Acute and Chronic Complications</td>
<td>Diabetic Foot Disparities—Treatment With and Without a Multidisciplinary Team</td>
<td>W208</td>
</tr>
<tr>
<td></td>
<td>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</td>
<td>Survey Says—Psychosocial Screening Tools and Their Psychometric Properties for Youth and Adults with Diabetes</td>
<td>W314</td>
</tr>
<tr>
<td></td>
<td>Clinical Diabetes/Therapeutics</td>
<td>Big P, Little P—Diabetes Policies for Public Health</td>
<td>W307</td>
</tr>
<tr>
<td></td>
<td>Epidemiology/Genetics</td>
<td>Big P, Little P—Diabetes Policies for Public Health</td>
<td>W307</td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td>Professional Development</td>
<td>Keeping Up with Hollywood—Who Should Be Prioritized for New Antibesity Medications?</td>
<td>W306</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Big P, Little P—Diabetes Policies for Public Health</td>
<td>W307</td>
</tr>
<tr>
<td>6:00 p.m.</td>
<td></td>
<td>Prioritizing Diversity in Clinical Trials</td>
<td>W307</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Controversies in Continuous Glucose Monitoring (CGM) Use during Pregnancy— Time in Range and Beyond</td>
<td>W307</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Time in Range</td>
<td>W307</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multiple Faces of Therapeutic Inertia in Diabetes</td>
<td>W311</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joint ADA/PAHO Symposium—Latin America and the Caribbean Regional Approach to Prevent and Control Diabetes</td>
<td>W304 E-H</td>
</tr>
<tr>
<td></td>
<td></td>
<td>THE STEP-HFpEF and STEP-HFpEF-DM Trials—Targeting Obesity to Treat Heart Failure (INCLUDES LIVESTREAM)</td>
<td>W310 (Draper Theater)</td>
</tr>
</tbody>
</table>
8:00 a.m.–9:30 a.m.

SYMPOSIUM
AC-SY15-1.5
A Means to an Endpoint—Establishing Meaningful Outcomes in Clinical Neuropathy Trials
Room: W206

SYMPOSIUM
BM-SY08-1.5
Innovative Programs That Take on the Challenge of Hard-to-Reach Populations (INCLUDES LIVESTREAM)
Room: W415B (Valencia Ballroom)

ORAL PRESENTATIONS
CT-0247-1.5
New Technology—Insulin Delivery Monitoring
Room: W334

SYMPOSIUM
CT-0104-1.5
Myth Busters on “Category X” Drugs in Pregnancy—Evidence for Stopping Commonly Used Medications during Pregnancy, Preconception, and Lactation (INCLUDES LIVESTREAM)
Room: W414

SYMPOSIUM
CT-0103-1.5
Towards Innovative and Equitable Care in Youth-Onset Type 2 Diabetes
Room: W335

SYMPOSIUM
CT-0102-1.5
ADA Symposium—Major Advances and Discoveries in Diabetes—The Year in Review (INCLUDES LIVESTREAM)
Room: W415C (Valencia Ballroom)

SYMPOSIUM
CT-0100-1.5
Consensus Monitoring Guidance in Early-Stage Type 1 Diabetes (INCLUDES LIVESTREAM)
Room: W320 (Chapin Theater)

9:45 a.m.–11:15 a.m.

Outstanding Scientific Achievement Award Lecture and Banting Medal for Scientific Achievement Award Lecture (INCLUDES LIVESTREAM)
West Hall B3-4 (General Session)

EPOSTER THEATER
ePoster13
(*) Tailoring Diabetes Self-Management Education to Improve Success
Room: Exhibit Hall (West A1-A3) ePoster Theater A

PROFESSIONAL INTEREST GROUP
CT-IG01-1
Discussion on Diabetes Technology—Enhancing Clinic Efficiency through the Integration of Diabetes Technologies
Room: W334 A-D

PROFESSIONAL INTEREST GROUP
CT-IG04-1
Discussion on Health Care Delivery and Quality Improvement
Room: W320 A-D

PROFESSIONAL INTEREST GROUP
CT-IG01-1
Discussion on Public Health and Epidemiology—Kids Are Not Little Adults—Challenges and Opportunities in the Use of Pharmacotherapy for Youth With and at Risk for Type 2 Diabetes
Room: W320 C-D

PROFESSIONAL INTEREST GROUP
CT-IG01-1
Discussion on Overview of Public Health and Epidemiology—Kids Are Not Little Adults—Challenges and Opportunities in the Use of Pharmacotherapy for Youth With and at Risk for Type 2 Diabetes
Room: W320 E-H

PROFESSIONAL INTEREST GROUP
CT-IG04-1
Discussion on Health Care Delivery and Quality Improvement
Room: W320 E-H

SYMPOSIUM
IBC-SY01-1
Cross Talk between Beta Cells and Immune Cells
Room: W304 A-D

SYMPOSIUM
IBA-SY02-1.5
Molecular Integration of Amino Acid and Fat Metabolism in Health and Metabolic Disease
Room: W304 A-D

SYMPOSIUM
IP-SY03-1.5
Metabolism and Aging-Related Diseases
Room: W308

SYMPOSIUM
IP-SY04-1.5
Beyond the Scale—Exploring Causes and Consequences of Weight Fluctuation (INCLUDES LIVESTREAM)
Room: W307

11:30 a.m.–12:30 p.m.

EPOSTER THEATER
ePoster14
(*) Research Advances in Metabolic Regulation
Room: Exhibit Hall (West A1-A3) ePoster Theater B

PROFESSIONAL INTEREST GROUP
IBC-IG01-1
Discussion on Immunology/Beta-Cell Replacement—Beta-Cell Stressors, Autoantigen Targets, and How This Provokes Immune Attack
Room: West Hall B3-4 (General Session)

PROFESSIONAL DEVELOPMENT
PD-03-1
Negotiations (INCLUDES LIVESTREAM)
Room: W307

(*) Continuing Education Credit Is Not Awarded for this Session.
**Acute and Chronic Complications**

- **Behavioral Medicine, Clinical Nutrition, Education, and Exercise**

- **Clinical Diabetes/Therapeutics**

- **Epidemiology/Genetics**

### 12:30 p.m. – 1:30 p.m.

**General Poster Session**—Poster Hall (West Hall A4-B2, Second Level)

**Session Break** (Take this opportunity to visit the Exhibit and Poster Halls)

### 1:30 p.m. – 3:00 p.m.

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th>Topic</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>AC-SY08-1.5</td>
<td>Demystifying Impaired Awareness of Hypoglycemia—Diagnosis, Experience, and Treatment in the Real World</td>
<td>W207</td>
</tr>
<tr>
<td>BM-SY09-1.5</td>
<td>How Diabetes Technology Is Changing Diabetes Care in the Real World</td>
<td>W311</td>
</tr>
<tr>
<td>BM-SY17-1.5</td>
<td>Nutrition and Diabetes Self-Management Education and Support (DSMES)</td>
<td>W415C (Valencia Ballroom)</td>
</tr>
<tr>
<td>CT-SY07-1.5</td>
<td>Impact of Precision Medicine on Diabetes</td>
<td>W314</td>
</tr>
<tr>
<td>CT-SY10-1.5</td>
<td>Just Do It—Incorporating What We Know into What We Do</td>
<td>W315</td>
</tr>
<tr>
<td>CT-SY11-1.5</td>
<td>ADA Diabetes Care/Diabetes/Diabetologia Symposium—The Heterogeneity of Type 1 Diabetes—Pathogenesis, Treatment, and Prevention (INCLUDES LIVESTREAM)</td>
<td>W320 (Chapin Theater)</td>
</tr>
<tr>
<td>CT-SY16-1.5</td>
<td>Lancet Journal Symposium—Time for a Paradigm Shift? Should We Treat Early Gestational Diabetes Mellitus?</td>
<td>W304 A-D</td>
</tr>
<tr>
<td>CT-SY18-1.5</td>
<td>The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist—Once-Weekly Semaglutide and the FLOW Trial Results (INCLUDES LIVESTREAM)</td>
<td>W415B (Valencia Ballroom)</td>
</tr>
</tbody>
</table>

### 3:00 p.m. – 4:00 p.m.

<table>
<thead>
<tr>
<th>PANEL</th>
<th>Topic</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBC-PN03-1.5</td>
<td>Modulating Cytokines—Mechanisms Underlying Type 1 Diabetes Treatment (INCLUDES LIVESTREAM)</td>
<td>W304 A-D</td>
</tr>
<tr>
<td>IA-OR04-1.5</td>
<td>Revving Up the Adipose to Impact Insulin Sensitivity and Glucose Homeostasis</td>
<td>W304 A-D</td>
</tr>
<tr>
<td>IP-SY05-1.5</td>
<td>Mitochondria as a Therapeutic Target for Diabetes</td>
<td>W308</td>
</tr>
<tr>
<td>IP-SY10-1.5</td>
<td>Food Noise Explained—Satiety Responsiveness and Motivation Processing in the Brain (INCLUDES LIVESTREAM)</td>
<td>W307</td>
</tr>
<tr>
<td>IB-PN03-1.5</td>
<td>Are We Using the Right Tools to Establish Causality in Islet Function and Dysfunction?</td>
<td>W206</td>
</tr>
</tbody>
</table>

---

(**) Continuing Education Credit is Not Awarded for this Session.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 p.m.–</td>
<td><strong>SYMPOSIUM</strong> AC-SY11-1 Cardiovascular Disease Risk Prediction in Obesity and Type 2 Diabetes—Emerging Tools for the Clinician</td>
<td>W206</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td><strong>ASK THE EXPERT</strong> BM-AE04-1 The Highs and Lows of Cannabis Use in Diabetes—Behavioral and Psychosocial Considerations</td>
<td>W314</td>
</tr>
<tr>
<td></td>
<td><strong>PANEL</strong> BM-PN11-1 Are We Close to Closing the Loop? Automated Insulin Delivery during Exercise</td>
<td>W312 (Valencia Ballroom)</td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> CT-SY16-1 Results from a Randomized Trial of Intensive Glucose Management Using Continuous Glucose Monitoring (CGM) Versus Usual Care in Hospitalized Adults with Type 2 Diabetes—The TIGHT Study (INCLUDES LIVESTREAM)</td>
<td>W210 (Chapin Theater)</td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> CT-SY17-1 Use of SGLT2i in Youth with Type 1 Diabetes—Results from ATTEMPT (The Adolescent Type 1 Diabetes Treatment with SGLT2i for hyperglycEMia &amp; hyperfiltration trial) (INCLUDES LIVESTREAM)</td>
<td>W314</td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> CT-SY18-1 Prevalence of Hypercortisolism in Difficult-to-control Type 2 Diabetes</td>
<td>W315B (Valencia Ballroom)</td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> EG-SY16-1 Diabetes Genetic Convergence—Shared Networks of Rare and Common Variants</td>
<td>W207</td>
</tr>
<tr>
<td></td>
<td><strong>DEBATE</strong> CT-DB02-1 Do Immune or Beta Cells Drive Transition from Stage 1 to Stage 3 Type 1 Diabetes?</td>
<td>W304.A-D</td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> IBC-SY08-1 The Future of Diabetes Care as Cell Replacement or Regeneration Therapies (INCLUDES LIVESTREAM)</td>
<td>W307</td>
</tr>
<tr>
<td></td>
<td><strong>PANEL</strong> IP-PN01-1 Leptin, 30 Years Later</td>
<td>W304.E-H</td>
</tr>
<tr>
<td></td>
<td><strong>PANEL</strong> IP-PN09-1 Ripple Effects after the Advent of Highly Effective Antiobesity Pharmacotherapy—Pharmacoequity in the United States</td>
<td>W308</td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> EG-SY16-1 Diabetes Genetic Convergence—Shared Networks of Rare and Common Variants</td>
<td>W207</td>
</tr>
<tr>
<td></td>
<td><strong>SYMPOSIUM</strong> IBC-SY08-1 The Future of Diabetes Care as Cell Replacement or Regeneration Therapies</td>
<td>W307</td>
</tr>
</tbody>
</table>
PROGRAM INFORMATION

84th Scientific Sessions
June 21-24, 2024
Orange County Convention Center
Orlando, Florida

Program information is subject to change at any time. For full program details, please use the online planner/mobile app.

The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

© 2024 American Diabetes Association.
FRIDAY, JUNE 21, 2024

Scientific Sessions
10:30 a.m.-11:30 a.m.

Special Lectures and Addresses
Session Number: WP-01-1
Welcome to the 84th ADA Scientific Sessions—Keynote Address by Robert M. Califf, MD and Panel Discussion (Includes Livestream)
Room: West Hall B3-4 (General Session)
Chair: Robert A. Gabbay, MD, PhD
10:30 a.m.-10:35 a.m. Welcome to the 84th ADA Scientific Sessions!
    Charles Henderson
10:35 a.m.-10:40 a.m. Introduction
    Mandeep Bajaj, MBBS
10:40 a.m.-11:10 a.m. Keynote Address—The Dissociation Between Technology Advances and Health Outcomes for Diabetes in the US—What Should We Do Differently?
    Robert M. Califf, MD
11:10 a.m.-11:15 a.m. Introduction of Panel
    Robert A. Gabbay, MD, PhD
11:10 a.m.-11:30 a.m. Panel Discussion
    Alice Y.Y. Cheng, MD, FRCPC
    Robert M. Califf, MD
    Christopher S. Holliday, PhD, MPH, MA, FACHE
    Griffin Rodgers, MD, MACP

Pathway Symposium
Session Number: PTH-01-1
"Pathway to Stop Diabetes" (Includes Livestream)
Room: West Hall B3-4 (General Session)
Chair: Robert A. Gabbay, MD, PhD
11:40 a.m.-11:48 a.m. Introduction
    Robert A. Gabbay, MD, PhD
11:48 a.m.-11:56 a.m. Is There Such a Thing as Good Fat?
    Paul Cohen, MD, PhD
11:56 a.m.-12:02 p.m. Decoding the Puzzle—Unveiling Type 2 Diabetes Genetics via Multi-Omic Insights
    Debora Sobreira, PhD
12:02 p.m.-12:11 p.m. Early Encounters—Diabetes Exposure Before Birth Shapes Brain Pathways and Metabolic Risk
    Kathleen A. Page, MD
12:11 p.m.-12:15 p.m. Closing Remarks
    Marlon Pragnell, PhD
**Debate**

**Theme Area: Epidemiology/Genetics**

**Session Number: EG-DB01-1**

**Race and Ethnicity-Based Cut Points in Diabetes Screening and Diagnosis—Benefit or Harm for Reducing Disparities? (Includes Livestream)**

Room: W320 (Chapin Theater)

Chair: Alan Kinlaw, PhD

12:45 p.m.-1:00 p.m. **Using Race and Ethnicity-Based Cut Points Has the Potential to REDUCE Health Disparities in the Diagnosis of Diabetes**

Quyen Ngo-Metzger, MD, MPH

1:00 p.m.-1:15 p.m. **Using Race and Ethnicity-Based Cut Points Has the Potential to INCREASE Health Disparities in the Diagnosis of Diabetes**

Jessica Cerdeña, MD, PhD

1:15 p.m.-1:20 p.m. **Rebuttal**

Quyen Ngo-Metzger, MD, MPH

1:20 p.m.-1:25 p.m. **Rebuttal**

Jessica Cerdeña, MD, PhD

1:25 p.m.-1:45 p.m. **Question and Discussion Period**

---

**Debate**

**Theme Area: Islet Biology/Insulin Secretion**

**Session Number: IB-DB01-1**

**Setting the Record Straight—Does SARS-CoV-2 Cause Type 1 Diabetes? (Includes Livestream)**

Room: W415B (Valencia Ballroom)

Chair: Mark A. Atkinson, PhD

12:45 p.m.-1:00 p.m. **SARS-CoV-2 Infects Human Beta Cells and Compromises Beta-Cell Function**

Peter K. Jackson, PhD

1:00 p.m.-1:15 p.m. **Infection Does Not Equal Causation—Unraveling the Complicated Relationship Between SARS-CoV-2 and Diabetes**

Carmella Evans-Molina, MD, PhD

1:15 p.m.-1:20 p.m. **Rebuttal**

Peter K. Jackson, PhD

1:20 p.m.-1:25 p.m. **Rebuttal**

Carmella Evans-Molina, MD, PhD

1:25 p.m.-1:45 p.m. **Question and Discussion Period**
12:45 p.m.-1:45 p.m.  
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications  
Session Number: AC-OR06-1
Multiorgan Cross Talk in Lipid Metabolism  
Room: W206  
Chair: Rebecca Haeusler, PhD

12:45 p.m.-1:00 p.m.

1-OR  The Improvement Effects of Glucokinase Loss-of-Function Mutation on Lipid Metabolism  
Presenting Author: Ziyan Xie, PhD

2-OR  WITHDRAWN

1:00 p.m.-1:15 p.m.

3-OR  Lipoprotein(a) Levels and Epicardial Adipose Tissue in Diabetes—Unraveling Novel Connections  
Presenting Author: Emmanuel Cosson, Professor

1:15 p.m.-1:30 p.m.

4-OR  Fat Contents in Pancreatic Body and Liver Are Synergistic Risk Factors for Impaired Glucose Regulation in PCOS  
Presenting Author: Tao Tao, Doctorate
12:45 p.m.-1:45 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Acute and Chronic Complications*  
Session Number: AC-OR11-1

**Metabolic Pathways to Protection—Innovative Approaches in Diabetes-Induced Kidney Disease**  
Room: W207  
Chair: Kalie L. Tommerdahl, MD

12:45 p.m.-1:00 p.m.  
5-OR  Renal Hypermetabolism in Youth-Onset Type 2 Diabetes (T2D)—A C-11 Acetate PET Scan Analysis  
Presenting Author: Melissa Leroux, BS

1:00 p.m.-1:15 p.m.  
6-OR  Renal Cell Type—Associated Therapeutic Effects of Semaglutide in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease  
Presenting Author: Michael Christensen, PhD

1:15 p.m.-1:30 p.m.  
7-OR  Causal Associations between Glyoxalase 1 Expression and Kidney Disease in Type 1 Diabetes  
Presenting Author: Krishna Adeshara, PhD

1:30 p.m.-1:45 p.m.  
8-OR  Longitudinal Patterns of Heterogeneity in Metabolic Decompensation among Diabetes Prevention Program Outcomes Study (DPPOS) Participants over 20 Years  
Presenting Author: Emily Kobayashi, BS
12:45 p.m.-1:45 p.m.  
(continued)

**Oral Presentations**

_Theme Area: Acute and Chronic Complications_

_Session Number: AC-OR13-1_

**Innovative Approaches in Diagnosing and Managing Diabetic Neuropathy (With ADA Presidents' Select Abstract Presentation) (Includes Livestream)**

Room: W307

Chair: Kara R. Mizokami-Stout, MD

12:45 p.m.-1:00 p.m.

9-OR  ADA Presidents' Select Abstract: Targeting Inflammation with Salsalate in Type 1 Diabetes Neuropathy (TINSAL–T1DN Trial)

Presenting Author: Lynn Ang, MD

1:00 p.m.-1:15 p.m.

10-OR  Diffusion Tensor Imaging and T2 Mapping of the Tibial Nerve Can Detect Nerve Damage in Type 2 Diabetes

Presenting Author: Hyeong-Kyu Park, MD

1:15 p.m.-1:30 p.m.

11-OR  Combined DPNCheck and SUDOSCAN as a Screening Tool for DPN—The Sheffield Prospective Study

Presenting Author: Mohummad Shaan Goonoo, MBBS, MRCPE

12-OR  WITHDRAWN
12:45 p.m.-1:45 p.m. (continued)

**Oral Presentations**

*Theme Area: Acute and Chronic Complications*

**Session Number: AC-OR15-1**

**Innovations in Diabetic Eye Care—Advancements, Therapeutic Strategies, and Disease Associations**

*Room: W208*  
*Chair: Renu A. Kowluru, MS, PhD*

12:45 p.m.-1:00 p.m.  
**13-OR**  
**Relationship between Visit-to-Visit Variability of HbA1c and Development/Progression of Diabetic Retinopathy**  
Presenting Author: Masahiro Yuki, MD

1:00 p.m.-1:15 p.m.  
**14-OR**  
**Autonomous Artificial Intelligence Diabetic Eye Exams Mitigates Disparities in Screening Completion for Youth**  
Presenting Author: T.Y. Alvin Liu, MD

1:15 p.m.-1:30 p.m.  
**15-OR**  
**Diabetic Retinopathy (DR) Is Associated with Markers of Alzheimer's Disease (AD) in Type 1 Diabetes (T1D)**  
Presenting Author: Meghan E. Pauley, DO

1:30 p.m.-1:45 p.m.  
**16-OR**  
**Preadministration of SGLT2 Inhibitor Reduces Frequency of Anti-VEGF Agent Administration in Patients with Mild Diabetic Macular Edema—A Multicenter Randomized Controlled Open-Label Trial**  
Presenting Author: Ryoichi Ishibashi, MD, PhD
12:45 p.m.-1:45 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
*Session Number: BM-OR04-1*

**Exploring the Impact of Food/Food Additives on Insulin Sensitivity and Postprandial Glucose**  
(With ADA Presidents' Select Abstract Presentation)  
*Room: W315*  
*Chair: Lorena Drago, MS, RDN, CDN, CDCES*

**12:45 p.m.-1:00 p.m.**  
17-OR  
ADA Presidents' Select Abstract: Oral Bisphenol A Administration Decreased Peripheral Insulin Sensitivity in Healthy Adults  
Presenting Author: Todd Hagobian, PhD

**1:00 p.m.-1:15 p.m.**  
18-OR  
The Effect of a Dietary Intervention on Insulin Sensitivity in Type 1 Diabetes and the Role of Dietary Advanced Glycation End-Products—A 12-Week Randomized Clinical Trial  
Presenting Author: Hana Kahleova, MD, PhD, MBA

**1:15 p.m.-1:30 p.m.**  
19-OR  
Sucralose Consumption Decreases Insulin Sensitivity and Modifies the Gut Microbiota in Healthy Individuals  
Presenting Author: Alonso Romo-Romo, PhD

**1:30 p.m.-1:45 p.m.**  
20-OR  
Digital Twin (DT) Technology in Type 2 Diabetes Remission and Glycemic Improvement—Eighteen Months Results from a Randomized Controlled Trial  
Presenting Author: Paramesh Shamanna, MD
FRIDAY, JUNE 21, 2024

12:45 p.m.-1:45 p.m.
(continued)

Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR06-1
Tools for Health Care Professionals That Assist in Personalizing Care
Room: W314
Chair: Curtis L. Triplett, PharmD, CDCES

12:45 p.m.-1:00 p.m.
21-OR  Use of Electronic Best Practice Advisories (BPA) to Increase Referral to Diabetes Self-Management Education and Support (DSMES) Services
Presenting Author: Laura A. Young, MD, PhD

1:00 p.m.-1:15 p.m.
22-OR  Burden of Diabetes Survey—Perspectives from People Living with Diabetes in the United States
Presenting Author: Kirsten Yehl, MS, MLIS

1:15 p.m.-1:30 p.m.
23-OR  Streamlining Diabetes Device Integration into the Electronic Health Record
Presenting Author: Roma Gianchandani, MD

1:30 p.m.-1:45 p.m.
24-OR  Inaccurate and Unaware—Perceived and Objective Diabetes Knowledge among Adults with Type 2 Diabetes
Presenting Author: Colter K. Clayton, BS
Oral Presentations

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR08-1

Back to the Basics (Sciences) of Exercise and Diabetes
Room: W304 E-H
Chair: John R. Ussher, PhD

12:45 p.m.-1:00 p.m.

25-OR Two Weeks of Exercise Alters Neuronal Extracellular Vesicle Insulin Signaling in Adults with Prediabetes
Presenting Author: Steven K. Malin, PhD

1:00 p.m.-1:15 p.m.

26-OR METTL3 Is Essential for Exercise-Induced Cardiac Benefits in Diabetic Cardiomyopathy
Presenting Author: Jiayi Kang, BS

1:15 p.m.-1:30 p.m.

27-OR Effect of Acute Exercise and Exercise Training on the Ability of Insulin to Clear Branched-Chain Amino Acids from Plasma in Obesity and Type 2 Diabetes
Presenting Author: Pauline M. Møller, MS

1:30 p.m.-1:45 p.m.

28-OR Posttranslational Modifications in Skeletal Muscle Direct Divergent Metabolic Responses to Different Exercise Training Modes
Presenting Author: Mark W. Pataky, PhD
12:45 p.m.-1:45 p.m. (continued)

Oral Presentations

Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR03-1
Practicable Methods to Improve Metabolic Parameters
Room: W311
Chair: Michael J. Haller, MD

12:45 p.m.-1:00 p.m.

29-OR Analysis of Fib-4 Index Changes in Adults with Type 2 Diabetes in an Effective Comprehensive Diabetes Care Program
Presenting Author: Rubén Silva-Tinoco, MD

1:00 p.m.-1:15 p.m.

30-OR Diabetes Rescue, Engagement, and Management (D-REM)—Results of a Pragmatic Clinical Trial of a Community Paramedicine Program to Improve Diabetes Care
Presenting Author: Rozalina G. McCoy, MD, MS

1:15 p.m.-1:30 p.m.

31-OR ROCKET Type 1 Diabetes—Launching Diabetes Self-Management Habits in Youth with New-Onset Type 1 Diabetes
Presenting Author: Daniel DeSalvo, MD

1:30 p.m.-1:45 p.m.

32-OR First Impact on A1C of Medically Underserved Patients with Type 2 Diabetes Using a Hybrid Chronic Care Model
Presenting Author: Joyce Y. Lee, PharmD, APh, FCCP, BCPS, BCACP, CDCES
12:45 p.m.-1:45 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-OR11-1*  
**Diabetes Potpourri**  
Room: W415C (Valencia Ballroom)  
Chair: Tamara Spaic, MD

12:45 p.m.-1:00 p.m.  
**33-OR**  
*The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk*  
Presenting Author: Helen Tesfaye, PharmD, MSc

1:00 p.m.-1:15 p.m.  
**34-OR**  
*The Effect of Combined Activin A and Myostatin Blockade on Body Composition—A Phase 1 Trial*  
Presenting Author: Dinko Gonzalez Trotter, PhD

1:15 p.m.-1:30 p.m.  
**35-OR**  
*Lantidra, First FDA Approved Cellular Therapy to Treat Type 1 Diabetes*  
Presenting Author: Yi Li, PhD

1:30 p.m.-1:45 p.m.  
**36-OR**  
*Modulation of Cardiorenal Benefits for GLP-1RAs Treatment by GLP1R Genetic Variants*  
Presenting Author: Qiaochu Xue, PhD, MPH
FRIDAY, JUNE 21, 2024

12:45 p.m.-1:45 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR16-1
New Technology—The Inpatient Setting *(Includes Livestream)*
Room: W414
Chair: Jayachidambaram Ambalavanan, MD

12:45 p.m.-1:00 p.m.
37-OR Effectiveness of Continuous Glucose Monitoring on Short-Term In-Hospital Mortality among Frail Critically Ill Patients with COVID-19—An Exploratory, Prospective, Randomized, Open-Label, Parallel, Single-Center, Randomized Clinical Trial
Presenting Author: Yun Shen, Doctor

1:00 p.m.-1:15 p.m.
38-OR Implementation of an EHR-Integrated Hospital-Wide CGM Protocol for Insulin Dosing
Presenting Author: Susan M. Seav, MD

1:15 p.m.-1:30 p.m.
39-OR Real-Time Continuous Glucose Monitoring—Guided Glucose Management in Hospitalized Patients with Diabetes Receiving Short-Term Continuous Subcutaneous Insulin Infusion—A Randomized Clinical Trial
Presenting Author: Yaxin Wang, MD

1:30 p.m.-1:45 p.m.
40-OR The Association of Continuous Glucose Monitoring Metrics with Hospital Related Clinical Outcomes
Presenting Author: Kristen L. Flint, MD
12:45 p.m.-1:45 p.m.
(continued)

Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-OR05-1
Secreted Factors and Insulin Action
Room: W304 A-D
Chair: Katrin Svensson, PhD

12:45 p.m.-1:00 p.m.
41-OR Insulin Regulates Exosomal MicroRNA Secretion from Adipocytes Completing a Novel Feedback Loop
Presenting Author: Marsel Lino, PhD

1:00 p.m.-1:15 p.m.
42-OR A Small Intestinal Bile Acid Modulates the Gut Microbiome to Improve Glucose Regulation following Bariatric Surgery
Presenting Author: Yingjia Chen, PhD

1:15 p.m.-1:30 p.m.
43-OR Endothelial Cell Regeneration by Secretome Secreted from P53-Silenced Bone Marrow-Derived BMSCs
Presenting Author: Seshagiri Rao Nandula, PhD

1:30 p.m.-1:45 p.m.
44-OR Cell Intrinsic Alterations in miRNA Expression and Secretion in Muscle in Type 2 Diabetes
Presenting Author: Allah Nawaz, PhD
12:45 p.m.-1:45 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Obesity/Integrated Physiology*  
*Session Number: IP-OR06-1*  
**New Frontier in Immunometabolism**  
Room: W308  
Chair: Pingwen Xu, PhD

**45-OR**  
**WITHDRAWN**

12:45 p.m.-1:00 p.m.  
**46-OR**  
Palmitic Acid Coordinates Impaired Adipose Tissue ICOS-high Treg  
Immunosuppression and Systemic Metabolic Disturbance during Obesity  
Presenting Author: Weitong Su, Bachelor’s Degree

1:00 p.m.-1:15 p.m.  
**47-OR**  
OPA1 Reprograms Macrophage Metabolism to Enforce Tolerance of  
Inflammation in Obesity  
Presenting Author: Daixi Wang, PhD

1:15 p.m.-1:30 p.m.  
**48-OR**  
Novel Lipidated Interleukin-22 Reduces Body Weight and Improves Glucose  
Homeostasis in Mice  
Presenting Author: Martijn van de Bunt, MD, DPhil
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.

Ask the Expert
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-AE14-1.5
How Will Artificial Intelligence Change Diabetes Clinical Practice? (Includes Livestream)
Room: W320 (Chapin Theater)
Chair: Edward C. Chao, DO
2:00 p.m.-2:20 p.m. Artificial Intelligence in Health Care and the Future of Diabetes Data Science
   Boris Kovatchev, PhD
2:20 p.m.-2:40 p.m. Artificial Intelligence and the Future of Diabetes Devices
   Peter G. Jacobs, PhD
2:40 p.m.-3:00 p.m. Artificial Intelligence and the Future of the Multidisciplinary Team
   Mudassir M. Rashid, PhD
3:00 p.m.-3:30 p.m. Question and Discussion Period
Oral Presentations

Theme Area: Acute and Chronic Complications
Session Number: AC-OR10-1.5

Emerging Molecular Mechanisms of ASCVD Progression in Cardiometabolic Disease (With Edwin Bierman Award Lecture) (Includes Livestream)
Room: W307
Chair: Helmy Siragy, MD

2:00 p.m.-2:30 p.m.

Edwin Bierman Award Lecture

*Diabetes and Cardiovascular Disease—The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications*
Darren K. McGuire, MD, MHSc, FAHA, FACC, FESC

2:30 p.m.-2:45 p.m.

**49-OR** GPSM1 Regulates Atherosclerosis Progression by Controlling Macrophage Chemotaxis through PKA/KLF4/PMP22-MAPK Pathway
Presenting Author: Yuemei Zhang, PhD

2:45 p.m.-3:00 p.m.

**50-OR** Metabolic Dysfunction Attenuates D-dopachrome Tautomerase (DDT) Expression in the Heart—A Key Mechanism Exacerbates Myocardial Post-ischemic Injury
Presenting Author: Lisha Li, MSc, MD

3:00 p.m.-3:15 p.m.

**51-OR** Vascular Sorbs2 Deficiency Is an Independent Risk of Vascular Complications in Diabetes
Presenting Author: Tong Lu, MD, PhD
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.
(continued)

**Oral Presentations**
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR03-1.5

**Exploring Dimensions of Diversity in Diabetes Distress (With Richard R. Rubin Award Lecture)**
(Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Elizabeth A. Beverly, PhD

2:00 p.m.-2:30 p.m.
**Richard R. Rubin Award Lecture**

*Richard R. Rubin Award Lecture— Life Lessons and Diabetes Research*
Paula M. Trief, PhD

2:30 p.m.-2:45 p.m.
52-OR Emotional Distress and Insulin Initiation in the GRADE Trial
Presenting Author: Caroline A. Presley, MD, MPH

2:45 p.m.-3:00 p.m.
53-OR Individual Sources of Diabetes Distress—A Precision Mental Health Approach Combining Ecological Momentary Assessment and Continuous Glucose Monitoring
Presenting Author: Dominic Ehrmann, PhD

3:00 p.m.-3:15 p.m.
54-OR Feasibility of a Multidisciplinary Pilot Intervention for Parent/Caregiver Diabetes Distress
Presenting Author: Einas Alkhatib, MD

3:15 p.m.-3:30 p.m.
55-OR Diabetes Distress among Persons Living with Latent Autoimmune Diabetes of Adults in the Canadian Cohort BETTER—A Cross-Sectional Study
Presenting Author: Maya Nehme, BSc
Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR01-1.5
Screening for and Delaying Vascular Complications
Room: W315
Chair: Mohammed K. Ali, MD, MSc, MBA

2:00 p.m.-2:15 p.m.
56-OR Impact of Delays in Statin Therapy Due to Statin Nonacceptance on Cardiovascular Outcomes in Patients with Diabetes
Presenting Author: Alexander Turchin, MD, MS

2:15 p.m.-2:30 p.m.
57-OR Enhancing Diabetic Eye Disease Detection through Autonomous Artificial Intelligence Implementation in a Federally Qualified Health Center
Presenting Author: Milibeth Castro, MPH

2:30 p.m.-2:45 p.m.
58-OR Screening for Diabetic Retinopathy Increases by 32% with Education and Intervention Program in Primary Care
Presenting Author: Lesley Simon, BA

2:45 p.m.-3:00 p.m.
59-OR Improving Diabetic Kidney Disease Screening in a Veterans Affairs Primary Care Clinic
Presenting Author: Kristina P. Frangella, PharmD, BCPS, CDE, BCACP

3:00 p.m.-3:15 p.m.
60-OR Implementing a Machine-Learning Model to Predict Risk of Chronic Kidney Disease (CKD) Progression
Presenting Author: Thomas Ferguson, MSc

3:15 p.m.-3:30 p.m.
61-OR Effectiveness of Telemedicine plus Conventional Care vs. Conventional Care Alone in Reducing Complications of Diabetes—A Pilot Study
Presenting Author: Jothydev Kesavadev, MD, FRCP, FACP, FACE
Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR04-1.5
Novel Insights from CGM Use during Pregnancy
Room: W208
Chair: Amy M. Valent, DO, MCR

2:00 p.m.-2:15 p.m.
62-OR Continuous Glucose Monitoring in Pregnancies with Type 1 Diabetes—A Retrospective Study
Presenting Author: Stephanie A. Fisher, MD, MPH

2:15 p.m.-2:30 p.m.
63-OR Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes
Presenting Author: Zoey Li, MS

2:30 p.m.-2:45 p.m.
64-OR Continuous Glucose Monitoring among Pregnant Individuals with Glucose Intolerance
Presenting Author: Rachel D. Gordon, MD

2:45 p.m.-3:00 p.m.
65-OR Continuous Glucose Monitoring Metrics and Suboptimal Pregnancy Outcomes in Women with Gestational Diabetes—Secondary Analysis of the DiGest Trial
Presenting Author: Claire L. Meek, MB, ChB, MRCP, FRCPath, PhD

3:00 p.m.-3:15 p.m.
66-OR Using Continuous Glucose Monitoring to Identify Neonatal Hypoglycemia following Gestational Diabetes—The DiGest Newborn Study
Presenting Author: Danielle Jones, BSc, MSc

3:15 p.m.-3:30 p.m.
67-OR Postprandial Glycemic Patterns throughout Uncomplicated Pregnancies
Presenting Author: Anders L. Carlson, MD
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR07-1.5
New Approaches to Prevent or Reverse Diabetes
Room: W415C (Valencia Ballroom)
Chair: Catherine Kim, MD, MPH

2:00 p.m.-2:15 p.m.
68-OR Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention
Presenting Author: Maria J. Redondo, MD, PhD, MPH

2:15 p.m.-2:30 p.m.
69-OR Preclinical Studies Indicate That Insparin Is a New Class of Antidiabetes Agent
Presenting Author: Nikhil Dhurandhar, PhD

2:30 p.m.-2:45 p.m.
70-OR PROTECT Per-Protocol Analysis—Preserving β-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)
Presenting Author: Kevan C. Herold, MD

2:45 p.m.-3:00 p.m.
71-OR Rates of Remission and Metabolic Responses in Data-Driven High-Risk Prediabetes Clusters
Presenting Author: Sarah Katzenstein, MD

3:00 p.m.-3:15 p.m.
72-OR Mechanisms of Prediabetes Remission in People with Weight Gain after Lifestyle Intervention
Presenting Author: Arvid Sandforth, MD

3:15 p.m.-3:30 p.m.
73-OR The Plant-Based Substance Totum-63 (T63) Reduces Fasting Plasma Glucose and HbA1c in People with Prediabetes or Type 2 Diabetes (T2D)—A 24-Week Multicenter Randomized Controlled Trial (REVERSE-IT)
Presenting Author: Andre Marette, PhD
Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR13-1.5
New Technology—What's New? (With ADA Presidents' Select Abstract Presentation)
Room: W311
Chair: Chlodys Johnstone, PA-C

2:00 p.m.-2:15 p.m.
74-OR  ADA Presidents' Select Abstract: CGM Metrics from Five Studies Identify Participants at High Risk of Imminent Type 1 Diabetes (T1D) Development
Presenting Author: Peter Calhoun, PhD

2:15 p.m.-2:30 p.m.
75-OR  In-Silico Replay of Insulin Degludec and Liraglutide Clinical Trial Data in Subjects with Type 2 Diabetes
Presenting Author: Mohammadreza Ganjiarjenaki, Bachelor's Degree

2:30 p.m.-2:45 p.m.
76-OR  Diabetes Technology and Waste—A Real-World Study in a Specialized Practice in Germany
Presenting Author: Lutz Heinemann, PhD

2:45 p.m.-3:00 p.m.
77-OR  Time in Range Is Associated with Glucagon/C-Peptide Index Ratio in Type 2 Diabetes Patients
Presenting Author: Miki Kamigishi, MD

3:00 p.m.-3:15 p.m.
78-OR  Breath Acetone Correlates with Capillary Beta Hydroxybutyrate in Type 1 Diabetes
Presenting Author: Kai Jones, MD

3:15 p.m.-3:30 p.m.
79-OR  A Novel Decision Support System for Automated Adaptations of Insulin Injections in Type 1 Diabetes—A Randomized Controlled Trial
Presenting Author: Anas El Fathi, PhD
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.
(continued)

Oral Presentations
Theme Area: Epidemiology/Genetics
Session Number: EG-OR01-1.5
Diabetes and the Liver—A Canary in the Coal Mine
Room: W207
Chair: Justin Echouffo Tcheugui, MD, PhD

2:00 p.m.-2:15 p.m.

80-OR UNABLE TO ATTEND

2:15 p.m.-2:30 p.m.

81-OR Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology
Presenting Author: Cyrielle Caussy, MD, PhD

2:30 p.m.-2:45 p.m.

82-OR Association of Diabetic Complications and Various Comorbidities with Major Adverse Cardiovascular Events in Type 2 Diabetes and Their Development over Time—A Danish Registry-Based Case-Control Study
Presenting Author: Nicklas H. Rasmussen, MD, PhD

2:45 p.m.-3:00 p.m.

83-OR Metabolic Dysfunction—Associated Steatotic Liver Disease and Nonalcoholic Fatty Liver Disease Have Similar Clinical Profiles and Mortality
Presenting Author: Zobair Younossi, MD, MPH

3:00 p.m.-3:15 p.m.

84-OR Performance of FIB-4 Score in Predicting Mortality among Patients with Nonalcoholic
Presenting Author: Zobair Younossi, MD, MPH

3:15 p.m.-3:30 p.m.

85-OR The Impact of Type 2 Diabetes (T2D) on the Outcomes of Liver Transplantation in the United States from 2007–2022
Presenting Author: Zobair Younossi, MD, MPH
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.
(continued)

Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-OR01-1.5
Adipocyte Differentiation and Function
Room: W308
Chair: Phillip J. White, PhD

86-OR WITHDRAWN

2:00 p.m.-2:15 p.m.
87-OR A PKA to mTORC1 Signaling Axis Controls Metabolic Homeostasis via Phosphorylation of Raptor
Presenting Author: Fubiao Shi, PhD

2:15 p.m.-2:30 p.m.
88-OR Glucose Regulation of Adipose Tissue Browning by CBP/p300 and HDAC3 Mediated Reversible Acetylation of CREBZF
Presenting Author: Yu Li, PhD

2:30 p.m.-2:45 p.m.
89-OR UNABLE TO ATTEND

2:45 p.m.-3:00 p.m.
90-OR Neddylation Targets Cullin 3 to Regulate Adipocyte Differentiation
Presenting Author: Hongyi Zhou, PhD

3:00 p.m.-3:15 p.m.
91-OR Selenite-Induced Glutathione Peroxidase 3 In the Control of Insulin Receptor Expression in Adipocytes
Presenting Author: Robert Hauffe, PhD
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.
(continued)

Oral Presentations
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-OR01-1.5

Immune Features of Immune Therapy and Evolution—Fickle or Fixed?
Room: W304 A-D
Chair: Cate Speake, PhD

2:00 p.m.-2:15 p.m.
92-OR Defining Type 1 Diabetes Endotypes
Presenting Author: Amina Bedrat, PhD

2:15 p.m.-2:30 p.m.
93-OR Clonal Expansion of Islet Reactive CD4 T-Cells with Early Disease Progression in Type 1 Diabetes
Presenting Author: Karen Ceresaletti, PhD

2:30 p.m.-2:45 p.m.
94-OR Pathogenic Action of GAD65 Autoantibodies on Islet Function in Type 1 Diabetes
Presenting Author: Ian Sweet, PhD

2:45 p.m.-3:00 p.m.
95-OR Diurnal Variation of Islet Autoantibodies in Established Type 1 Diabetes
Presenting Author: Linda A. DiMeglio, MPH, MD

3:00 p.m.-3:15 p.m.
96-OR Pancreatic Adverse Events and Mortality in Patients with Immune Checkpoint Inhibitor–Associated Diabetes Mellitus—A 10-Year Follow-up Study
Presenting Author: Shafaq Raza Rizvi, MBBS

3:15 p.m.-3:30 p.m.
97-OR Preclinical Characterization of MTX-101, a Novel KIRxCD8 Targeting Bispecific CD8 Treg Modulator
Presenting Author: Courtney Crane, PhD
2:00 p.m.-3:00 p.m.

**Oral Presentations**

*Theme Area: Islet Biology/Insulin Secretion*

**Session Number: IB-OR01-1.5**

**Fueling the Fire—Islet Stimulus–Secretion Coupling**

*Room: W206*

*Chair: Yumi Imai, MD*

2:00 p.m.-2:15 p.m.

**98-OR**  
**β-Cell Dysfunction and Mitochondrial Loss Occur Independently of Insulitis in Type 1 Diabetes Pathogenesis**

*Presenting Author: Mollie Huber, BS*

2:15 p.m.-2:30 p.m.

**99-OR**  
**SLC7A2-Dependent Arginine Transport in α-Cells Signals Arginine tone to Regulate Insulin Secretion**

*Presenting Author: Jade Stanley, BS*

2:30 p.m.-2:45 p.m.

**100-OR**  
**Investigating the Mechanisms of Cross Talk between Endocrine Beta Cells and Pericytes in Pancreatic Islets**

*Presenting Author: Luciana Mateus Goncalves, PhD*

2:45 p.m.-3:00 p.m.

**101-OR**  
**Revelations in Regulation—Sodium/Potassium ATPase Subunit Control of Beta-Cell Cation Handling and Insulin Secretion**

*Presenting Author: Matthew Dickerson, PhD*

3:00 p.m.-3:15 p.m.

**102-OR**  
**A Novel Strategy for Detecting In Vivo Functional β-Cells Using Positron Emission Tomography (PET) Imaging**

*Presenting Author: Junfeng Li, PhD*

3:15 p.m.-3:30 p.m.

**103-OR**  
**Signaling Mechanisms Underlying Islet Compensation in a Novel Mouse Model of β-Cell Replication Deficiency**

*Presenting Author: Hannah R. Foster, PhD*
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.
(continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR01-1.5
Actions of Incretins in the Brain and Beyond (Includes Livestream)
Room: W414
Chair: Daisy Duan, MD

2:00 p.m.-2:15 p.m.
104-OR State-Dependent Activity in Hindbrain Glucagon-Like Peptide 1–Producing Neurons Regulates Consummatory and Valence Behavior through Functionally Interconnected Hypothalamic and Limbic Circuits
Presenting Author: James A. Hardaway, PhD

2:15 p.m.-2:30 p.m.
105-OR Single-Cell Multiomic Analysis of the Effect of GIP and GIP-1 Mono- and Multi-agonism on the Hypothalamus and Hindbrain
Presenting Author: Robert M. Gutgesell, HBSc, MSc

2:30 p.m.-2:45 p.m.
106-OR Semaglutide Reduces Tumor Burden in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH with Advanced Fibrosis and HCC
Presenting Author: Henrik H. Hanse, PhD

2:45 p.m.-3:00 p.m.
107-OR Brain GLP-1R Is Likely Required for Peripheral Liraglutide Treatment on Stimulating Hepatic FGF21
Presenting Author: Jia Nuo Feng, BS (Hons)

3:00 p.m.-3:15 p.m.
108-OR Insulin Resistance Is Associated with Alterations in the Dynamics of Incretin Secretion
Presenting Author: Gianfranco Di Giuseppe, MD

3:15 p.m.-3:30 p.m.
109-OR GIP Acutely Blunts Insulin- and GLP-1–Induced Muscle Microvascular Perfusion
Presenting Author: Jia Liu, PhD
Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR05-1.5
Emerging New Players in Metabolic Regulation
Room: W314
Chair: Meilian Liu, PhD

2:00 p.m.-2:15 p.m.
110-OR  Paternal Metabolism Modulates the Metabolome of Offspring during the Early Embryonic Period
Presenting Author: Rafael Ferraz-Bannitz, PhD

2:15 p.m.-2:30 p.m.
111-OR  Vascular Endothelium-Specific ROCK2 Deficiency Inhibits the Progression of Obesity via Adipocyte Browning
Presenting Author: Shinji Ohashi, MD

2:30 p.m.-2:45 p.m.
112-OR  A Novel Function of Endothelial Insulin-Like Growth Factor 1 Receptor—Regulation of Gastrointestinal Microbiota as a Defensive Mechanism against Obesity-Induced Metabolic Dysfunction
Presenting Author: Natalie J. Haywood, PhD

2:45 p.m.-3:00 p.m.
113-OR  Lipocalin-2, a Mitokine That Mediates White-to-Brown Fat Cross Talk
Presenting Author: Fenfen Wang, PhD

3:00 p.m.-3:15 p.m.
114-OR  Proteome-Wide Analysis of USP2 Substrates Revealed Its Role in Thermogenesis via Stabilization of EBF2
Presenting Author: Yuejie Xu, Doctor

3:15 p.m.-3:30 p.m.
115-OR  Adipose m6A Reader YTHDF2 Regulates White Adipose Tissue Growth and Metabolism
Presenting Author: Ruoyu Zhou, MD
Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY01-1.5
Systemic Medications for Diabetic Retinopathy—Protective and Risk Factors
Room: W208
Chair: Thomas W. Gardner, MD, MS

3:45 p.m.-3:55 p.m. Introduction
3:55 p.m.-4:15 p.m. The Effect of Fenofibrate on Progression of Diabetic Retinopathy—Results from the LENS Trial
   David Preiss, MBChB, MRCP, FRCPath, PhD
4:15 p.m.-4:30 p.m. Role of Systemic Pharmacotherapy in the Prevention and Management of Diabetic Macular Edema
   Andrew J. Barkmeier, MD
4:30 p.m.-4:45 p.m. The FAME 1 Eye Trial
   Alicia Jenkins, MBBS, MD, FRACP, FRCP
4:45 p.m.-5:00 p.m. GLP-1 Receptor Agonist and Diabetic Retinopathy Worsening
   Satish K. Garg, MD
5:00 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY07-1.5
Sex and Gender Dimorphism in Cardiovascular Disease Risk in Diabetes
Room: W308
Chair: Wendy L. Bennett, MD, MPH

3:45 p.m.-4:05 p.m. Sex and Gender-Specific Cardiovascular Disease Risk Factors
   Wendy L. Bennett, MD, MPH
4:05 p.m.-4:25 p.m. Is High-Density Lipoprotein a Risk Factor for Men?
   Ernst J. Schaefer, MD
4:25 p.m.-4:45 p.m. Impact of Biological and Chromosomal Sex on Postprandial Lipid Metabolism
   Karen Reue, PhD
4:45 p.m.-5:05 p.m. Sex Differences in Lipoprotein Metabolism
   John M. Stafford, MD, PhD
5:05 p.m.-5:15 p.m. Question and Discussion Period
3:45 p.m.-5:15 p.m.
(continued)

**Symposium**
*Theme Area: Acute and Chronic Complications*
*Session Number: AC-SY17-1.5*
*Joint Diabetes Care/Centers for Disease Control and Prevention Symposium—Pressure Points and Future Directions in the Prevention of Acute and Chronic Diabetes–Related Complications (Includes Livestream)*
*Room: W307*

Co-Chairs: Christopher S. Holliday, PhD, MPH, MA, FACHE and Steven E. Kahn, MB, ChB

3:45 p.m.-4:05 p.m.  *Trends and Inequalities in Diabetes–Related Complications among U.S. Adults with Diabetes, 2000–2020*
   Ryan Saelee, MPH, PhD

4:05 p.m.-4:25 p.m.  *Ameliorating Care Fragmentation to Prevent Diabetes–Related Microvascular Complications*
   Francisco J. Pasquel, MD, MPH

4:25 p.m.-4:45 p.m.  *Advancing Cardiometabolic Health and Reducing Cardiovascular Risk in Diabetes through Academic–Community–Government–Industry Partnerships*
   Joshua J. Joseph, MD, MPH, FAHA

4:45 p.m.-4:55 p.m.  *Discussant*
   Shivani A. Patel, PhD

4:55 p.m.-5:15 p.m.  *Question and Discussion Period*

**Symposium**
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*
*Session Number: BM-SY05-1.5*
*Consensus or Controversy? Hot Topics in Nutrition 2024*
*Room: W314*

Chair: Holly J. Willis, PhD, RDN, CDCES

3:45 p.m.-4:05 p.m.  *The WHO Said WHAT? Use of Nonnutritive Sweeteners for Weight Management, Prediabetes, and Diabetes*
   Katherine Appleton, PhD, RNutr

4:05 p.m.-4:25 p.m.  *Does the Gut Rule? Influence of the Microbiome on Diabetes and Obesity*
   Abby Johnson, PhD, RD

4:25 p.m.-4:45 p.m.  *Counting Calories or Counting the Hours—Time-Restricted Eating*
   Krista Varaday, PhD

4:45 p.m.-5:05 p.m.  *Protein Quantity, Quality, and Timing for Weight Management and Glycemia*
   Alpana Shukla, MD

5:05 p.m.-5:15 p.m.  *Question and Discussion Period*
3:45 p.m.-5:15 p.m. (continued)

Case Studies
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-CS12-1.5
New Tools, Old Approaches—Rethinking Glucose Monitoring in Real-Life Settings
Room: W311
Chair: Natalie J. Bellini, DNP, FNP-BC, BC-ADM
3:45 p.m.-4:05 p.m. The Time Was Yesterday—Continuous Glucose Monitoring (CGM) in the Inpatient Setting
   Eileen R. Faulds, PhD, RN, FNP-BC, CDCES
4:05 p.m.-4:25 p.m. Classroom or Clinic? Continuous Glucose Monitoring (CGM) in the School Setting
   Christine March, MD, MS
4:25 p.m.-4:45 p.m. Let Campers (and Counselors) Sleep! Remote Glucose Monitoring at Camp
   Jamie R. Wood, MD
4:45 p.m.-5:05 p.m. Continuous Glucose Monitoring (CGM) in Long-Term Care Facilities
   Medha Munshi, MD
5:05 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY08-1.5
Important Safety Information—Off-Target Effects of New Therapies for Diabetes (Includes Livestream)
Room: W414
Chair: John B. Buse, MD, PhD
3:45 p.m.-4:05 p.m. GLP-1 Receptor Agonists
   Tina Vilsbøll, MD, DMSc
4:05 p.m.-4:25 p.m. SGLT2 Inhibitors
   Ronald M. Goldenberg, MD, FRCPC, FACE
4:25 p.m.-4:45 p.m. New Insulin Formulations
   Anne L. Peters, MD
4:45 p.m.-5:05 p.m. Fixed-Ratio Insulin Combinations
   Liana K. Billings, MD, MMSc
5:05 p.m.-5:15 p.m. Question and Discussion Period
Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY33-1.5
Standards of Care 2024 Updates and Cost of Diabetes in United States
Room: W315
Chair: Nuha El Sayed, MD, MMSc
3:45 p.m.-4:30 p.m. Team-Based Care
   Nuha El Sayed, MD, MMSc
   Jason L. Gaglia, MD, MMSc
   Grazia Aleppo, MD, FACE, FACP
   Dennis Bruegger, MD, PhD
   Ildiko Lingvay, MD, MPH, MSCS
   Nicola Napoli, MD, PhD
4:30 p.m.-4:45 p.m. Economic Costs of Diabetes in the United States
   Nuha El Sayed, MD, MMSc
   Raveendhara Bannuru, MD, PhD, FAGE
4:45 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY49-1.5
SURMOUNT-OSA Trial Results and Potential Role of Tirzepatide in Treating Obesity-Related Obstructive Sleep Apnea (Includes Livestream)
Room: W320 (Chapin Theater)
Co-Chairs: Ania M. Jastreboff, MD, PhD and Atul Malhotra, MD
3:45 p.m.-4:00 p.m. Cardiometabolic Consequences of OSA—Towards Personalized Treatment
   Esra Tasali, MD
4:00 p.m.-4:15 p.m. Current Therapeutic Landscape for Treating Sleep Apnea and Potential Role of Incretins
   Vaishnavi Kundel, MD, MS
4:15 p.m.-4:25 p.m. Tirzepatide and SURMOUNT-OSA—Rationale, Hypotheses, and Study Design
   Richard J. Schwab, MD
4:25 p.m.-4:45 p.m. SURMOUNT-OSA—Efficacy and Safety
   Atul Malhotra, MD
4:45 p.m.-4:55 p.m. Putting SURMOUNT-OSA Results in Context, and Implications Regarding Treatment of Patients with Obesity-Related OSA
   Louis J. Aronne, MD, FACP, DABOM
4:55 p.m.-5:15 p.m. Question and Discussion Period
3:45 p.m.-5:15 p.m. (continued)

Symposium
Theme Area: Epidemiology/Genetics
Session Number: EG-SY02-1.5
United States Veterans and Diabetes—Not Gone and Not Forgotten
Room: W207
Chair: Dina H. Griauzde, MD, MSc
3:45 p.m.-4:05 p.m. Diabetes and Complications in Veterans
   Elizabeth M. Litkowski, PhD
4:05 p.m.-4:25 p.m. Mental Health and Diabetes in Veterans
   Naomi Kane, PhD
4:25 p.m.-4:45 p.m. Million Veterans Program
   Themistocles (Tim) Assimes, MD, PhD
4:45 p.m.-5:05 p.m. Telehealth Interventions to Improve Outcomes in Veterans with Diabetes
   Matthew J. Crowley, MD, MHS
5:05 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-SY05-1.5
Joint ADA/IPITA Symposium—Clinical Beta-Cell Replacement Therapy Today (Includes Livestream)
Room: W415B (Valencia Ballroom)
Co-Chairs: Michael R. Rickels, MD, MS and Melena Bellin, MD
3:45 p.m.-4:05 p.m. Evaluation of the Patient with Diabetes for Beta-Cell Replacement
   Anna Lam, MD, MSc
4:05 p.m.-4:25 p.m. The Psychological Impact of Islet or Pancreas Transplantation
   Jane Speight, MSc, PhD, CPsychol, FBPsS
4:25 p.m.-4:45 p.m. Monitoring and Treatment of Recipients for Rejection or Type 1 Diabetes Recurrence
   Michiel Nijhoff, MD, MSc
4:45 p.m.-5:05 p.m. Update on Clinical Trials Using Stem-Cell Replacement
   Piotr Witkowski, MD, PhD
5:05 p.m.-5:15 p.m. Question and Discussion Period
FRIDAY, JUNE 21, 2024

3:45 p.m.-5:15 p.m.
(continued)

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-SY03-1.5
The Second Act—Redefining the Signaling Mediators of Glucose Uptake in Muscle
Room: W304 A-D
Chair: Paul M. Titchenell, PhD
3:45 p.m.-4:05 p.m. Control of Glucose Transport by Novel Insulin-Signaling Pathways
Lykke Sylow, PhD
4:05 p.m.-4:25 p.m. Control of Muscle Glucose Metabolism by the Adipokine Isthmin-1
Katrin Svensson, PhD
4:25 p.m.-4:45 p.m. Linking Mitochondrial Energetics to Insulin Sensitivity and Glucose Metabolism
P. Darrell Neufer, PhD
4:45 p.m.-5:05 p.m. Regulation of GLUT4 by TUG Proteins
Jonathan Bogan, MD
5:05 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Obesity/Integrated Physiology
Session Number: IP-SY07-1.5
CNS Effects of GLP-1RA—Beyond Diabetes and Obesity
Room: W304 E-H
Chair: Janice J. Hwang, MD
3:45 p.m.-4:15 p.m. GLP-1RA in Alcohol Use Disorder
Lorenzo Leggio, MD, PhD
4:15 p.m.-4:45 p.m. GLP-1RA and Thirst
Derek Daniels, PhD
4:45 p.m.-5:15 p.m. GLP-1 Actions on Neurodegeneration and Neuroinflammation
Nigel H. Greig, PhD

Symposium
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-SY02-1.5
Taking a Closer Look—Subcellular Approaches to Islet Biology
Room: W206
Chair: Rafael Arrojo e Drigo, PhD
3:45 p.m.-4:15 p.m. Contributions of the Microtubule Cytoskeleton to Beta-Cell Biology
Irina Kaverina, PhD
4:15 p.m.-4:45 p.m. Cilia, Microvilli, and Membrane Localized Glycolysis in The Beta Cell
Matthew J. Merrins, PhD
4:45 p.m.-5:15 p.m. Metabolic Control of Beta-Cell Secretory Capacity
Samuel B. Stephens, PhD
3:45 p.m.–5:15 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR10-1.5
Beyond Glucose and Weight Reduction—Additional Effects of Incretin-Based Therapies
Room: W415C (Valencia Ballroom)
Chair: Michael A. Nauck, MD

3:45 p.m.–4:00 p.m.
116-OR GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice
Presenting Author: Rajamannar Thennati, PhD

4:00 p.m.–4:15 p.m.
117-OR Effects of Triple-Hormone Receptor Agonist Retatrutide on Lipid Profiling in Participants with Obesity
Presenting Author: Valentina Pirro, PhD

4:15 p.m.–4:30 p.m.
118-OR The Apelin Receptor Agonist Azelaprag Increases Weight Loss in Diet-Induced Obese Mice on Incretin Agonists and Restores Body Composition and Muscle Function to That of Lean Controls
Presenting Author: Paul Rubin, MD

4:30 p.m.–4:45 p.m.
119-OR Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Ultra-Long-Acting GLP-1 Receptor Agonist (ZT002) in Healthy Subjects
Presenting Author: Yuanyuan Zhang, PhD

4:45 p.m.–5:00 p.m.
120–OR Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT–2
Presenting Author: Naveed Sattar, MD, PhD

5:00 p.m.–5:15 p.m.
121–OR Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study
Presenting Author: Rajamannar Thennati, PhD
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m.

Debate

Theme Area: Acute and Chronic Complications
Session Number: AC-DB05-1
Sulfonylureas in Type 2 Diabetes Management—Should They Stay or Should They Go? (Includes Livestream)
Room: W307
Chair: Rozalina G. McCoy, MD, MS
5:30 p.m.-5:45 p.m. Sulfonylureas Remain Useful Agents in the Management of Type 2 Diabetes
   Elbert S. Huang, MD, MPH, FACP
5:45 p.m.-6:00 p.m. We Need to Stop Using Sulfonylureas for the Treatment of Type 2 Diabetes
   Deborah J. Wexler, MD, MSc
6:00 p.m.-6:05 p.m. Rebuttal
   Elbert S. Huang, MD, MPH, FACP
6:05 p.m.-6:10 p.m. Rebuttal
   Deborah J. Wexler, MD, MSc
6:10 p.m.-6:30 p.m. Question and Discussion Period

Symposium

Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY35-1
Liver Health in Diabetes (Includes Livestream)
Room: W320 (Chapin Theater)
Co-Chairs: Mandeep Bajaj, MD and Kenneth Cusi, MD
5:30 p.m.-5:40 p.m. Introduction, New Nomenclature and Team-Based Care
   Mandeep Bajaj, MD
   Kenneth Cusi, MD
5:40 p.m.-5:50 p.m. Epidemiology/Hepatology
   Zobair Younossi, MD, MPH
5:50 p.m.-6:00 p.m. Primary Care
   Caroline R. Richardson, MD
6:00 p.m.-6:05 p.m. Nutrition
   Karen Corbin, PhD, RD
6:05 p.m.-6:10 p.m. Physical Activity and Exercise
   Elizabeth J. Pekas, PhD
6:10 p.m.-6:20 p.m. Endocrinology and Obesity
   Michael Roden, MD
6:20 p.m-6:30 p.m. Question and Discussion Period
5:30 p.m.–6:30 p.m. (continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR07-1

New Biomarkers to Inform Lipid Therapies in Diabetes (With ADA Presidents' Select Abstract Presentation)
Room: W206
Chair: Laura den Hartigh, PhD

5:30 p.m.–5:45 p.m.
122-OR ADA Presidents’ Select Abstract: Lower Plasma Levels of Truncated Apolipoprotein C-II Are Associated with Increased Risk of Diabetes Multiethnic Study of Atherosclerosis
Presenting Author: Juraj Koska, MD, PhD

5:45 p.m.–6:00 p.m.
123-OR MiR103 as a Potential Inhibitor for Dyslipidemia through Modulation of ANGPTL8 Level
Presenting Author: Jehad Abubaker, PhD

6:00 p.m.–6:15 p.m.
124-OR Intervention of Select Lipid Signaling Reduces Type 1 Diabetes Incidence
Presenting Author: Sasanka Ramanadham, PhD

6:15 p.m.–6:30 p.m.
125-OR New Lipid Biomarkers for Worsening Glucose Tolerance in Nondiabetic Relatives of People with Type 2 Diabetes
Presenting Author: Ismail Syed, MS, PhD
5:30 p.m.-6:30 p.m. (continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR14-1
Unraveling Molecular Signatures, Biomarkers, and Methods for Neuropathy, Cognitive Decline, and Foot Ulcers
Room: W208
Chair: Rayaz A. Malik, MD, PhD

5:30 p.m.-5:45 p.m.
126-OR Differences of Three-Dimensional Pathology of Dorsal Root Ganglia in Neuropathy of Type 1 and Type 2 Diabetes Mellitus
Presenting Author: Hiroki Mizukami, MD, PhD

5:45 p.m.-6:00 p.m.
127-OR Identification of Exosomal miRNA as a Novel Causal Biomarker for Cognitive Impairment in Type 2 Diabetes Mellitus—Triangulating Evidence from Mendelian Randomization Analyses and Multicenter Cohort
Presenting Author: Sijue Yang, PhD Candidate

6:00 p.m.-6:15 p.m.
128-OR Investigating C-Fiber Activity Using Depolarizing Stimuli Provides Insight into the Natural Course of Diabetic Polyneuropathy
Presenting Author: Zoltan Kender, MD, PhD

6:15 p.m.-6:30 p.m.
129-OR Increased Triglyceride Levels Are Associated with a Distinct Lipid-Associated Protein Biomarker Profile of Diabetic Foot Ulcers
Presenting Author: Marija Petkovic, PhD
Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR05-1
Medical Nutrition Therapy—Moving Beyond Traditional Outcome Measures
Room: W314
Chair: Gretchen Benson, RDN, CDCES

5:30 p.m.-5:45 p.m.
130-OR Mediterranean Diet and Gestational Diabetes—What Is the Role of Exposure to Persistent Organic Pollutants
Presenting Author: Guoqi Yu, PhD

5:45 p.m.-6:00 p.m.
131-OR A Multiomics Study of Individual Responses to Long-Term Mediterranean Diet Interventions in the DIRECT-PLUS Trial
Presenting Author: Danyue Dong, PhD

6:00 p.m.-6:15 p.m.
132-OR Structured Medical Nutrition Therapy Improves Glycemia, Reduces Percentage Body Fat while Maintaining Fat-Free Mass in Individuals with Overweight/Obesity and Type 2 Diabetes
Presenting Author: Adham Mottalib, MD

6:15 p.m.-6:30 p.m.
133-OR Efficacy of a Culturally Tailored Mediterranean-Like Diet Intervention on Cardiometabolic Risk Factors
Presenting Author: Josiemer Mattei, PhD, MPH
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m.
(continued)

Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR07-1
Innovative Diabetes Self-Management Education across Diverse Populations
Room: W308
Chair: Rebecca Longo, MSN, ACNP-BC, CDCES

5:30 p.m.-5:45 p.m.
134-OR The Safety and Efficacy of Virtual Insulin Pump Initiation in Children and Adolescents with Type 1 Diabetes in the United States
Presenting Author: Margaret Pellizzari, MBA, MS, RN, CDCES, CPT, FADCES

5:45 p.m.-6:00 p.m.
135-OR UNABLE TO ATTEND

6:00 p.m.-6:15 p.m.
136-OR Examining New-Onset Type 1 Diabetes Educational Practices among Centers in the T1D Exchange Quality Improvement Collaborative (T1DX-QI)
Presenting Author: Ryan McDonough, DO

6:15 p.m.-6:30 p.m.
137-OR Outcomes of Real-World Deployment of the Dulce Digital Texting Education Platform for Low-Income Diverse Populations with Diabetes
Presenting Author: Monica Ruiz, MA
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR12-1
SGLT2 Inhibition Impact on Human Physiology
Room: W415C (Valencia Ballroom)
Chair: Hiddo L. Heerspink, PhD

5:30 p.m.-5:45 p.m.
138-OR Pioglitazone Amplifies the Decrease in HbA1c and Prevents the Increase in Plasma Ketone Caused by Dapagliflozin in Type 1 Diabetes Mellitus Patients
Presenting Author: Gozde Baskoy, MD

5:45 p.m.-6:00 p.m.
139-OR Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate—A Randomized Trial
Presenting Author: Siham Abdelgani, MD

6:00 p.m.-6:15 p.m.
140-OR The Coronary Flow Reserve Increase after Dapagliflozin Treatment in Patients with Type 2 Diabetes Is Maintained after Four Years—A Four-Year DAPAHEART Follow-up Study
Presenting Author: Cassandra Morciano, MD

6:15 p.m.-6:30 p.m.
141-OR Cardioprotective Effect of Empagliflozin and Modification of Sirtuins and Their Noncoding RNAs Regulators in Patients with Myocardial Infarction
Presenting Author: Anna Nowak, MD
Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR17-1
New Technology—Equity and Access
Room: W315
Chair: Priya Prahalad, MD, PhD

5:30 p.m.-5:45 p.m.
142-OR A1C and Average Glucose Discordance—Personalized A1C Improves the Discrepancy, Particularly in Black Individuals
Presenting Author: Ramzi Ajjan, MD, PhD, FRCP, MMedSci

5:45 p.m.-6:00 p.m.
143-OR A1C Change after Initiating Continuous Glucose Monitoring (CGM) for People with Diabetes in a Large U.S. Managed Health Care Plan
Presenting Author: Gregory J. Norman, PhD

6:00 p.m.-6:15 p.m.
144-OR A Randomized Clinical Trial of Automated Insulin Delivery in Elderly with Type 1 Diabetes
Presenting Author: Yogish C. Kudva, MD

6:15 p.m.-6:30 p.m.
145-OR Assessing the Current State of Diabetes Care in Long-Term Facilities Using Continuous Glucose Monitoring
Presenting Author: Medha Munshi, MD
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m.  
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR18-1
Pediatric Obesity and Type 2 Diabetes
Room: W311
Chair: Fida Bacha, MD, FAAP

5:30 p.m.-5:45 p.m.
146-OR  Clustering Pediatric Type 2 Diabetes Patients Exposes Differential Responses to Therapeutic Interventions
Presenting Author: Raymond J. Kreienkamp, MD, PhD

5:45 p.m.-6:00 p.m.
147-OR  Obesity Is Associated with Increased Clearance and Reduced Drug Exposure to Metformin in Youth with Type 2 Diabetes
Presenting Author: Shylaja Srinivasan, MD, MAS

6:00 p.m.-6:15 p.m.
148-OR  Increased Insulin Secretion and Decreased Insulin Sensitivity in South Asian Youth without Diabetes
Presenting Author: Sheela N. Magge, MD, MSCE

6:15 p.m.-6:30 p.m.
149-OR  Liver Health in Adolescents with Youth-Onset Type 2 Diabetes
Presenting Author: Amy S. Shah, MD, MS
5:30 p.m.-6:30 p.m.  
(continued)

Oral Presentations  
*Theme Area: Epidemiology/Genetics*  
*Session Number: EG-OR03-1*

**The New Frontier in Risk Profiling for Diabetes—Blood, Guts, and Glory**  
Room: W207  
Chair: Sagar B. Dugani, MD, PhD, MPH

5:30 p.m.-5:45 p.m.  
150-OR  
**Gut Microbial Metabolism of Bile Acids, Mediterranean Diet and Cardiometabolic Risk in the DIRECT-PLUS Trial**  
Presenting Author: Peipei Gao, MSc

5:45 p.m.-6:00 p.m.  
151-OR  
**Metabolomics Profiles Underlying Development of Microvascular Complications in the Diabetes Prevention Project Outcome Study (DPPOS)**  
Presenting Author: Wei Perng, PhD, MPH

6:00 p.m.-6:15 p.m.  
152-OR  
**Sex Differences in Metabolomics and Risk of Coronary Heart Disease in Type 2 Diabetes**  
Presenting Author: Yilin Yoshida, PhD, MPH

6:15 p.m.-6:30 p.m.  
153-OR  
**Gut Microbiota, Blood Metabolome, and Incident Type 2 Diabetes in U.S. Hispanics**  
Presenting Author: Kai Luo, PhD
5:30 p.m. - 6:30 p.m.
(continued)

Oral Presentations
Theme Area: Epidemiology/Genetics
Session Number: EG-OR06-1
Type 1 Diabetes Genome, Epigenome, and CRISPR Screens (Includes Livestream)
Room: W414
Chair: Catherine C. Robertson, PhD

5:30 p.m. - 5:45 p.m.
154-OR Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention
Presenting Author: Lu You, PhD

5:45 p.m. - 6:00 p.m.
155-OR Genetic Variation and Time to Progression in TN10 (Teplizumab)
Presenting Author: Dominika A. Michalek, BS, MS

6:00 p.m. - 6:15 p.m.
156-OR Genome-Wide CRISPR Screen Identified That Alternative Splicing Regulates in Insulin Secretion
Presenting Author: Siying Wei, PhD

6:15 p.m. - 6:30 p.m.
157-OR Epigenome-Wide Discovery of the Maternal Effect in Type 1 Diabetes Risk
Presenting Author: Randi K. Johnson, MPH, PhD
5:30 p.m.-6:30 p.m.  
(continued)

Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-OR06-1
Clinical Efforts to Study the Pathogenesis of Insulin Resistance
Room: W304 E-H
Chair: Daniel F. Vatner, MD, PhD

5:30 p.m.-5:45 p.m.
158-OR Relationship between Obesity, Sarcopenia, and Insulin Resistance in Older Adults
Presenting Author: Ali A. Rizvi, MD

5:45 p.m.-6:00 p.m.
159-OR Sequential Measurements of Insulin Resistance in the Assessment of Individuals Participating In Diabetes Prevention Programs
Presenting Author: Michael J. McPhaul, MD

6:00 p.m.-6:15 p.m.
160-OR PI3K Inhibition with Single-Dose Alpelisib as a Model of Insulin Resistance in Healthy Adults
Presenting Author: Joshua R. Cook, MD, PhD

6:15 p.m.-6:30 p.m.
161-OR Type A Insulin Resistance Can Be Misdiagnosed as Type 1 or Type 2 Diabetes—A Cautionary Tale
Presenting Author: Kaci Wirthwein, BA
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m.  
(continued)

Oral Presentations  
Theme Area: Immunology/Beta-Cell Replacement  
Session Number: IBC-OR03-1  
Immune and Adipose Tissue Intersection  
Room: W304 A-D  
Chair: Clive Wasserfall, MS, PhD

5:30 p.m.-5:45 p.m.  
162-OR Sustained TNF-α Transcription Triggered in Obesity through H3K9/K18 Acetylation Is Associated with Metabolic Impairments  
Presenting Author: Rasheed Ahmad, PhD

5:45 p.m.-6:00 p.m.  
163-OR RNAseq Analysis Reveals Temporal Dynamics of Colonic Immune Response to High-Fat Diet in Mice  
Presenting Author: Lena Keller, MS, PhD Student

6:00 p.m.-6:15 p.m.  
164-OR UNABLE TO ATTEND

6:15 p.m.-6:30 p.m.  
165-OR Lipid Signaling in Macrophages Contributes to Inflammatory Transcriptome in Immune Cells  
Presenting Author: Abdulaziz Almutairi, MS
5:30 p.m.-6:30 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Islet Biology/Insulin Secretion*  
*Session Number: IB-OR05-1*  
**Islet Potpourri Oral Abstracts (Includes Livestream)**  
Room: W415B (Valencia Ballroom)  
Chair: Barak Blum, PhD

5:30 p.m.-5:45 p.m.  
166-OR  
**The Alpha–Catenin–Cholesterol Biosynthesis Axis Regulates Tight Junction Formation in Pancreatic Islets**  
Presenting Author: Wilma Tixi, PhD

5:45 p.m.-6:00 p.m.  
167-OR  
**Targeting Alpha Cells to Treat Hypoglycemia in Type 1 Diabetes**  
Presenting Author: Julia Panzer, PhD

6:00 p.m.-6:15 p.m.  
168-OR  
**Perilipin 2 Regulates Fatty Acid Trafficking to Mitochondria through Microlipophagy in Beta Cells**  
Presenting Author: Siming Liu, MD, PhD

6:15 p.m.-6:30 p.m.  
169-OR  
**LC3+ Extracellular Vesicles (EVs) Are Associated with Altered β-Cell Autophagy, Islet Inflammation, and Diabetes**  
Presenting Author: Jerry Xu, PhD
American Diabetes Association Networking Reception

Exhibit Hall (West A1-A3)
### Symposium

**Theme Area: Acute and Chronic Complications**

**Session Number: AC-SY09-1.5**

**SELECT Trial—New Looks at Glycemia, Inflammation, and Heart Failure (Includes Livestream)**

Room: W415B (Valencia Ballroom)

Chair: Darren K. McGuire, MD, MHSc, FAHA, FACC, FESC

- **8:00 a.m.-8:20 a.m.** *SELECT—An Overview of the Study and the Weight Outcomes*
  - Donna H. Ryan, MD
- **8:20 p.m.-8:40 p.m.** *Semaglutide and Prediabetes Progression/Regression in People with Vascular Disease—What Have We Learned from SELECT?*
  - Steven E. Kahn, MB, ChB
- **8:40 a.m.-9:00 a.m.** *Role of Glycemia on Cardiovascular Outcomes—New Data from SELECT*
  - Ildiko Lingvay, MD, MPH, MSCS
- **9:00 a.m.-9:20 a.m.** *Heart Failure and Inflammation Outcomes in SELECT*
  - Jorge Plutzky, MD
- **9:20 a.m.-9:30 a.m.** *Discussant*
  - Shivani Misra, MD, PhD

### Symposium

**Theme Area: Acute and Chronic Complications**

**Session Number: AC-SY12-1.5**

**Navigating the Spatial Landscape—Omics in Diabetic Kidney Disease**

Room: W208

Chair: Jennifer A. Schaub, MD

- **8:00 a.m.-8:30 a.m.** *Mapping the Transcriptomic Universe—Spatial Transcriptomics in Deciphering Diabetic Nephropathy*
  - Parker C. Wilson, MD, PhD
- **8:30 a.m.-9:00 a.m.** *Metabolites in 3D—How Spatial Metabolomics Revolutionizes Our Understanding of Diabetic Kidney Disease*
  - Kumar Sharma, MD
- **9:00 a.m.-9:30 a.m.** *A Deeper Look at Proteins—Spatial Proteomics in Diabetic Kidney Pathogenesis*
  - Victor Puelles, MD, PhD

### Symposium

**Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise**

**Session Number: BM-SY13-1.5**

**Type 2 Diabetes and Exercise—Where Do We Stand?**

Room: W314

Chair: Judith G. Regensteiner, PhD

- **8:00 a.m.-8:30 a.m.** *Incretin-Based Pharmacotherapy, (Osteo)sarcopenia, and Exercise*
  - Samuel Klein, MD
- **8:30 a.m.-9:00 a.m.** *It’s About Time—The Interaction of Exercise and Meal Timing*
  - Melissa Erickson, PhD
- **9:00 a.m.-9:30 a.m.** *Maintaining Muscle Mass and Metabolic Health—Resistance Exercise in Type 2 Diabetes*
  - Ronald J. Sigal, MD, MPH, FRCPC
SATURDAY, JUNE 22, 2024

8:00 a.m.-9:30 a.m. (continued)

**Session Type: Symposium**

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

Session Number: BM-SY14-1.5

**NIDDK Early Career Investigator Symposium—Leveraging Social Support to Improve Diabetes Self-Management and Health Outcomes—Innovative Methods and Interventions**

Room: W311

Co-Chairs: Maureen Monaghan Center, PhD and Miranda Broadney, MD, MPH

8:00 a.m.-8:05 a.m. *Welcome Remarks from the NIDDK Director*

Griffin Rodgers, MD, MACP

8:05 a.m.-8:20 a.m. *You're Not the Boss of Me!—Innovative Methods and Analyses to Assess the Impact of Caregivers on Diabetes Management and Psychosocial Outcomes of Adolescents with Diabetes*

Daniel R. Tilden, MD, MPH

8:20 a.m.-8:35 a.m. *Innovative Methods and Analyses to Assess the Impact of Supportive Others on Diabetes Self-Management and Outcomes—Evaluation of Social Support and Social Networks in Rural-Dwelling Older Adults with Type 2 Diabetes*

Brittany L. Smalls, PhD, MHSA, MSHPsych

8:35 a.m.-8:50 a.m. *Interventions Leveraging Social Support to Improve Diabetes Self-Management and Outcomes—Adaptation and Tailoring of a Type 1 Diabetes Education and Support (T1DES) Intervention to Improve Diabetes Distress among Black Young Adults*

Teaniese L. Davis, PhD

8:50 a.m.-9:05 a.m. *Leveraging Social Support to Improve Diabetes Self-Management and Outcomes—Mobile Health Interventions for Adults with Type 2 Diabetes and Support Persons*

Lindsay S. Mayberry, PhD

9:05 a.m.-9:30 a.m. *Panel—Question and Discussion Period*

---

**Symposium**

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

Session Number: BM-SY15-1.5

**ADA Education Recognition Program (ERP)—Diversifying Diabetes Self-Management Education and Support (DSMES) Delivery Models**

Room: W304 A-D

Chair: Gene Arnold, MS, RD, LD, CDE

8:00 a.m.-8:15 a.m. *Aligning Therapeutic Education with DSMES*

Zoltan Pataky, MD

8:15 a.m.-8:30 a.m. *Improving Diabetes Management in the Elderly—DSMES in Home Health*

Kyle Lavergne, DNP

8:30 a.m.-8:45 a.m. *Operationalizing Delivery of DSMES in Home Health*

Rena' Thompson, RN, WTA, CDCES

8:45 a.m.-9:00 a.m. *Providing DSMES within Blue Cross and Blue Shield*

Linda Roberto, RN

9:00 a.m.-9:15 a.m. *Innovative Approaches to State-Funded Delivery of DSMES at Scale*

Gene Arnold, MS, RD, LD, CDCES

9:15 a.m.-9:30 a.m. *Question and Discussion Period*
8:00 a.m.-9:30 a.m.  
(continued)

Panel  
Theme Area: Clinical Diabetes/Therapeutics  
Session Number: CT-PN06-1.5  
**Newly-Diagnosed Type 2 Diabetes—What Should Be the Focus of Management in 2024?**  
*Includes Livestream*  
Room: W307  
Chair: Ravi Retnakaran, MD, FRCPC  
8:00 a.m.-8:15 a.m.  *Treat Obesity First!*  
Ania M. Jastreboff, MD, PhD  
8:15 a.m.-8:30 a.m.  *Prevent Future Complications!*  
Roopa Mehta, MD, PhD  
8:30 a.m.-8:45 a.m.  *Achieve Remission!*  
Roy Taylor, MD  
8:45 a.m.-9:00 a.m.  *It’s Still about Glucose, Until Proven Otherwise*  
David M. Nathan, MD  
9:00 a.m.-9:30 a.m.  *Panel Discussion*

Panel  
Theme Area: Clinical Diabetes/Therapeutics  
Session Number: CT-PN16-1.5  
**The Role of the Interdisciplinary Team in Technology Onboarding in Primary Care**  
Room: W415C (Valencia Ballroom)  
Chair: Richard M. Bergenstal, MD  
8:00 a.m.-8:20 a.m.  *Is Primary Care the Best Place for Continuous Glucose Monitoring (CGM) Initiation?*  
Eden Miller, DO  
8:20 a.m.-8:40 a.m.  *What Is the Role of Primary Care Practices in Automated Insulin Delivery?*  
Sean Oser, MD, MPH  
8:40 a.m.-9:00 a.m.  *Diabetes Care and Education Specialists as Technology Champions*  
Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM  
9:00 a.m.-9:20 a.m.  *Patient Perspective*  
Zachary Jones  
9:20 a.m.-9:30 a.m.  *Question and Discussion Period*
8:00 a.m.-9:30 a.m.
(continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY23-1.5
Navigating the Early Phases of Pediatric Type 1 Diabetes
Room: W315
Chair: Stephen E. Gitelman, MD
8:00 a.m.-8:20 a.m. Patient Perspective
Amanda Twigg, MD
8:20 a.m.-8:40 a.m. Pediatric Type 1 Diabetes Screening Programs
Anette-Gabriele Ziegler, MD
8:40 a.m.-9:00 a.m. Continuous Glucose Monitoring (CGM) and Early Stage Type 1 Diabetes
Andrea Steck, MD
9:00 a.m.-9:20 a.m. The Economics of Early-Stage Type 1 Diabetes Detection and Treatment
R. Brett McQueen, PhD
9:20 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY27-1.5
ADA Diabetes Care Symposium—The Final Frontier—Implementing the Learning from Implementation Science
Room: W308
Chair: John B. Buse, MD, PhD
8:00 a.m.-8:20 a.m. Diabetes Prevention—What Do We Know Now That We Didn't Know 20 Years Ago?
Brian Oldenburg, MPsy chol, PhD
8:20 a.m.-8:40 a.m. Using Telehealth to Improve Diabetes Control in Real-World Practice
Matthew J. Crowley, MD, MHS
8:40 a.m.-9:00 a.m. Multifactorial Cardiovascular Risk Reduction—The COORDINATE-Diabetes Implementation Example
Jennifer B. Green, MD
9:00 a.m.-9:20 a.m. Commentary and Future Direction
Nisa M. Maruthur, MD, MHS
9:20 a.m.-9:30 a.m. Question and Discussion Period
8:00 a.m.-9:30 a.m.  
(continued)

Panel  
Theme Area: Epidemiology/Genetics  
Session Number: EG-PN05-1.5  
Diabetes Genome-Wide Association Study—Why Keep Going?  
Room: W207  
Chair: Cassandra N. Spracklen, PhD  
8:00 a.m.-8:20 a.m.  Type 1 Diabetes Multiancestry Genome-Wide Association Study  
   Stephen S. Rich, PhD, FAHA  
8:20 a.m.-8:40 a.m.  Type 2 Diabetes Global Genetics Initiative  
   Eleftheria Zeggini, PhD  
8:40 a.m.-9:00 a.m.  Type 2 Diabetes Genome-Wide Association Study Cluster Partitioning  
   Miriam Udler, MD, PhD  
9:00 a.m.-9:20 a.m.  Type 2 Diabetes Genome-Wide Association Studies in Underrepresented Populations  
   Adebowale A. Adeyemo, MD  
9:20 a.m.-9:30 a.m.  Question and Discussion Period

Symposium  
Theme Area: Immunology/Beta-Cell Replacement  
Session Number: IBC-SY06-1.5  
Clinical Beta-Cell Replacement Therapy in the Near Future (Includes Livestream)  
Room: W414  
Chair: Melena Bellin, MD  
8:00 a.m.-8:20 a.m.  How to Design the Optimal Beta-Cell Surrogate  
   Cristina Nostro, PhD  
8:20 a.m.-8:40 a.m.  Materials to Prevent Immune Rejection  
   Alice A. Tomei, PhD  
8:40 a.m.-9:00 a.m.  Islet Vascularization  
   Appakalai N. Balamurugan, PhD  
9:00 a.m.-9:20 a.m.  Integration of Tools for Monitoring Therapeutic Success  
   Katy Digovich  
9:20 a.m.-9:30 a.m.  Question and Discussion Period
8:00 a.m.-9:30 a.m. (continued)

**Symposium**

*Theme Area: Obesity/Integrated Physiology*

Session Number: IP-SY08-1.5

**Obesity in United States Hispanic/Latino Populations—Challenges and Strategies**

Room: W304 E-H

Chair: Rodolfo J. Galindo, MD

8:00 a.m.-8:20 a.m.  
*Obesity Inequity among Hispanic/Latino Adults and Children in the United States—Drivers and Implications*  
Erica G. Soltero, PhD

8:20 a.m.-8:40 a.m.  
*Metabolic-Dysfunction—Associated Steatotic Liver Disease among Hispanic/Latino Children and Adults*  
Jeffrey Schwimmer, MD

8:40 a.m.-9:00 a.m.  
*Tailoring Obesity Treatments to the United States Hispanic/Latino Population—Success and Challenges*  
Jaime P. Almandoz, MD, MBA, FTOS

9:00 a.m.-9:20 a.m.  
*Neighborhood Determinants of Health and Policy Changes—Lessons Outside the United States*  
Carolina Perez-Ferrer, PhD

9:20 a.m.-9:30 a.m.  
*Question and Discussion Period*

**Symposium**

*Theme Area: Clinical Diabetes/Therapeutics*

Session Number: CT-SY45-1.5

**The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Multiple Daily Insulin Injections in Adults with Type 1 Diabetes—Results of the INHALE-3 Randomized Trial (Includes Livestream)**

Room: W320 (Chapin Theater)

Chair: Roy W. Beck, MD, PhD

8:00 a.m.-8:10 a.m.  
*Inhaled Insulin’s History and Study Rationale*  
Halis K. Akturk, MD

8:10 a.m.-8:20 a.m.  
*Study Methods and Participant Baseline Characteristics*  
Yogish C. Kudva, MD

8:20 a.m.-8:30 a.m.  
*Study Results I—Comparison of Inhaled Insulin vs. Rapid-Acting Analogue Insulin in Users of Automated Insulin Delivery or Multiple Daily Insulin Injections during Standardized In-Clinic Meal Challenges*  
Ruth S. Weinstock, MD, PhD

8:30 a.m.-8:40 a.m.  
*Study Results II—Primary Efficacy, Safety, and Quality of Life Outcomes*  
Carol J. Levy, MD, CDCES

8:40 a.m.-8:50 a.m.  
*Study Results III—Effect of Inhaled Insulin-Degludec Compared with Automated Insulin Delivery and in Subgroups According to Participant Characteristics*  
Grazia Aleppo, MD, FACE, FACP

8:50 a.m.-9:00 a.m.  
*Critique of Study Design and Results*  
Irl B. Hirsch, MD

9:00 a.m.-9:10 a.m.  
*Use of Inhaled Insulin in Clinical Practice*  
Thomas Blevins, MD

9:10 a.m.-9:30 a.m.  
*Question and Discussion Period*
8:00 a.m.-9:30 a.m.
(continued)

Symposium
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-SY05-1.5
The Good, The Bad, and The Ugly of Lipids in the Beta-Cell Microenvironment
Room: W206
Chair: Marc Prentki, PhD

8:00 a.m.-8:30 a.m. Lipoproteins-Induced Beta-Cell Impairment and Impact on the Action of Beta-Cell—Derived Exosomes
Victor García-González, PhD

8:30 a.m.-9:00 a.m. Glucose Metabolism Primes Lipogenesis in the β-cell Through Epigenomic Signaling
Matthew Worthman, PhD

9:00 a.m.-9:30 a.m. Cholesterol Redistribution in Pancreatic Beta-Cells—A Flexible Path to Regulate Insulin Secretion
Carla Perego, PhD
SATURDAY, JUNE 22, 2024

9:45 a.m.-11:15 a.m.

**Special Lectures and Addresses**
Session Number: HCE-01
ADA Chief Executive Officer and Chairman of the Board Fireside Chat; President, Health Care & Education Address; and Outstanding Educator in Diabetes Award Lecture *(Includes Livestream)*
Room: West Hall B3-4 (General Session)

9:45 a.m.-10:10 a.m. *ADA Chief Executive Officer and Chairman of the Board Fireside Chat*
   Charles Henderson
   Rhodes Ritenour, JD

10:10 a.m.-10:13 a.m. *Introduction of President, Health Care & Education Address*
   Robert A. Gabbay, MD, PhD

10:13 a.m.-10:43 a.m. *Lessons Learned—Diabetes Education for One and All*
   Patti Urbanski, MEd, RD, LD, CDCES, FADCES

10:43 a.m.-10:45 a.m. *Introduction of Outstanding Educator Award*
   Patti Urbanski, MEd, RD, LD, CDCES, FADCES

10:45 a.m.-11:15 a.m. *Meeting People Where They Are—Improving Diabetes Care and Outcomes through Education and Collaboration*
   Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

11:30 a.m.-12:30 p.m.

**Professional Interest Group**
*Theme Area: Acute and Chronic Complications*
Session Number: AC-IG02-1
**Discussion on Foot Care—Lower Extremity Complications**
Room: W206
Chair: Laura Shin, DPM, PhD

11:30 a.m.-11:35 a.m. *Introduction*

11:35 a.m.-12:20 p.m. *Current Surgical Techniques in Diabetic Foot/Ankle Reconstruction*
   Patrick R. Burns, DPM

12:20 p.m.-12:30 p.m. *Question and Discussion Period*
11:30 a.m.-12:30 p.m.  
(continued)

Professional Interest Group  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
Session Number: BM-IG02-1  
Discussion on Exercise Physiology—Syncing Up—Exploring the Interplay of Circadian Rhythms and Exercise  
Room: W304 A-D  
Chair: Melissa Erickson, PhD  
11:30 a.m.-11:36 a.m.  *Introduction*  
11:36 a.m.-11:54 a.m.  *Exercise Timing and Metabolic Rhythmicity in Type 2 Diabetes*  
Juleen R. Zierath, PhD  
11:54 a.m.-12:12 p.m.  *Interaction of Circadian System and Physical Activity on Cardiovascular Health*  
Jingyi Qian, PhD  
12:12 p.m.-12:30 p.m.  *Does Timing of Exercise Matter? Time of Day Effects of Physical Activity on Glycemic Outcomes*  
Roeland J.W. Middelbeek, MD, MSc

Professional Interest Group  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
Session Number: BM-IG04-1  
Discussion on Nutritional Sciences and Metabolism—The Science of Ultraprocessed Foods and Impacts on Metabolic Diseases  
Room: W304 E-H  
Chair: Ranee Chatterjee Montgomery, MD, MPH  
11:30 a.m.-11:35 a.m.  *Introduction*  
11:35 a.m.-11:55 a.m.  *Challenges and Opportunities of Ultraprocessed Food Research*  
Lauren E. O’Connor, PhD  
11:55 a.m.-12:15 p.m.  *Ultraprocessed Foods and Chronic Disease Across the Lifespan*  
William Heerman, MD, MPH  
12:15 p.m.-12:30 p.m.  *Question and Discussion Period*

Professional Interest Group  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
Session Number: BM-IG05-1  
Discussion on Women’s Interprofessional Network of the ADA (WIN ADA)—How to Say “No” So You Can Say “Yes”—Optimizing Time Management  
Room: W308  
Chair: Rebecca L. Scalzo, PhD  
11:30 a.m.-11:35 a.m.  *Introduction*  
11:35 a.m.-11:55 a.m.  *How to Say “No” So You Can Say “Yes”—Optimizing Time Management*  
Linda M. DiMeglio, MD, MPH  
11:55 a.m.-12:15 p.m.  *Panel Discussion*  
Jane E. B. Reusch, MD  
Darleen A. Sandoval, PhD  
12:15 p.m.-12:30 p.m.  *Question and Discussion Period*
SATURDAY, JUNE 22, 2024

11:30 a.m.-12:30 p.m.  (continued)

Professional Interest Group
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-IG03-1
Discussion on Diabetes in Youth—Perspectives on Universal Antibody Screening
Room: W207
Co-Chairs: Stuart A. Weinzimer, MD and Persis V. Commissariat, PhD, CDCES
11:30 a.m.-11:35 a.m.  Introduction
11:35 a.m.-11:55 a.m.  Universal Antibody Screening—Pediatric Perspective
Desmond Schatz, MD
11:55 a.m.-12:15 p.m.  Universal Antibody Screening—Behavioral Medicine Perspective
Suzanne B. Johnson, PhD
12:15 p.m.-12:30 p.m.  Question and Discussion Period

Professional Interest Group
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-IG05-1
Discussion on Pregnancy and Reproductive Health—Should Continuous Glucose Monitoring Be Used in Pregnancy Complicated by Gestational Diabetes?
Room: W208
Co-Chairs: Camille E. Powe, MD and Greyne O'Malley, MD
11:30 a.m.-11:35 a.m.  Introduction
11:35 a.m.-11:50 a.m.  Continuous Glucose Monitoring Should Be Used Now in Pregnancy Complicated by Gestational Diabetes
Eleanor M. Scott, BM, BS, MD, FRCP
11:50 a.m.-12:05 p.m.  Continuous Glucose Monitoring Should Not Yet Be Used in Pregnancy Complicated by Gestational Diabetes
Christina M. Scifres, MD
12:05 p.m.-12:10 p.m.  Rebuttal
Eleanor M. Scott, BM, BS, MD, FRCP
12:10 p.m.-12:15 p.m.  Rebuttal
Christina M. Scifres, MD
12:15 p.m.-12:30 p.m.  Question and Discussion Period
**Professional Interest Group**

*Theme Area: Islet Biology/Insulin Secretion*

*Session Number: IB-IG01-1*

**Discussion on Islet Biology, Development, and Function—Right on Target—Strategies to Selectively Regenerate and Protect Beta Cells**

Room: W311

Chair: Jeffrey S. Tessem, PhD

11:30 a.m.-12:30 p.m. (continued)

11:30 a.m.-11:35 a.m.  Introduction

11:35 a.m.-11:50 a.m.  *Islet Cell Targeting Using a ZnT8 Ab for Beta-Cell Mass Imaging and Regeneration*

Dax Fu, PhD

11:50 a.m.-12:05 p.m.  *Nanoparticle Targeting of the Beta Cell*

Nikki L. Farnsworth, PhD

12:05 p.m.-12:20 p.m.  *Zinc Targeting of the Beta Cell*

Wen-Hong Li, PhD

12:20 p.m.-12:30 p.m.  *Question and Discussion Period*

**Professional Development**

*Theme Area: Professional Development*

*Session Number: PD-01-1*

**Creating Talks That Are Talked About—How to Bring Memorability to Your Presentation(s)**

(Includes Livestream)

Room: W307

Chair: Barbara Eichorst, MS, RD, CDCES

11:30 a.m.-12:30 p.m.  *Creating Talks That Are Talked About—How to Bring Memorability To Your Presentation(s)*

Kari Goetz, BFA, MA
11:30 a.m.-12:30 p.m. (continued)

**ePoster Theater**

*Theme Area: Acute and Chronic Complications*

Session Number: ePoster01

(*) **Diabetic Kidney Disease—From Genetic Pathways to Social Determinants**

Room: Exhibit Hall (West A1-A3) ePoster Theater A

Moderator: Laura Pyle, PhD

(*) *Continuing Education Credit Is Not Awarded for this Session.*

11:30 a.m.-11:40 a.m.

396-P  **Consequences of Knockout of the Histone Demethylase KDM6B from Myeloid Cells Are Context Dependent in Diabetic Kidney Disease**

Presenting Author: Lisa Y. Q. Hong, BSc

11:40 a.m.-11:50 a.m.

397-P  **The C/EBPβ-XOR Axis and Genetic Risk for Diabetic Kidney Disease**

Presenting Author: Ilse S. Daehn, PhD

11:50 a.m.-12:00 p.m.

398-P  **Dissecting Adiponectin Receptor Expression in Renal Vasculature and Its Correlation with Insulin Sensitivity in Type 1 Diabetes**

Presenting Author: Kalie L. Tommerdahl, MD

12:00 p.m.-12:10 p.m.

399-P  **Association of Social Determinants of Health with Initiation of Novel Glucose-Lowering Drugs in Patients with Diabetes—A Post Hoc Analysis of the Kidney-CHAMP Trial**

Presenting Author: Linda-Marie U. Lavenburg, DO, MS

12:10 p.m.-12:20 p.m.

400-P  **KidneyIntelX Impact on ADA DKD Prevention Model Metrics**

Presenting Author: Steven Coca, DO, MS
SATURDAY, JUNE 22, 2024

11:30 a.m.—12:30 p.m.  
(continued)

ePoster Theater  
*Theme Area: Epidemiology/Genetics*  
Session Number: ePoster02  
(*) *Diabetes and CVD—Heartbreak in Motion*  
Room: Exhibit Hall (West A1-A3) ePoster Theater B  
Moderator: Janet K. Snell-Bergeon, PhD, MPH

(*) *Continuing Education Credit Is Not Awarded for this Session.*

11:30 a.m.—11:40 a.m.  
1266-P  
The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk  
Presenting Author: Elisabetta Patorno, MD, DrPH

11:40 a.m.—11:50 a.m.  
1366-P  
Cardiovascular Complications (Myocardial Infarction, Stroke, and End-Stage Renal Disease) and Mortality in Youth-Onset Type 1 and Type 2 Diabetes Based on National Health Insurance Service (NHIS) Data  
Presenting Author: Sungeun Kim, Doctor

11:50 a.m.—12:00 p.m.  
1376-P  
Association of Lung Function and Glycemic Control with All-Cause and Cardiovascular Mortality in Persons with Type 2 Diabetes  
Presenting Author: Chia-Ing Li, PhD

1377-P  
WITHDRAWN

12:10 p.m.—12:20 p.m.  
1437-P  
Blood Pressure (BP) Trajectories and 32-Year Cardiovascular Disease (CVD) Incidence in Women and Men with Type 1 Diabetes (T1D)  
Presenting Author: Rachel G. Miller, PhD
SATURDAY, JUNE 22, 2024

12:30 p.m.-1:30 p.m.

ePoster Theater
Theme Area: Clinical Diabetes/Therapeutics
Session Number: ePoster03
(*) Insights into the Treatment, Mechanistic Underpinnings, and Determinants of Outcomes in Pregancies Complicated by Diabetes
Room: Exhibit Hall (West A1-A3) ePoster Theater A
Moderator: Samantha F. Ehrlich, PhD, MPH

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.
1213-P The Effect of Bile Acid–RNA Methylation on Intergenerational Inheritance of Diabetes Mellitus by Microbiota Vertical Transmission
Presenting Author: Qinyuan Xie, PhD

12:40 p.m.-12:50 p.m.
1214-P Prepregnancy Use of Glucagon–Like Peptide 1 Receptor Agonists and Gestational Weight Gain in Type 2 Diabetes
Presenting Author: Jacqueline Maya, MD

12:50 p.m.-1:00 p.m.
1215-P Maternal Glycemia Associations with Cord Blood DNA Methylation in the Hyperglycemia and Adverse Pregnancy Outcome Study
Presenting Author: Monica E. Bianco, MD

1:00 p.m.-1:10 p.m.
1216-P Maternal Obesity and Human Milk Metabolomics—Unraveling the Link to Infant Obesity Risk
Presenting Author: Lewis DeCicco, BS

1:10 p.m.-1:20 p.m.
1217-P Insulin Sensitivity and Insulin Secretion Differentially Affect Birthweight and Postpartum Glucose
Presenting Author: Emily A. Rosenberg, MD
SATURDAY, JUNE 22, 2024

12:30 p.m.-1:30 p.m.
(continued)

ePoster Theater
Theme Area: Clinical Diabetes/Therapeutics
Session Number: ePoster04
(*) Pediatric Research Update—Type 1 Diabetes, Type 2 Diabetes, Obesity
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Sarah A. MacLeish, DO

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.
1161-P Are There Sex Differences in Response to Metabolic/Bariatric Surgery among Adolescents with Severe Obesity?
Presenting Author: Subin Jang, MPH

12:40 p.m.-12:50 p.m.
1162-P Global Burden Attributable to High Body Mass Index in Young Adults from 1990 to 2019, with Projections to 2050
Presenting Author: Jingxuan Wang, BS

12:50 p.m.-1:00 p.m.
1163-P Type 2 Diabetes Remission Persists Ten Years after Adolescent Metabolic and Bariatric Surgery
Presenting Author: Justin R. Ryder, PhD

1:00 p.m.-1:10 p.m.
1164-P Effect of Metformin on Gut Microbial Metabolites in Overweight and Obese Youth with Type 1 Diabetes (T1D)
Presenting Author: Elizabeth R. Flammer, MS

1:10 p.m.-1:20 p.m.
1165-P Untangling the Interactions of Glycemic Control and Obesity on Hypothalamic Gliosis in Youth with Type 1 Diabetes
Presenting Author: Alyssa Huang, MD
SATURDAY, JUNE 22, 2024

12:30 p.m.-1:30 p.m.

Session Break
(Take this opportunity to visit the Exhibit and Poster Halls)

1:30 p.m.-3:00 p.m.

Debate
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-DB15-1.5
Innovation or Access in Diabetes Technology—What Should Be Our Global Priority?
Room: W415C (Valencia Ballroom)
Chair: David M. Maahs, MD, PhD
1:30 p.m-1:50 p.m. Access Should Be Our Top Priority!
Apoorva Gomber, MBBS, MD, MPH
1:50 p.m.-2:10 p.m. Innovation Should Be Our Top Priority!
Rayhan Lal, MD
2:10 p.m.-2:25 p.m. Rebuttal
Apoorva Gomber, MBBS, MD, MPH
2:25 p.m.-2:40 p.m. Rebuttal
Rayhan Lal, MD
2:40 p.m.-3:00 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY30-1.5
ADA Primary Care Council—What Does a Person with Diabetes Need from Their Primary Care Team? (Includes Livestream)
Room: W320 (Chapin Theater)
Chair: Kevin A. Peterson, MD, MPH
1:30 p.m.-3:00 p.m. Team-Based Care
Benjamin M. Bluml, RPh
Sarah Candler, MD, MPH, FACP
Andrea Haynes, MD
Cara Orr, MS, MMS, PA-C
Kimberly D. Broughton-Miller, DNP, APRN, FNP-C, ENP-C, FAANP
Pamela Stamm, PharmD, BCPS, BCACP, CDCES, FASHP, FACCNP
Greg Cohen, DO, FACOFP
SATURDAY, JUNE 22, 2024

1:30 p.m.-3:00 p.m. (continued)

Symposium
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-SY03-1.5
Channeling Mechanisms Underlying Islet Function and Dysfunction *(Includes Livestream)*
Room: W415B (Valencia Ballroom)
Chair: Show-Ling Shyng, PhD

1:30 p.m.-2:00 p.m.  *Impact of Intracellular Calcium Flux on Beta-Cell Insulin Secretion*
   Marjan Slak Rupnik, PhD

2:00 p.m.-2:30 p.m.  *Channeling Euglycemia—TALK-1 Channel Modulation of Islet Hormone Secretion and Glucose Homeostasis*
   David Jacobson, PhD

2:30 p.m.-3:00 p.m.  *Impacts of Swell Channels on Insulin Secretion*
   Rajan Sah, MD, PhD
SATURDAY, JUNE 22, 2024

1:30 p.m.-3:00 p.m.  
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR02-1.5
Cell and Molecular Approaches to Diabetes-Related Foot Complications (With Roger Pecoraro Award Lecture) *(Includes Livestream)*
Room: W307
Chair: Tyler Lawrence Coye, DPM

1:30 p.m.-2:00 p.m.
Roger Pecoraro Award Lecture

*Roger Pecoraro Award Lecture 2024*
Frances L. Game, BSc, MBBCh (Hons), MRCP(UK), MRCPath, FRCP

2:00 p.m.-2:15 p.m.
170-OR Case-Control Study on Whole-Methylome Analysis of Monocytes in Acute Diabetic Charcot Foot—Identifying Differentially Methylated Genes
Presenting Author: Naween Kumar, MD

2:15 p.m.-2:30 p.m.
171-OR Tissue Nanotransfection–Based Endothelial-Targeted Epigenetic Gene Editing In Vivo to Rescue Diabetic Ischemic Wounds
Presenting Author: Kanhaiya Singh, PhD

2:30 p.m.-2:45 p.m.
172-OR Lineage Tracing of Vasculogenic Fibroblasts In Vivo and Their Significance in the Rescue of Diabetic Ischemic Tissue
Presenting Author: Kanhaiya Singh, PhD

2:45 p.m.-3:00 p.m.
173-OR A Clinical Study of Novel Antimicrobial Peptide PL-5 Topical Spray for Mild to Moderate Infectious Wounds of Diabetic Foot
Presenting Author: Li Qian, MD, PhD
SATURDAY, JUNE 22, 2024

1:30 p.m.–3:00 p.m.
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR03-1.5
Hypoglycemia in the Real World—Who’s Really at Risk?
Room: W208
Chair: Michael Bancks, PhD, MPH

1:30 p.m.-1:45 p.m.
174-OR Genetic Variation in GLP-1R Modify the Risk of Hypoglycemia in Response to Intensive Glycemic Control in Adults with Type 2 Diabetes
Presenting Author: Qiaochu Xue, PhD, MPH

1:45 p.m.-2:00 p.m.
175-OR Level 3 Hypoglycemia in Diabetes—An Age-Old but Not (Just) Old-Age Problem (iNPHORM, USA)
Presenting Author: Alexandria Ratzi-Leewing, PhD

2:00 p.m.-2:15 p.m.
176-OR Association between Clustering of Hypoglycemic Symptoms, Psychological Traits, and Problem-Solving Abilities in Adults with Type 1 Diabetes
Presenting Author: Naoki Sakane, MD, PhD

2:15 p.m.-2:30 p.m.
177-OR Time Below Range (TBR) and Its Link to Impaired Awareness of Hypoglycemia (IAH) and Severe Hypoglycemia (SH)—Evidence from the Association of British Clinical Diabetologists (ABCD) Study
Presenting Author: Harshal Deshmukh, MBBB, MPH, MRCP, PhD, CCT

2:30 p.m.-2:45 p.m.
178-OR Assessing Hypoglycemia Awareness—Validating HypoA-Q within the T1D Exchange Registry
Presenting Author: Yu Kei Lin, MD

2:45 p.m.-3:00 p.m.
179-OR Assessing the Impact of Hypoglycemia among People with Diabetes in the U.S. and EU
Presenting Author: Alan Beltran, Bachelor’s Degree
1:30 p.m.-3:00 p.m.  
(continued)

Oral Presentations  
Theme Area: Acute and Chronic Complications  
Session Number: AC-OR08-1.5  
Clinical Biomarkers of ASCVD Risk Progression in Diabetes Mellitus and Metabolic Disease  
Room: W308  
Chair: Om Ganda, MD

1:30 p.m.-1:45 p.m.  
180-OR  Glycemic Markers Are Differentially Associated with Cardiovascular Imaging and Outcomes in Long-Duration Type 1 Diabetes  
Presenting Author: Marc Gregory Yu, MD

1:45 p.m.-2:00 p.m.  
181-OR  Declining eGFR over Time Predicts the Risk of a Composite of Primary or Secondary Major Adverse Cardiovascular Events or Heart Failure Hospitalization, in People with Type 2 Diabetes—EXSCEL Post Hoc analysis  
Presenting Author: Harald Sourij, MD

2:00 p.m.-2:15 p.m.  
182-OR  The Triglyceride–Glucose Index and the Presence of Coronary Artery Disease are Mutually Independent Predictors for the Development of Type 2 Diabetes Mellitus  
Presenting Author: Andreas Leiherer, Doz Dr

2:15 p.m.-2:30 p.m.  
183-OR  Risk Factors for Combined Severe Diabetic Complications (CSDC) in Patients with Type 2 Diabetes Mellitus (T2DM)  
Presenting Author: Tanaka Nanako, Bachelor’s Degree

2:30 p.m.-2:45 p.m.  
184-OR  Association between Composite Dietary Antioxidant Index and Stroke among U.S. Adults with Diabetes—Insights from NHANES  
Presenting Author: Hongqiang Zhang, Master's Degree

2:45 p.m.-3:00 p.m.  
185-OR  The Role of Optical Coherent Tomography in the Estimation of Cardiovascular Risk in Asymptomatic Patients with Type 1 Diabetes  
Presenting Author: Michal Dubsky, MD, PhD
Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR01-1.5
Social Drivers of Health and Advancement towards Social Justice
Room: W314
Chair: Persis V. Commissariat, PhD, CDCES

1:30 p.m.-1:45 p.m.
186-OR Longitudinal Effect of Diabetes Fatalism on Clinical Outcomes and QOL in AA with Type 2 Diabetes Mellitus
Presenting Author: Sandra C. Iregbu, PhD

1:45 p.m.-2:00 p.m.
187-OR Pathway between Race, Historic and Contemporary Measures of Structural Racism, and Prevalence of Diabetes in the U.S.
Presenting Author: Leonard E. Egede, MD, MS

2:00 p.m.-2:15 p.m.
188-OR Association of Social Determinants of Health with Efficacy of Metabolic Bariatric Surgery (MBS) vs. Medical Therapy (MT) for Type 2 Diabetes
Presenting Author: Mary-Elizabeth Patti, MD

2:15 p.m.-2:30 p.m.
189-OR Food Insecurity and Inability to Obtain Recommended Medications, Diabetes Technology, and Multidisciplinary Services in Youth and Young Adults with Diabetes
Presenting Author: Angela D. Liese, PhD, MPH, FACE, FAHA

2:30 p.m.-2:45 p.m.
190-OR Development and Validation of a Social Risk Screening Tool for Adults with Type 2 Diabetes
Presenting Author: Joni S. Williams, MD, MPH

191-OR WITHDRAWN
Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR02-1.5
Using Teams and Technology to Improve Outcomes
Room: W315
Chair: Peter Rossing, MD, DMSc

1:30 p.m.-1:45 p.m.
192-OR Effect of Video Conferences between Endocrinologists and Family Doctors on Levels of Recommended Medication among Persons with Type 2 Diabetes—Pragmatic RCT
Presenting Author: Thim Prætorius, PhD

1:45 p.m.-2:00 p.m.
193-OR Virtual Diabetes Optimization Program vs. Standard Endocrine Care for Veterans with Uncontrolled Diabetes
Presenting Author: Thomas Adel, BS

2:00 p.m.-2:15 p.m.
194-OR Improved Linkage to the Health System and Better Diabetes Control Due to Community-Based m-Health—Enabled Screening and Follow-up in India
Presenting Author: Sailesh Mohan, MD, MPH, PhD

2:15 p.m.-2:30 p.m.
195-OR Efficacy and Feasibility of a Telemedicine Program for Institutionalized Elderly People with Insulin-Treated Diabetes Using Continuous Glucose Monitoring and a Connected Insulin Pen Cap—The Trescasas Study
Presenting Author: Fernando Gomez-Peralta, PhD, MD

2:30 p.m.-2:45 p.m.
196-OR A Scalable Application of Artificial Intelligence (AI) to Transform Type 2 Diabetes Management in Clinical Practice
Presenting Author: Mark L. Warren, MD

2:45 p.m.-3:00 p.m.
197-OR Algorithmic Identification May Improve Racial and Ethnic Diversity of Clinical Study Recruitment
Presenting Author: Sara Jane Cromer, MD
1:30 p.m.-3:00 p.m. (continued)

**Oral Presentations**

**Theme Area: Clinical Diabetes/Therapeutics**

**Session Number: CT-OR05-1.5**

**Novel Insights into Pathophysiology, Diagnosis, and Outcomes in GDM**

Room: W311

Chair: Mary R. Loeken, PhD, MS

1:30 p.m.-1:45 p.m.

198-OR  **Should We Improve or Replace the Antenatal Oral Glucose Tolerance Test for Diagnosis of Gestational Diabetes?**
Presenting Author: Laura C. Kusinski, PhD, BSc (Hons)

1:45 p.m.-2:00 p.m.

199-OR  **Beta-Cell IRS1 Deficiency Predisposes Female Mice to Developing Gestational Diabetes**
Presenting Author: Taofeek Usman, PhD

2:00 p.m.-2:15 p.m.

200-OR  **Postpartum Islet-Cell Function in Individuals With and Without Gestational Diabetes**
Presenting Author: Aoife M. Egan, MB, BCh, BAO

2:15 p.m.-2:30 p.m.

201-OR  **Fasting and Postprandial Triglycerides in Early Pregnancy Correlate with Mean Glucose and Time-in-Range by CGM at 28 Weeks of Gestation**
Presenting Author: Linda A. Barbour, MD, MSPH, FACP

2:30 p.m.-2:45 p.m.

202-OR  **Prediction of Late Gestational Diabetes Mellitus in Those without Early GDM**
Presenting Author: David Simmons, MA, MBBS, FRACP, FRCP, MD

2:45 p.m.-3:00 p.m.

203-OR  **Metabolic and Clinical Outcomes with One Abnormal Value on Carpenter Coustan Criteria**
Presenting Author: Christina M. Scifres, MD
1:30 p.m.–3:00 p.m.  
(continued)

Oral Presentations  
Theme Area: Epidemiology/Genetics  
Session Number: EG-OR02-1.5  
The Safety Net Unraveled—Social and Geographical Factors in Diabetes Disparities  
Room: W206  
Chair: Jessica L. Harding, PhD  

1:30 p.m.–1:45 p.m.  
204-OR Social Vulnerability, Rurality, and Prevalence of Obesity and Inactivity in U.S. Counties, 2004–2019  
Presenting Author: Ben T. Varghese, MBBS, MSc  

1:45 p.m.–2:00 p.m.  
205-OR Association of Geographic Factors with Use of Metabolic Disease Specialty Care among Adults with Type 2 Diabetes and ASCVD  
Presenting Author: Jessica Bauer, MD  

2:00 p.m.–2:15 p.m.  
206-OR Assessing Connection to Outpatient Care among Patients Screening Positive for Previously Undiagnosed Diabetes in the Emergency Department  
Presenting Author: Vidhyasai Annem, BSA  

2:15 p.m.–2:30 p.m.  
207-OR Food Insecurity Patterns and Mental Health among Youth and Young Adults with Diabetes  
Presenting Author: Ali M. Alfalki, MPH  

2:30 p.m.–2:45 p.m.  
208-OR Impact of Carbohydrate-Restricted Nutrition Therapy and Continuous Remote Care among People with Type 2 Diabetes in Rural vs. Urban Areas  
Presenting Author: Shaminie J. Athinarayanan, PhD  

2:45 p.m.–3:00 p.m.  
209-OR Direct and Indirect Effects of Redlining on Diabetes Prevalence via Food Access  
Presenting Author: Rebekah J. Walker, PhD
Oral Presentations
Theme Area: Epidemiology/Genetics
Session Number: EG-OR04-1.5
Type 2 Diabetes and Related Trait GWAS Variant Effects through Omics Profiles (With ADA Presidents' Select Abstract Presentation)
Room: W207
Chair: Adelaide Tovar, PhD

1:30 p.m.-1:45 p.m.
210-OR ADA Presidents' Select Abstract: Discovering Stimulatory State-Specific Type 2 Diabetes GWAS Mechanisms with Single-Cell Multiomics on iPSC-Derived Fibro-adipogenic Progenitor Cell Villages
Presenting Author: Christa Ventresca, PhD Candidate

1:45 p.m.-2:00 p.m.
211-OR Massively Parallel Characterization of Thousands of Type 2 Diabetes–Associated Variants in Multiple Cell Types Nominates Candidate Causal Regulatory Alleles and Mechanisms
Presenting Author: Madhav Kothari, MS

2:00 p.m.-2:15 p.m.
212-OR Differential Cell-Type-Specific Gene Expression and Chromatin Accessibility by Type 2 Diabetes Status and Physical Activity Levels in Human Skeletal Muscle
Presenting Author: Dan Ciotlos, Master's Degree

2:15 p.m.-2:30 p.m.
213-OR Widespread Age-Associated Changes in the Chromatin Architecture of Skeletal Muscle Cell Types
Presenting Author: Keagan G. Moo, BS

2:30 p.m.-2:45 p.m.
214-OR Human Genetic Study of Triglyceride to HDL-C Ratio Adjusted for BMI Identifies New Insulin Resistance-Associated Loci, Genes, Pathways, and Disease Subtypes
Presenting Author: Antonino Oliveri, PhD

215-OR UNABLE TO ATTEND
Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-OR02-1.5
Novel Regulators of Insulin Action and Insulin Sensitivity (Includes Livestream)
Room: W414
Chair: Terry Unterman, MD

1:30 p.m.-1:45 p.m.
216-OR CREG1 Promotes Insulin Receptor Recycling to Enhance Insulin Signaling in Hepatocytes
Presenting Author: Yechaan Joo, BS, MPH

1:45 p.m.-2:00 p.m.
217-OR Depalmitoylation Inhibition Improves Glucose Tolerance by Promoting Endothelial Insulin Transcytosis
Presenting Author: Wei Zhang, PhD

2:00 p.m.-2:15 p.m.
218-OR Disrupted Circadian Glucocorticoid Rhythms and High-Fat Diet Drive Obesity and Insulin Resistance through Distinct Mechanisms
Presenting Author: Mary Teruel, PhD

2:15 p.m.-2:30 p.m.
219-OR Loss of Insulin Signaling in Microglia Impairs Cellular Uptake of Aβ and Neuroinflammatory Response Exacerbating Alzheimer-Like Neuropathology
Presenting Author: Wenqiang Chen, PhD

2:30 p.m.-2:45 p.m.
220-OR Reduced Apolipoprotein C-I Truncation Is Associated with Worsening of Insulin Resistance and Risk of Diabetes in Persons with Impaired Glucose Tolerance
Presenting Author: Juraj Koska, MD, PhD

2:45 p.m.-3:00 p.m.
221-OR Skeletal Muscle Insulin Resistance—The Rate-Limiting Step in Humans Is at the Level of the Vasculature
Presenting Author: Daniël van Raalte, MD, PhD
Oral Presentations
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-OR05-1.5
The “Barrier Reef”—Overcoming Hurdles to Beta-Cell Replacement Therapies
Room: W304 A-D
Chair: Clayton E. Mathews, PhD

1:30 p.m.-1:45 p.m.
222-OR Overcoming Islet Scarcity through In Vitro Differentiation of Human Pluripotent Stem Cells
Presenting Author: Jeffrey R. Millman, PhD

1:45 p.m.-2:00 p.m.
223-OR Characterization of Regenerative Adult Islet Progenitor Cells from Human Pancreatic Tissue
Presenting Author: Jayachandra Kuncha, PhD

2:00 p.m.-2:15 p.m.
224-OR Effect of PD-L1 Overexpression on Autoreactive T-Cell Responses toward Stem Cell–Derived Beta Cells
Presenting Author: Jessie Barra, PhD

2:15 p.m.-2:30 p.m.
225-OR Sequential Islet Transplants for Type 1 Diabetes Do Not Cumulatively Increase Hepatic Portal Venous Pressure
Presenting Author: Alice L. J. Carr, PhD, MSci

2:30 p.m.-2:45 p.m.
226-OR Immunoprivileged Hydrogels Recover Normoglycemia for Extended Duration in Immunocompetent Diabetic Animals
Presenting Author: Harald Stover, PhD
SATURDAY, JUNE 22, 2024

1:30 p.m.-3:00 p.m.
(continued)

ePoster Theater
Theme Area: Clinical Diabetes/Therapeutics
Session Number: ePoster05
(*) Learning Across Diabetes
Room: Exhibit Hall (West A1-A3) ePoster Theater A
Moderator: Alanna Weisman, MD, PhD, FRCPC

(*) Continuing Education Credit Is Not Awarded for this Session.

1:30 p.m.-1:40 p.m.  
733-P  Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial  
Presenting Author: Lin Liu, PhD

1:40 p.m.-1:50 p.m.  
734-P  Use of GLP-1 Agonists and Perioperative Complications in Patients Undergoing Elective Surgery  
Presenting Author: Carlos E. Mendez, MD, FACP

1:50 p.m.-2:00 p.m.  
735-P  Association between Glucagon-Like Peptide 1 Receptor Agonists and Risk of Depression in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study  
Presenting Author: Ying Lu, BA

2:00 p.m.-2:10 p.m.  
843-P  Multinational Analysis of Factors Associated with Missed Bolus Insulin Injections Using Smart Pen Data  
Presenting Author: Francisco Javier Ampudia Blasco, MD, PhD

2:10 p.m.-2:20 p.m.  
844-P  Insulin-Like Growth Factor Binding Protein 3 Levels Modulate the Glucose Lowering Effect of Intensive Lifestyle Intervention for Weight Loss in Type 2 Diabetes  
Presenting Author: Wendy L. Bennett, MD

2:20 p.m.-2:30 p.m.  
845-P  The Menin Inhibitor Ziftomenib Induces Insulin Production and Improves Insulin Sensitivity in a Rat Model of Type 2 Diabetes Mellitus (T2DM)  
Presenting Author: Asako McCloskey, PhD

2:30 p.m.-2:40 p.m.  
909-P  Impact of SGLT2 Inhibition on Glucosuria in HNF1A-MODY  
Presenting Author: Henrik Maagensen, MD
SATURDAY, JUNE 22, 2024

1:30 p.m.-3:00 p.m.
(continued)

ePoster Theater
Theme Area: Acute and Chronic Complications
Session Number: ePoster06
(*) From Macrovascular to Microvascular
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Carol H. Wysham, MD

(*) Continuing Education Credit Is Not Awarded for this Session.

1:30 p.m.-1:40 p.m.
1791-LB Metabolic Syndrome (MS) as a Risk Factor for Myocardial Infarction (MI), Coronary Heart Disease (CHD), Stroke, and Peripheral Artery Disease (PAD) in 41,215 People with Type 1 Diabetes (PwT1D)
Presenting Author: Jochen Seufert, MD, PhD, FRCPE

1:40 p.m.-1:50 p.m.
1799-LB Identification of Proteomics Signature for Vascular Complications in Type 2 Diabetes
Presenting Author: Habib Francis, PhD

1:50 p.m.-2:00 p.m.
1795-LB Elevation of Endogenous Glucose Production in Persons with Dysglycemia and Impaired Cardiac Function upon Myocardial Infarction
Presenting Author: Clara Möser

2:00 p.m.-2:10 p.m.
1937-LB Coordinated Approach to Improve Quality of Care and Address Disparities in Patients with Cardiometabolic Disease—Analysis from the Cardiometabolic Center Alliance Registry
Presenting Author: Mikhail N. Kosiborod, MD

2:10 p.m.-2:20 p.m.
1958-LB Overnight Glycemia’s Relevance to Insulin Resistance (IR) in Type 1 Diabetes (T1D)
Presenting Author: Melanie G. Cree, MD, PhD

2:20 p.m.-2:30 p.m.
1995-LB Prevalence, Risk Factors, and Clinical Characteristics of NAFLD in Individuals with Type 1 Diabetes Mellitus
Presenting Author: Weiwei Jiang

(continued on next page)
2:30 p.m.-2:40 p.m.
1811-LB  Improvement in Diabetic Retinopathy and Achieving Remission of Type 2 Diabetes Mellitus through Digital Twin Technology—A One-Year Intervention Study
Presenting Author: Shashank Joshi, MD, DM, FRCP, FACP, FACE

2:40 p.m.-2:50 p.m.
1817-LB  Association between the Neutrophil Percentage–to–Albumin Ratio and Mortality in Patients with Diabetic Foot Ulcer
Presenting Author: Hong Zhu, PhD
3:15 p.m.-4:15 p.m.

**Panel**
*Theme Area: Acute and Chronic Complications*
*Session Number: AC-PN03-1*

**From the Cutting Room Floor—Semi-live Surgery for Healing Diabetic Foot Ulcers for the Referring Practitioner**
*Room: W206*
*Chair: Ryan T. Crews, PhD, CCRP*

3:15 p.m.-3:40 p.m. *After the Referral—Watch How Podiatrists Surgically Treat Foot Ulcers*
Haywan Chiu, DPM

3:40 p.m.-4:05 p.m. *Kidney-Friendly Vascular Surgery Interventions for Diabetic Peripheral Arterial Disease*
Michael Siah, MD

4:05 p.m.-4:15 p.m. *Question and Discussion Period*

**Panel**
*Theme Area: Acute and Chronic Complications*
*Session Number: AC-PN08-1*

**Beyond Statins—Treating and Evaluating Residual Atherosclerotic Cardiovascular Disease Risk**
*Room: W207*
*Chair: Chiadi E. Ndumele, MD, PhD*

3:15 p.m.-3:25 p.m. *New Lipid-Lowering Pharmacotherapies in Diabetes*
Erin Michos, MD, MHS

3:25 p.m.-3:35 p.m. *Lp(a) Therapeutics—Are We There Yet?*
Marlys Koschinsky, PhD

3:35 p.m.-3:45 p.m. *Advanced Diagnostic Imaging—Is Your Lipid Therapy Good Enough?*
Yasmin S. Hamirani, MD

3:45 p.m.-4:15 p.m. *Panel Discussion*

**Symposium**
*Theme Area: Acute and Chronic Complications*
*Session Number: AC-SY02-1*

**Diabetic Retinopathy Care and Screening—Is Artificial Intelligence Changing the Future?**
*Room: W208*
*Chair: Paolo S. Silva, MD*

3:15 p.m.-3:30 p.m. *Overview of DRCR Retina Network Studies and Standards of Diabetes Eye Care*
Mohamed Elmasry, MD, PhD

3:30 p.m.-3:45 p.m. *Emerging Treatment Strategies for Diabetic Retinopathy*
Thomas W. Gardner, MD, MS

3:45 p.m.-4:00 p.m. *Artificial Intelligence and Novel Retinal Imaging in Diabetic Retinopathy Screening*
Aaron Y. Lee, MD, MSCI

4:00 p.m.-4:15 p.m. *Leveraging Diabetic Retinopathy Screening Programs in Clinical Trials*
David Preiss, MBChB, MRCP, FRCPath, PhD
3:15 p.m. - 4:15 p.m.
(continued)

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY14-1
The Many Faces of Kidney Disease in Diabetes—Not All Are Diabetic Nephropathy (Includes Livestream)
Room: W307
Chair: Ashish Verma, MB, BS

3:15 p.m.-3:35 p.m. Acute Kidney Injury and Its Long-Term Consequences in Diabetes
Andrew Advani, BSc, MBChB(Hons), PhD, FRCP(UK), FRCP(Edin), FASN

3:35 p.m.-3:55 p.m. The Vascular Crossroads—Hypertension and Vascular Disease in Diabetic Kidney Disease Progression
Jeffrey B. Hodgin, MD, PhD

3:55 p.m.-4:15 p.m. Decoding Diabetic Kidney Disease—Molecular Subtypes and the Future of Nosology
Timothy Sutton, MD

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY16-1
Updates in Autonomic Neuropathy
Room: W308
Chair: Andrew J.M. Boulton, MD, DSc (Hon), FACP, FICP, FRCP

3:15 p.m.-3:35 p.m. Autonomic Dysfunction—Challenging Clinical Scenarios
Christian S. Hansen, MD, PhD

3:35 p.m.-3:55 p.m. Gastroparesis—Myths and Facts
Karen L. Jones, Dip App Sc (Nuclear Medicine), PhD

3:55 p.m.-4:15 p.m. Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY06-1
Optimizing Outcomes of GLP-1+/GIP Receptor Agonists—How to Help Patients Succeed
Room: W315
Chair: Ka Hei Karen Lau, MS, RDN, LDN, CDCES

3:15 p.m.-3:45 p.m. Is Weight Loss Everything? Nutrition and Lifestyle Are Missing Puzzle Pieces
Colleen Dawkins, FNP-C, RDN, CSOWM

3:45 p.m.-4:15 p.m. Protocol in Practice—Standing Orders for RD/RN Management of GLP-1/GIP Receptor Agonists
Maureen Chomko, RD, CDCES
Debate
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-DB18-1
Diabetes Prevention Program (DPP) vs. GLP-1RA—Which Tool Is Best to Battle the Obesity and Diabetes Epidemics?
Room: W304 E-H
Chair: Amisha Wallia, MD, MS
3:15 p.m.-3:35 p.m. The Diabetes Prevention Program Is the Best Tool to Battle Prediabetes and Obesity (NDPP)
   David G. Marrero, PhD
3:35 p.m.-3:55 p.m. GLP-1RAs Are the Best Tools to Battle Prediabetes and Obesity
   Ildiko Lingvay, MD, MPH, MSCS
3:55 p.m.-4:00 p.m. Rebuttal
   David G. Marrero, PhD
4:00 p.m.-4:05 p.m. Rebuttal
   Ildiko Lingvay, MD, MPH, MSCS
4:05 p.m.-4:15 p.m. Question and Discussion Period

Panel
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-PN11-1
GLP-1 +/- GIP Receptor Agonists in the Perioperative Setting—To Stop or Not to Stop?
Room: W415C (Valencia Ballroom)
Chair: Leigh Perreault, MD, FACE, FACP
3:15 p.m.-3:30 p.m. Anesthesia Perspective
   Girish P. Joshi, MBBS, MD, FFARCSI
3:30 p.m.-3:45 p.m. Gastroenterology Perspective
   Jana G. Al Hashash, MD, MSc, FACG, AGAF
3:45 p.m.-4:00 p.m. Endocrinology Perspective
   Sue D. Pedersen, MD, FRCPC C-ENDO, DABOM
4:00 p.m.-4:15 p.m. Panel Discussion

Panel
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-PN19-1
Health Care Policy and Diabetes—How to Improve Population Health from Multiple Perspectives (Includes Livestream)
Room: W320 (Chapin Theater)
Chair: Elbert S. Huang, MD, MPH, FACP
3:15 p.m.-4:15 p.m. Health Care Policy and Diabetes—How to Improve Population Health from Multiple Perspectives
   Neda Laiterrapong, MD, MS, FACP
   Irl B. Hirsch, MD
   Mohammed K. Ali, MD, MSc, MBA
   Keri J. Whitaker, RN
   Aaron Winn, PhD
3:15 p.m.-4:15 p.m.  
(continued)

**Symposium**

*Theme Area: Clinical Diabetes/Therapeutics*

*Session Number: CT-SY13-1*

**How I Feel Matters, Too—The Psychosocial Aspects of Automated Insulin Delivery** *(Includes Livestream)*

Room: W415B (Valencia Ballroom)

Chair: William H. Polonsky, PhD, CDCES

3:15 p.m.-3:45 p.m.  
*It's Still a Lot of Work—Mitigating Diabetes Technology Burnout*

Jill Weissberg-Benchell, PhD, CDCES

3:45 p.m.-4:15 p.m.  
*Psychosocial Considerations of Automated Insulin Delivery*

Marisa E. Hilliard, PhD

---

**Symposium**

*Theme Area: Clinical Diabetes/Therapeutics*

*Session Number: CT-SY34-1*

**Hyperglycemic Crises in Diabetes**

Room: W314

Co-Chairs: Nuha El Sayed, MD, MMSc  and Guillermo Umpierrez, MD, CDCES, MACP, FACE

3:15 p.m.-3:25 p.m.  
*Welcome and Introduction—Rationale and Methods*

Guillermo Umpierrez, MD, CDCES, MACP, FACE

3:25 p.m.-3:35 p.m.  
*Epidemiology—Global Trends, Costs, Mortality*

Georgia M. Davis, MD

3:35 p.m.-3:45 p.m.  
*Pathogenesis and Diagnostic Criteria*

Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD

3:45 p.m.-3:55 p.m.  
*Management—Acute and Transition Protocol*

Rodolfo J. Galindo, MD

3:55 p.m.-4:05 p.m.  
*Complications and Discharge Protocol*

David C. Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE

4:05 p.m.-4:15 p.m.  
*Question and Discussion Period*

---

**Debate**

*Theme Area: Insulin Action/Molecular Metabolism*

*Session Number: IA-DB01-1*

**Boosting Energy Expenditure in Obesity—Debating the Potential of Thermogenic Adipose Tissue and Skeletal Muscle Bioenergetics as Antiobesity Targets in Humans**

Room: W304 A-D

Chair: Shingo Kajimura, PhD

3:15 p.m.-3:30 p.m.  
*Brown Fat Is a Regulator of Energy Balance in Humans*

Denis Blondin, PhD

3:30 p.m.-3:45 p.m.  
*The Role of BAT in Obesity and Weight Loss*

Kirsi M. Virtanen, MD

3:45 p.m.-3:50 p.m.  
*Rebuttal*

Denis Blondin, PhD

3:50 p.m.-3:55 p.m.  
*Rebuttal*

Kirsi M. Virtanen, MD

3:55 p.m.-4:15 p.m.  
*Question and Discussion Period*
3:15 p.m.-4:15 p.m.  
(continued)

**Symposium**  
*Theme Area: Obesity/Integrated Physiology*  
*Session Number: IP-SY06-1*  
**Intermittent Fasting in Various Forms of Diabetes Care (Includes Livestream)**  
*Room: W414*  
*Chair: Kelsey Gabel, RD, MS, PhD*  
3:15 p.m.-3:35 p.m. *Possibilities of Fasting in Patients with Diabetes*  
Lisa S. Chow, MD, MS  
3:35 p.m.-3:55 p.m. *Can Time-Restricted Eating Inhibit the Progression of Prediabetes?*  
Courtney M. Peterson, PhD, MSc, MA, MS  
3:55 p.m.-4:15 p.m. *Can Time-Restricted Eating Treat Polycystic Ovary Syndrome?*  
Sofia Cienfuegos, PhD, MS  

**Symposium**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
*Session Number: BM-SY18-1*  
**International Consensus Statement and Movement to End Diabetes Stigma**  
*Room: W311*  
*Chair: Jane Speight, MSc, PhD, CPyschol, FBPsS*  
3:15 p.m.-3:30 p.m. *International Consensus Statement for Ending Diabetes Stigma—Background, Methodology of the Consensus Statement, and Overview of Recommendations for Health Professional and Researchers*  
Matthew Garza, Bachelor's Degree  
3:30 p.m.-3:45 p.m. *Prevalence and Impact of Diabetes Stigma—Implications for Health Outcomes*  
Mary de Groot, PhD  
3:45 p.m.-4:00 p.m. *Research in Diabetes Stigma—What's Next?*  
Kevin Joiner, PhD, APRN, ANP-BC, CDCES  
4:00 p.m.-4:15 p.m. *Integration into Care Settings—Patient Perspective and Identifying Resources*  
Susan Guzman, PhD
4:30 p.m.–6:00 p.m.

**Symposium**

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

*Session Number: BM-SY01-1.5*

**The Evolution of Diabetes Behavioral Care (Includes Livestream)**

*Room: W307*

*Chair: Mary de Groot, PhD*

**4:30 p.m.–5:00 p.m.**

*Establishing the Evidence Base for Patient Empowerment in Behavioral Diabetes Care*

Gretchen Piatt, PhD, MPH

**5:00 p.m.–5:30 p.m.**

*Harnessing Advanced Methods and Technologies for Behavioral Diabetes Care*

Molly L. Tanenbaum, PhD

**5:30 p.m.–6:00 p.m.**

*Advancing Health Equity in Behavioral Diabetes Care*

Nadia Islam, MA, MPhil, PhD

**Main Event**

*Theme Area: Main Event*

*Session Number: CT-ME40-1.5*

(*) **Innovation Challenge (Includes Livestream)**

(*) **Continuing Education Credit Is Not Awarded for this Session**

*Room: West Hall B3-4 (General Session)*

*Co-Chairs: Robert A. Gabbay, MD, PhD and Nicole Johnson, DrPH, MPH, MA*

**4:30 p.m.–6:00 p.m.**

*Innovation Challenge*

Craig Cooper, MBA

Bari Krein

Sean Sullivan, PhD

**Symposium**

*Theme Area: Clinical Diabetes/Therapeutics*

*Session Number: CT-SY09-1.5*

**Diabetes and the Lung—Cause and Consequence (Includes Livestream)**

*Room: W414*

*Chair: Vanita R. Aroda, MD*

**4:30 p.m.–4:50 p.m.**

*What Do We Know about Diabetes and the Lung?*

Juan C. Celedón, MD, DrPH

**4:50 p.m.–5:10 p.m.**

*Insulin Resistance as a Treatable Trait in Asthma*

Tianshi D. Wu, MD, MHS

**5:10 p.m.–5:30 p.m.**

*GLP-1 Receptor Agonists and the Respiratory Outcomes in Patients with Asthma and Chronic Obstructive Pulmonary Disease*

Dinah Foer, MD

**5:30 p.m.–5:50 p.m.**

*Immunometabolic Pathways in Lung Inflammation—Novel Therapeutic Opportunities*

M. Furkan Burak, MD

**5:50 p.m.–6:00 p.m.**

*Question and Discussion Period*
Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY29-1.5
Heterogeneity of Diabetes—Pathophysiology to Global Considerations (Includes Livestream)
Room: W320 (Chapin Theater)
Chair: Stephen S. Rich, PhD, FAHA

4:30 p.m.-4:45 p.m. Heterogeneity of Diabetes—A Global Perspective
Paul W. Franks, PhD

4:45 p.m.-5:05 p.m. Heterogeneity in Type 2 Diabetes
Shivani Misra, MD, PhD

5:05 p.m.-5:25 p.m. Heterogeneity in Treatment Strategies for Diabetes
Ronald C.W. Ma, MB, BChir, FRCP

5:25 p.m.-5:45 p.m. Heterogeneity from Social Determinants of Health
Tiffany L. Gary-Webb, PhD, MHS

5:45 p.m.-6:00 p.m. Panel Discussion

Panel
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-PN02-1.5
Technical Challenges and Solutions in Metabolomics (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Caroline Chidley, PhD

4:30 p.m.-4:50 p.m. Subcellular Metabolomics for Mapping Nutrient Responses
Sophie Trefely, PhD

4:50 p.m.-5:10 p.m. Nuclear Magnetic Resonance–Based Metabolism
Stanislaw Deja, PhD

5:10 p.m.-5:30 p.m. Stable Isotope Tracing In Vivo and Imaging Mass Spec
Tara TeSlaa, PhD

5:30 p.m.-5:50 p.m. New Metabolite ID in Metabolomics
Caroline Chidley, PhD

5:50 p.m.-6:00 p.m. Question and Discussion Period
4:30 p.m.–6:00 p.m.  
(continued)

**Oral Presentations**

*Theme Area: Clinical Diabetes/Therapeutics*

Session Number: CT-OR09-1.5

**Leveling Up Incretin-Based Therapy in Type 2 Diabetes**

Room: W415C (Valencia Ballroom)
Chair: Tina Vilsbøll, MD, DMSc

4:30 p.m.–4:45 p.m.

227-OR  *Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo Regardless of Insulin Sensitivity and Beta-Cell Function—Post Hoc Analysis from SURMOUNT-2*

Presenting Author: Tim Heise, MD

4:45 p.m.–5:00 p.m.

228-OR  *Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids*

Presenting Author: John J. Suschak, PhD

5:00 p.m.–5:15 p.m.

229-OR  *Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes*

Presenting Author: Julio Rosenstock, MD

5:15 p.m.–5:30 p.m.

230-OR  *Comparative Effectiveness of Semaglutide in Type 2 Diabetes—Year 2 Results of a Randomized Pragmatic Clinical Trial*

Presenting Author: John B. Buse, MD, PhD

5:30 p.m.–5:45 p.m.

231-OR  *Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2*

Presenting Author: Rodolfo J. Galindo, MD

5:45 p.m.–6:00 p.m.

232-OR  *Glucagon-Like Peptide 1 Receptor Agonists and Risk of Suicide/Self-Harm in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study*

Presenting Author: Huilin Tang, MSc
Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR08-1.5
Towards Targeted Weight-Loss Therapy—New Considerations for GLP-1RA or Surgery
Room: W304 A-D
Chair: Daniel S. Hsia, MD

233-OR WITHDRAWN

4:30 p.m.-4:45 p.m.
234-OR Performance of a Machine-Learning Gene Risk Score Biomarker to Predict Weight-Loss Response to Tirzepatide and Semaglutide
Presenting Author: Maria D. Hurtado, MD, PhD

4:45 p.m.-5:00 p.m.
235-OR Quality of Life and Health Utility 12 Years after Randomization to Bariatric Surgery vs. Medical Therapy in Patients with Type 2 Diabetes and Obesity—The ARMMS-T2D Study
Presenting Author: Donald C. Simonson, MD, MPH, ScD

5:00 p.m.-5:15 p.m.
236-OR Short-Term Effects of Semaglutide and Tirzepatide on Body Composition in Patients with Obesity Undergoing a Low-Calorie Diet
Presenting Author: Masamitsu Naka, MD

237-OR WITHDRAWN

5:15 p.m.-5:30 p.m.
238-OR Effect of Baseline Antihyperglycemic Medications on Weight Reduction with Tirzepatide—SURMOUNT-2 Subgroup Analysis
Presenting Author: Sriram Machineni, MD
**SUNDAY, JUNE 23, 2024**

**Scientific Sessions**
8:00 a.m.–9:30 a.m.

**Panel**
*Theme Area: Acute and Chronic Complications*
Session Number: AC-PN10-1.5

**A Multidisciplinary Approach—Challenging Cases from the Cardiometabolic Clinic** *(Includes Livestream)*
Room: W307
Chair: Melissa L. Magwire, RN, MSN, CDCES

8:00 a.m.–9:00 a.m. **A Multidisciplinary Approach—Challenging Cases from the Cardiometabolic Clinic**
- Chiadi E. Ndumele, MD, PhD
- Bruce A. Perkins, MD, MPH, FRCP(C)
- Goutham Rao, MD
- Evan M. Sisson, PharmD, MHA, CDCES

9:00 a.m.–9:30 a.m. **Question and Discussion Period**

**Symposium**
*Theme Area: Acute and Chronic Complications*
Session Number: AC-SY13-1.5

**The Changing Climate of Diabetic Kidney Disease—Environmental Triggers and Vulnerabilities**
Room: W206
Chair: Meda E. Pavkov, MD, PhD

8:00 a.m.–8:30 a.m. **Heat Waves and Kidneys—How Climate Change Aggravates Diabetic Nephropathy**
- Vivek Bhalla, MD

8:30 a.m.–9:00 a.m. **Clear Waters Ahead? The Impacts of PFAS on Diabetic Kidney Health**
- Jesse Goodrich, PhD

9:00 a.m.–9:30 a.m. **The Exposome Imperative—Unlocking the Full Spectrum of Exposure Sciences to Prevent Diabetic Kidney Disease**
- Ana Navas-Acien, MD, PhD

**Symposium**
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*
Session Number: BM-SY02-1.5

**Loneliness Is a Real Heartbreaker** *(Includes Livestream)*
Room: W414
Chair: Kevin Joiner, PhD, APRN, ANP-BC, CDCES

8:00 a.m.–8:30 a.m. **The Epidemic of Loneliness and Isolation**
- Anne Gaglioti, MD, MS, FAAFP

8:30 a.m.–9:00 a.m. **The Link between Loneliness and Diabetes**
- Xuan Wang, PhD

9:00 a.m.–9:30 a.m. **The Psychological Toll of Loneliness**
- Ariana Chao, PhD, MSN, BSN, RN
8:00 a.m.-9:30 a.m. (continued)

Panel
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-PN10-1.5
Noninsulin Treatment for Type 1 Diabetes
Room: W311
Chair: Richard M. Bergenstal, MD
8:00 a.m.-8:20 a.m. Is There a Place for SGLT Inhibition in Type 1 Diabetes Mellitus?
Ele Ferrannini, MD
8:20 a.m.-8:40 a.m. Is There a Place for GLP-1RA in Type 1 Diabetes Mellitus?
Michael A. Nauck, MD
8:40 a.m.-9:00 a.m. Is There a Place for MRA in Type 1 Diabetes Mellitus?
Hiddo L. Heerspink, PhD
9:00 a.m.-9:20 a.m. The Lived Experience
Wes Unger
9:20 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY01-1.5
Metformin Reexamined—Pleiotropic Effects in Mother and Offspring in Humans and Animal Models
Room: W315
Chair: Linda A. Barbour, MD, MSPH, FACP
8:00 a.m.-8:15 a.m. First Do No Harm—Potential Fetal Programming Perils with Maternal Metformin Use in Pregnancy
Kjersti M. Aagaard, MD, PhD, FACOG
8:15 a.m.-8:30 a.m. Effects and Consequences of Metformin Action in the Fetal Liver from Nonhuman Primates and Sheep
Stephanie R. Wesolowski, PhD
8:30 a.m.-8:45 a.m. Effects of Metformin and Maternal Overnutrition on Fetal Pancreas and Islet Mitochondria in Nonhuman Primates
Maureen Gannon, PhD
8:45 a.m.-9:00 a.m. Evidence for Long-Term Effects of In Utero Metformin Exposure—Where Do We Go from Here?
Susan Ozanne, PhD
9:00 a.m.-9:30 a.m. Question and Discussion Period
8:00 a.m.-9:30 a.m. (continued)

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY24-1.5*
**Joint ADA/ISPAD Symposium—Pediatric Diabetes Insights and Innovations**
Room: W415C (Valencia Ballroom)
Co-Chairs: Jamie R. Wood, MD and Eda Cengiz, MD, MHS
8:00 a.m.-8:20 a.m. *What Is New in Treatment of Preschool Children with Type 1 Diabetes Mellitus?*
   - Carine de Beaufort, MD, PhD
8:20 a.m.-8:40 a.m. *Inpatient Pediatric Diabetes Technology Use*
   - Erin C. Cobry, MD
8:40 a.m.-9:00 a.m. *Innovations in Diabetes Education—App-Based Diabetes Technology Education and More...*
   - Brynn E. Marks, MD, MSHPEd
9:00 a.m.-9:20 a.m. *Rethinking First-Line Therapy in Pediatric Type 2 Diabetes*
   - Shylaja Srinivasan, MD, MAS
9:20 a.m.-9:30 a.m. *Question and Discussion Period*

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY36-1.5*
**The State of Health Equity and Disability—Supporting Diabetes Technology Usage in People Who Are Deaf/Hard of Hearing or Blind/Low Vision**
Room: W314
Co-Chairs: Nancy A. Allen, PhD and Jeremy Quiroga
8:00 a.m.-8:20 a.m. *Fostering Inclusivity—Advancing Diabetes Technology for Deaf and Hard of Hearing Individuals*
   - Michelle L. Litchman, PhD, FNP-BC
8:20 a.m.-8:40 a.m. *Hacks to Address the Lack of Diabetes Technology Accessible for Deaf and Hard of Hearing People with Diabetes*
   - Ryan Layton
8:40 a.m.-9:00 a.m. *Enhancing Diabetes Technology Accessibility for Individuals Who Are Blind or Have Low Vision*
   - Allyson S. Hughes, PhD
9:00 a.m.-9:20 a.m. *Real-World Challenges Using Diabetes Technology as a Person with Low Vision*
   - Chelcie Rice
9:20 a.m.-9:30 a.m. *Question and Discussion Period*
SUNDAY, JUNE 23, 2024

8:00 a.m.-9:30 a.m.  
(continued)

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY44-1.5*  
**Diabetes and Organ Transplantation—Pathophysiology, Inpatient and Outpatient Management**  
*Room: W208*  
*Chair: Boris Draznin, MD, PhD*  
8:00 a.m.-8:20 a.m.  
*Diabetes and Organ Transplantation—An Overview*  
Archana R. Sadhu, MD, FACE  
8:20 a.m.-8:40 a.m.  
*Management of Diabetes following Liver Transplantation*  
Palak Choksi, MD  
8:40 a.m.-9:00 a.m.  
*Diabetes and Kidney Transplantation*  
Robert J. Rushakoff, MD  
9:00 a.m.-9:30 a.m.  
*Question and Discussion Period*

**Panel**  
*Theme Area: Epidemiology/Genetics*  
*Session Number: EG-PN04-1.5*  
**When a Box Isn’t a Box—Research Frameworks for Understanding and Addressing Disparities in Type 2 Diabetes**  
*Room: W207*  
*Chair: Jacqueline A. Seiglie, MD, MSc*  
8:00 a.m.-8:20 a.m.  
*Adapting the NIMHD Research Framework for Diabetes Disparities across the Lifespan*  
Eyitayo O. Owolabi, PhD, RN  
8:20 a.m.-8:40 a.m.  
*Applying Implementation Science Frameworks to Advance Diabetes Prevention Efforts*  
Lillian Madrigal, PhD, MPH  
8:40 a.m.-9:00 a.m.  
*National Policy Frameworks for Addressing Type 2 Diabetes*  
Puneet Kaur Chehal, MA, PhD  
9:00 a.m.-9:20 a.m.  
*A Pragmatic Action-Based Framework to Address Global Inequities in Diabetes*  
Ashby F. Walker, PhD  
9:20 a.m.-9:30 a.m.  
*Question and Discussion Period*
SUNDAY, JUNE 23, 2024

8:00 a.m.-9:30 a.m.  
(continued)

**Symposium**  
*Theme Area: Immunology/Beta-Cell Replacement*  
*Session Number: IBC-SY04-1.5*  
**Translating Type 1 Diabetes Risk Alleles to Therapy**  
Room: W304 A-D  
Chair: Suna Onengut-Gumuscu, PhD  
8:00 a.m.-8:20 a.m.  
**IL2RA Variation Shapes Type 1 Diabetes Risk**  
Harikesh S. Wong, PhD, BSc  
8:20 a.m.-8:40 a.m.  
**HLA as a Target, Not a Predictor**  
Aaron W. Michels, MD  
8:40 a.m.-9:00 a.m.  
**Targeting TYK2 for Treatment of Type 1 Diabetes**  
Farooq Syed, PhD  
9:00 a.m.-9:20 a.m.  
**Fixing FOXP3+ Cells in Type 1 Diabetes**  
Matthew E. Brown, BS  
9:20 a.m.-9:30 a.m.  
**Question and Discussion Period**

**Symposium**  
*Theme Area: Insulin Action/Molecular Metabolism*  
*Session Number: IA-SY04-1.5*  
**Metabolite Transport and Molecular Metabolism**  
Room: W304 E-H  
Chair: Uptal Pajvani, MD, PhD  
8:00 a.m.-8:20 a.m.  
**Fumarate and Mitochondrial Energetics**  
Jessica Spinelli, PhD  
8:20 a.m.-8:40 a.m.  
**Lipid Transport and Metabolism**  
Judith Simcox, BA, PhD  
8:40 a.m.-9:00 a.m.  
**Insulin Signaling and Bile Acid Transport and Metabolism**  
Rebecca Haeusler, PhD  
9:00 a.m.-9:20 a.m.  
**Mitochondrial Pyruvate Transport and Liver Metabolism**  
Brian N. Finck, PhD  
9:20 a.m.-9:30 a.m.  
**Question and Discussion Period**

**Symposium**  
*Theme Area: Obesity/Integrated Physiology*  
*Session Number: IP-SY11-1.5*  
**Severe GLP-1RA Side Effects in Obesity Treatment—Fact or Fiction? (Includes Livestream)**  
Room: W415B (Valencia Ballroom)  
Chair: Mary-Elizabeth Patti, MD  
8:00 a.m.-8:20 a.m.  
**Pancreatitis and Gall Bladder Disease**  
Daniel J. Drucker, MD  
8:20 a.m.-8:40 a.m.  
**Suicide Risk**  
John-Michael Gamble, PhD  
8:40 a.m.-9:00 a.m.  
**Thyroid Cancer**  
Elizabeth N. Pearce, MD, MSc  
9:00 a.m.-9:20 a.m.  
**Fine-Tuning the Patient's GLP-1 Experience**  
Beverly G. Tchang, MD  
9:20 a.m.-9:30 a.m.  
**Question and Discussion Period**
SUNDAY, JUNE 23, 2024

8:00 a.m.-9:30 a.m.
(continued)

Symposium
Theme Area: Obesity/Integrated Physiology
Session Number: IP-SY12-1.5
ADA Diabetes Journal Symposium—It Is All in Your Head—Central Nervous System Control of Systemic Metabolism
Room: W308
Chair: Jennifer L. Estall, PhD

8:00 a.m.-8:20 a.m. Brain Defense of Glycemia in Health and Diabetes
Zaman Mirzadeh, MD, PhD

8:20 a.m.-8:40 a.m. Central Nervous System Regulation of Systemic Glucose—Lessons Learned from the Adaptation to Exercise
Kevin Williams, PhD

8:40 a.m.-9:00 a.m. What the Gut Says to the Brain About Food
Laura Rupprecht, PhD

9:00 a.m.-9:20 a.m. Neural Signaling To and From Adipose Tissue in the Regulation of Metabolic Health
Kristy L. Townsend, PhD

9:20 a.m.-9:30 a.m. Question and Discussion Period
SUNDAY, JUNE 23, 2024

9:45 a.m.-11:15 a.m.

Special Lectures and Addresses
Session Number: MSB-01
President, Medicine & Science Address and National Scientific & Health Care Achievement Awards Presentation *(Includes Livestream)*
Room: West Hall B3-4 (General Session)
9:45 a.m.-9:50 a.m. *Introduction of President, Medicine & Science*  
Robert A. Gabbay, MD, PhD
9:50 a.m.-10:20 a.m. *Fighting Diabetes—A Journey That Began in Childhood*  
Mandeep Bajaj, MBBS
10:20 a.m.-10:55 a.m. *National Scientific & Health Care Achievement Awards Presentation*  
10:55 a.m.-11:15 a.m. *Conclude*

11:30 a.m.-12:30 p.m.

Professional Interest Group
*Theme Area: Acute and Chronic Complications*
Session Number: AC-IG01-1
Discussion on Diabetes and Cardiovascular Disease—Obesity and Diabetes—Innovative Research to Inform Clinical Practice
Room: W206
Chair: Heather Ferris, MD, PhD
11:30 a.m.-11:33 a.m. *Introduction*
11:33 a.m.-11:48 a.m. *Ketone Metabolism and Cardiometabolic Disease*  
Peter A. Crawford, MD, PhD
11:48 a.m.-12:03 p.m. *Dapagliflozin According to Body Mass Index*  
Mikhail N. Kosiborod, MD
12:03 p.m.-12:18 p.m. *REAL HEALTH-Diabetes Trial*  
Deborah J. Wexler, MD, MSc
12:18 p.m.-12:30 p.m. *Question and Discussion Period*

Professional Interest Group
*Theme Area: Acute and Chronic Complications*
Session Number: AC-IG03-1
Discussion on Eye Health—Novel Diabetes Therapies in Diabetic Retinopathy—A Basic Science and Preclinical Perspective
Room: W207
Chair: Blake Cooper, MD, MPH
11:30 a.m.-11:35 a.m. *Introduction*
11:35 a.m.-11:55 a.m. *Novel Therapies in Clinical Trials and Treatment Strategies for Diabetic Retinopathy*  
T. Y. Alvin Liu, MD
11:55 a.m.-12:15 p.m. *Therapies in Development for Diabetic Retinopathy—A Basic Science*  
Thomas W. Gardner, MD, MS
12:15 p.m.-12:30 p.m. *Question and Discussion Period*
Professional Interest Group

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-IG01-1

Discussion on Behavioral Medicine and Psychology—Including the Excluded in Behavioral Diabetes Research
Room: W208
Chair: Marisa E. Hilliard, PhD

11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-11:45 a.m. Recruitment, Retention, and Engagement of Men from Minoritized Racial and Ethnic Groups in Behavioral Diabetes Research
   Jaclynn M. Hawkins, PhD, MSW
11:45 a.m.-11:55 a.m. Recruitment, Retention, and Engagement of People with Neurodiversity in Behavioral Research
   Susana R. Patton, PhD, ABPP, CDCES
11:55 a.m.-12:05 p.m. Recruitment, Retention, and Engagement of LGBTQIA+ People in Behavioral Research
   Lauren B. Beach, Esq., JD, PhD
12:05 p.m.-12:30 p.m. Question and Discussion Period

Professional Interest Group

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-IG03-1

Discussion on Diabetes Self-Management Education and Support (DSMES)—It’s Time to Change the Way We Talk about DSMES!
Room: W308
Chair: Joyce Y. Lee, PharmD, AP, FCCP, BCPS, BCACP, CDCES

11:30 a.m.-11:50 a.m. Prioritizing Health Equity in Diabetes Overview—Centers for Disease Control and Prevention DP23-0020
   Leslie Harrison, MPH
11:50 a.m.-12:05 p.m. Centers for Disease Control and Prevention DSMES Toolkit
   Melissa Bing, MPH
12:05 p.m.-12:20 p.m. Centers for Disease Control and Prevention DSMES Playbook—Let’s Get to It!
   Betsy Rodriguez, BSN, MSN, CDCES, FADCES
12:20 p.m.-12:30 p.m. Question and Discussion Period
SUNDAY, JUNE 23, 2024

11:30 a.m.-12:30 p.m.
(continued)

**Professional Interest Group**
*Theme Area: Clinical Diabetes/Therapeutics*
Session Number: CT-IG02-1
**Discussion on Diabetes in Primary Care—Tackling Diabetes in Primary Care—Training and Workforce Development**
Room: W304 A-D
Chair: Rozalina G. McCoy, MD MS
11:30 a.m.-11:35 a.m. *Introduction*
11:35 a.m.-12:00 p.m. *Training Primary Care Providers to Be Diabetes Specialists*
   Jay H. Shubrook, DO
12:00 p.m.-12:25 p.m. *Leveraging Specialty Diabetology within Primary Care*
   Sarah Cote, NP, CDCES, BC-ADM
12:25 p.m.-12:30 p.m. *Question and Discussion Period*

**Professional Interest Group**
*Theme Area: Clinical Diabetes/Therapeutics*
Session Number: CT-IG06-1
**Discussion on Clinical Centers and Programs—Challenges in Management of Diabetes in Older Adults and in Primary Care**
Room: W304 E-H
Chair: Ali A. Rizvi, MD
11:30 a.m.-11:35 a.m. *Introduction*
11:35 a.m.-12:00 p.m. *Success in Suboptimally Controlled Type 2 Diabetes—The Magic of CGM and Collaboration*
   Andrew Behnke, MD
12:00 p.m.-12:25 p.m. *Challenges in the Management of Diabetes in Older Adults*
   Tali Cukierman-Yaffee, MD, MSC
12:25 p.m.-12:30 p.m. *Question and Discussion Period*

**Workshop**
*Theme Area: Clinical Diabetes/Therapeutics*
Session Number: CT-WS37-1
**Improving Care for Deaf People with Diabetes Who Use ASL Interpreters—A Hands-On Workshop**
Room: W311
Chair: Michelle L. Litchman, PhD, FNP-BC
11:30 a.m.-11:50 a.m. *Language Access Disparity—The Link between Being Deaf and Having Diabetes*
   Karissa Mirus, MHSA
11:50 a.m.-12:10 p.m. *Best Practices for Working with Deaf Populations and ASL Interpreters*
   Susan Layton, CI, CT, NAD IV
12:10 p.m.-12:30 p.m. *Hands-on Simulation of Working with Deaf Populations and ASL Interpreters*
   Michelle L. Litchman, PhD, FNP-BC
   Jeremy Quiroga
Professional Development
Theme Area: Professional Development
Session Number: PD-02-1
Art of Writing a Winning Grant *(Includes Livestream)*
Room: W307
Chair: William T. Cefalu, MD
11:30 a.m.-11:50 a.m. **Basic Science Perspective**
    Philipp E. Scherer, PhD
11:50 a.m.-12:10 p.m. **Clinical/Translational Science Perspective**
    Dana Dabelea, MD, PhD
12:10 p.m.-12:30 p.m. **Question and Discussion Period**
11:30 a.m.-12:30 p.m.
(continued)

**ePoster Theater**
*Theme Area: Clinical Diabetes/Therapeutics*
Session Number: ePoster07
(**) Improving Efficacy and Safety of Incretin-Based Therapies
Room: Exhibit Hall (West A1-A3) ePoster Theater A
Moderator: Stewart B. Harris, CM, MD, MPH, FCFP, FACP

(**) Continuing Education Credit Is Not Awarded for this Session.

11:30 a.m.-11:40 a.m.
736-P Comparison of Semaglutide vs. Tirzepatide Therapy in Adults with Type 1 Diabetes (T1D)
Presenting Author: Henon Gebre, MPH

11:40 a.m.-11:50 a.m.
737-P Acute Healthcare Utilization, Mortality, and Cardiovascular Events following GLP-1RA Initiation by Patients with Advanced Chronic Kidney Disease—A Real-World Comparative Study
Presenting Author: Shuyao Zhang, MD

11:50 a.m.-12:00 p.m.
738-P Real-World Effectiveness among Patients with Type 2 Diabetes (T2D) Initiating Tirzepatide (TZP)
Presenting Author: Reema Mody, MBA, PhD

12:00 p.m.-12:10 p.m.
739-P Efficacy and Safety of Tirzepatide in Overweight (OW) and Obese (OB) Patients with Type 1 Diabetes (T1D)
Presenting Author: Janet K. Snell-Bergeon, PhD, MPH

12:10 p.m.-12:20 p.m.
740-P Persistence and Adherence of Once-Weekly GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in a Real-World Setting
Presenting Author: Tyler Dunn, PhD
SUNDAY, JUNE 23, 2024

11:30 a.m.-12:30 p.m.  
(continued)

ePoster Theater

Theme Area: Islet Biology/Insulin Secretion  
Session Number: ePoster08  
(*) Islet Biology

Room: Exhibit Hall (West A1-A3) ePoster Theater B  
Moderator: Joana Almaca, PhD

(*) Continuing Education Credit Is Not Awarded for this Session.

11:30 a.m.-11:40 a.m.
1728-P The Nkx6.1 Binding Partner Mef2D Modulates Beta-Cell Insulin Secretion and Cell Survival  
Presenting Author: Jeffery S. Tessem, PhD

11:40 a.m.-11:50 a.m.
1729-P Hypertonicity Mediates Glucose-Induced First-Phase Insulin Secretion  
Presenting Author: Ian Sweet, PhD

11:50 a.m.-12:00 p.m.
1730-P In Vitro and In Vivo Effects of Increased IAPP Expression on Human Islet Function  
Presenting Author: Jordan J. Wright, MD, PhD

12:00 p.m.-12:10 p.m.
1731-P Screening Human Islets to Identify Small Molecules Enhancing Glucagon Secretion under Hypoglycemia  
Presenting Author: Thomas Bate, PhD

1761-P WITHDRAWN
SUNDAY, JUNE 23, 2024

12:30 p.m.-1:30 p.m.

**ePoster Theater**

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
Session Number: ePoster09

(*) Exploring Eating Behaviors and Weight Loss in Youth and Adults with Type 1 and Type 2 Diabetes  
Room: Exhibit Hall (West A1-A3) ePoster Theater A  
Moderator: Lindsay S. Mayberry, PhD

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.
**640-P**  Disordered Eating Screening within a Pediatric Diabetes Clinic  
Presenting Author: Nicole Andorko, PhD

12:40 p.m.-12:50 p.m.
**641-P**  Body Image and Insulin Restriction among Adolescents with Type 1 Diabetes  
Presenting Author: Rachna Sannegowda, BS

12:50 p.m.-1:00 p.m.
**642-P**  Reasons behind Fasting Ramadan against Medical Advice for Individuals under 18 Years with Uncontrolled Type 1 Diabetes—A Tertiary Center Experience  
Presenting Author: Zahra Rahme, MSc

1:00 p.m.-1:10 p.m.
**643-P**  Exploring Eating Styles of Older Adults with Type 1 Diabetes (T1D)  
Presenting Author: Angelica Cristello Sarteaau, MSPH

1:10 p.m.-1:20 p.m.
**644-P**  Racial Ethnic Disparities in Prescription of GLP-1 Receptor Agonists for People at High Risk for Diabetes on Atypical Antipsychotics  
Presenting Author: Jithin Sam Varghese, PhD, MTech
SUNDAY, JUNE 23, 2024

12:30 p.m.-1:30 p.m.
(continued)

**ePoster Theater**
Theme Area: *Acute and Chronic Complications*
Session Number: ePoster10
(*) New Progress in Clinical Screening and Interventions for ASCVD Risk Mitigation in Metabolic Disease
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Jonathan Q. Purnell, MD

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.
**433-P** Status of Type 2 Diabetes among Young Adults in Community Health Centers
Presenting Author: Sean E. DeLacey, MD

12:40 p.m.-12:50 p.m.
**434-P** Type 2 Diabetes Rather than the Presence of Significant Coronary Stenoses Is Associated with Quality of Life in Angiographed Coronary Patients
Presenting Author: Christoph H. Saely, Prof.

**435-P** UNABLE TO ATTEND

12:50 p.m.-1:00 p.m.
**436-P** Stringent Glycemic Control and Long-Term Macrovascular Outcomes in People with Type 2 Diabetes in China—A Retrospective Study
Presenting Author: Qi Pan, Professor

1:00 p.m.-1:10 p.m.
**437-P** Three Decades of Lipid-Lowering Therapy in Type 2 Diabetic Patients with Angiographically Proven Stable Coronary Artery Disease
Presenting Author: Andreas Leiherer, Dr
12:30 p.m.-1:30 p.m.

Session Break
(Take this opportunity to visit the Exhibit and Poster Halls)

1:30 p.m.-3:00 p.m.

Debate
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-DB07-1.5
The Role of Artificial Intelligence in Transforming Nutrition and Diabetes Care—Ready for Prime Time or Not Quite?
Room: W311
Chair: Janice MacLeod, MD
1:30 p.m.-1:50 p.m. Yes, the Future Is Now—Harness the Benefits Artificial Intelligence Has to Offer
   Samantha Kleinberg, PhD
1:50 p.m.-2:10 p.m. Not Quite, but We Are on Our Way to Building the Evidence
   Holly Nicastro, PhD, MPH
2:10 p.m.-2:20 p.m. Rebuttal
   Samantha Kleinberg, PhD
2:20 p.m.-2:30 p.m. Rebuttal
   Holly Nicastro, PhD, MPH
2:30 p.m.-3:00 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY32-1.5
Global Burden of Cardiovascular Disease in People with Diabetes (Includes Livestream)
Room: W320 (Chapin Theater)
Co-Chairs: Nuha El Sayed, MD, MMSc and Raveendhara Bannuru, MD, PhD, FAGE
1:30 p.m.-1:45 p.m. Cardiometabolic Disease Introduction and United Kingdom Region
   Kamlesh Khunti, PhD, MD, FRCGP, FRCP, FMedSci
1:45 p.m.-2:00 p.m. Cardiovascular Disease in China
   Linong Ji, MD
2:00 p.m.-2:15 p.m. Cardiovascular Disease in India
   Rakesh Kumar Sahay, MD, DNB, DM
2:15 p.m.-2:30 p.m. Cardiometabolic Disease in Arabian Gulf Region
   Mohammed Hassanein, FRCP, CCST, MPHIL
2:30 p.m.-3:00 p.m. Question and Discussion Period
SUNDAY, JUNE 23, 2024

1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR04-1.5
Continuous Glucose Monitoring—Can It Reduce Hypoglycemia Burden? *(Includes Livestream)*
Room: W307
Chair: Ilias (Elias) Spanakis, MD

1:30 p.m.-1:45 p.m.
239-OR  CGM Has a Specific Effect on the Reduction of Nocturnal Hypoglycemia in People with Type 1 Diabetes on an MDI Treatment Regimen
Presenting Author: Norbert Hermanns, PhD

1:45 p.m.-2:00 p.m.
240-OR  Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey
Presenting Author: Jennifer L. Sherr, MD, PhD

2:00 p.m.-2:15 p.m.
241-OR  Health-Related Quality of Life and Burden of Type 1 Diabetes and Severe Hypoglycemia in Adult Continuous Glucose Monitor Users
Presenting Author: Adriana Boateng-Kuffour, MS, MPH

2:15 p.m.-2:30 p.m.
242-OR  The Impact of Glucose Threshold on the Number and Duration of Glucose Episodes
Presenting Author: Vaios Koutroukas, MBBS, MA

2:30 p.m.-2:45 p.m.
243-OR  Characterization of Behavioral Patterns Involving Hypoglycemic Episodes in Type 1 Diabetes—Results from the T1DEXI Study Cohort
Presenting Author: Jose F. Garcia-Tirado, PhD

2:45 p.m.-3:00 p.m.
244-OR  Association of Type 1 Diabetes Duration or Duration of Advanced Technology Utilization with Severe Hypoglycemic Event Frequency
Presenting Author: Patrick Callahan, PharmD, MS
Oral Presentations

Theme Area: Acute and Chronic Complications
Session Number: AC-OR09-1.5
Emerging Small Molecule Biomarkers of ASCVD Risk in Metabolic Disease
Room: W208
Chair: Zsu-Zsu Chen, MD

1:30 p.m.-1:45 p.m.
245-OR Proteomic Analysis of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA)—Results and Integrated Predictors of Response
Presenting Author: Armando Vergara-Martel, MS

1:45 p.m.-2:00 p.m.
246-OR Association of Erythritol and Erythronate with Cardiovascular Outcomes and Death
Presenting Author: Layla A. Abushamat, MD, MPH

2:00 p.m.-2:15 p.m.
247-OR Blood Monocyte Phenotype Predicts Cardiovascular Risk in Type 2 Diabetes
Presenting Author: Nicolas Venteclef, PhD

2:15 p.m.-2:30 p.m.
248-OR Pro-B-Type Natriuretic Peptide Strongly Predicts Major Cardiovascular Events and Cardiovascular Mortality in Cardiovascular Disease Patients with NAFLD as Well as in Those without NAFLD
Presenting Author: Christoph H. Saely, Prof

2:30 p.m.-2:45 p.m.
249-OR Cystatin C Predicts Cardiovascular Events in Patients with Coronary Artery Disease Both among Patients with and among Those without Type 2 Diabetes
Presenting Author: Christoph H. Saely, Professor

2:45 p.m.-3:00 p.m.
250-OR Ceramides Surpass LDL-Cholesterol in Predicting Cardiovascular Mortality in Diabetic and Nondiabetic Patients
Presenting Author: Andreas Leiherer, Doz. Dr.
Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR02-1.5
Multifaceted Insights into Behavioral and Psychosocial Care for Youth and Families
Room: W314
Chair: Lori M. Laffel, MD, MPH

1:30 p.m.-1:45 p.m.
251-OR COIN2DOSE—Proof of Concept That a Behavioral Economics Intervention Can Increase Mealtime Insulin Use in Adolescents with Type 1 Diabetes
Presenting Author: Susana R. Patton, PhD, ABPP, CDCES

1:45 p.m.-2:00 p.m.
252-OR Psychosocial Predictors of Diabetes Self-Efficacy in Young Adults with Youth-Onset Type 2 Diabetes
Presenting Author: Paula M. Trief, PhD

2:00 p.m.-2:15 p.m.
253-OR Exploring Incorporation of Type 1 Diabetes into Identity and Perceptions of Diabetes Technologies in Adolescents and Young Adults (AYAs)
Presenting Author: Persis V. Commissariat, PhD, CDCES

2:15 p.m.-2:30 p.m.
254-OR Sleep Disturbance and Diabetes Symptom Burden in Young Adults with Type 1 Diabetes
Presenting Author: Stephanie Griggs, PhD, RN

2:30 p.m.-2:45 p.m.
255-OR The Relationship between Daytime Child Glycemic Levels and Parent Fear of Hypoglycemia
Presenting Author: Alexandra Monzon, PhD

2:45 p.m.-3:00 p.m.
256-OR Understanding Parent and Youth Diabetes Device Satisfaction
Presenting Author: Jessie J. Wong, PhD
1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR06-1.5
Novel Approaches to Treatment and Characterization of Diabetes in Pregnancy (With Norbert Freinkel Award Lecture) (With ADA Presidents' Select Abstract Presentation) (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: William L. Lowe, Jr., MD

1:30 p.m.-2:00 p.m.
Norbert Freinkel Award Lecture

Atlantic DIP—Changing the Landscape for Better Maternal and Infant Health
Fidelma P. Dunne, MD, PhD, FRCP, FRCPI

2:00 p.m.-2:15 p.m.
257-OR ADA Presidents' Select Abstract: The Effect of a Reduced-Energy Diet upon Maternal Weight and Pregnancy Outcomes in Women with Gestational Diabetes—The DiGest Trial
Presenting Author: Claire L. Meek, MB, ChB, MRCP, FRCPath, PhD

2:15 p.m.-2:30 p.m.
258-OR The Effect of Early Initiation of Treatment on Glycemia and Pregnancy Outcomes in Women with Early Gestational Diabetes Mellitus
Presenting Author: Jincy Immanuel, PhD

2:30 p.m.-2:45 p.m.
259-OR Real-Time CGM Achieves Higher TIR among Pregnant Persons with GDM
Presenting Author: Amy M. Valent, DO, MCR

2:45 p.m.-3:00 p.m.
260-OR Differences in Adipocyte Expandability and Function between Healthy Pregnancies and Pregnancies Complicated by Gestational Diabetes Mellitus and Preeclampsia
Presenting Author: Zoe Lees, MSc
1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR08-1.5
Weighing Opportunities of Incretin-Based Therapy in Obesity (With ADA Presidents' Select Abstract Presentation)
Room: W415C (Valencia Ballroom)
Chair: Ildiko Lingvay, MD, MPH, MSCS

1:30 p.m.-1:45 p.m.
261-OR ADA Presidents' Select Abstract: Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia after Semaglutide Withdrawal in a Murine Model of Obesity
Presenting Author: Harith Rajagopalan, MD, PhD

1:45 p.m.-2:00 p.m.
262-OR Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial
Presenting Author: Louis Aronne, MD

2:00 p.m.-2:15 p.m.
263-OR Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain
Presenting Author: Owen Carmichael, PhD

2:15 p.m.-2:30 p.m.
264-OR Effect of Tirzepatide on Kidney Function in People with Excess Body Weight and Type 2 Diabetes—A Post-Hoc Analysis of the SURMOUNT-2 Trial
Presenting Author: Hiddo L. Heerspink, PhD

2:30 p.m.-2:45 p.m.
265-OR Understanding Patterns of GLP-1/GLP-1 RA Use among Individuals with Type 1 Diabetes—A T1D Exchange (T1DX) Online Registry Analysis
Presenting Author: Yogish C. Kudva, MD

2:45 p.m.-3:00 p.m.
266-OR Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity
Presenting Author: Melissa K. Thomas, MD, PhD
Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR14-1.5
New Technology—AID Focus
Room: W315
Chair: Elena Toschi, MD

267-OR WITHDRAWN

1:30 p.m.-1:45 p.m.

268-OR Perioperative Fully Closed-Loop vs. Standard Insulin Delivery in Adults Undergoing Major Abdominal Surgery—A Two-Center Randomized Controlled Trial
Presenting Author: Gabija Krutkyte, MD

1:45 p.m.-2:00 p.m.

269-OR Glucose Control in Free-Life under Hybrid Closed-Loop 6 and 12 Months after Initiation from a Nationwide Survey
Presenting Author: Jean-Pierre Riveline, MD, PhD

2:00 p.m.-2:15 p.m.

270-OR Real-World Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System for >7,500 Users with High HbA1c (>9%) at Baseline
Presenting Author: Gregory P. Forlenza, MD, MS

2:15 p.m.-2:30 p.m.

271-OR Automated Hybrid Closed-Loop (AHCL) Systems for the Treatment of Cystic Fibrosis Related Diabetes (CFRD)
Presenting Author: Valeria Grancini, MD, PhD

2:30 p.m.-2:45 p.m.

272-OR Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth with Type 1 Diabetes
Presenting Author: Julia Ware, MBChB
SUNDAY, JUNE 23, 2024

1:30 p.m.-3:00 p.m.  
(continued)

Oral Presentations
Theme Area: Epidemiology/Genetics  
Session Number: EG-OR05-1.5
Common and Rare Genetic Variant Associations and Molecular QTL Scans in Type 2 Diabetes Tissues  
Room: W207  
Chair: Marijana Vujkovic, PhD

1:30 p.m.-1:45 p.m.
273-OR Initial eQTL Discovery in Individual Pancreatic Cell Types from the Human Pancreas Analysis Program  
Presenting Author: Mary A. Weidekamp, BS

1:45 p.m.-2:00 p.m.
274-OR Population-Scale Single-Nucleus Skeletal Muscle Chromatin Dynamics and Nucleosome Positioning in the Context of Type 2 Diabetes  
Presenting Author: Xiaoou Wang, MS

2:00 p.m.-2:15 p.m.
275-OR Associations of Combined Genetic and Lifestyle Risks with Incident Type 2 Diabetes in the UK Biobank  
Presenting Author: Cassandra N. Spracklen, PhD

2:15 p.m.-2:30 p.m.
276-OR Common Variant Polygenic Risk Score Influences Penetrance of Rare Variants in Monogenic Diabetes Genes  
Presenting Author: Alicia Huerta, PhD

2:30 p.m.-2:45 p.m.
277-OR Whole-Genome Sequencing Identifies a Rare Noncoding Variant Proximal to METRN Associated with HbA1c Levels  
Presenting Author: Gareth Hawkes, PhD

2:45 p.m.-3:00 p.m.
278-OR Single-Nucleus Multiomics Profiling across 49 Individuals of Hispanic Ancestry Reveals Cell-Specific Skeletal Muscle Insulin-Responsive Gene Regulatory Signatures  
Presenting Author: Benjamin Li, BS
1:30 p.m.-3:00 p.m.  
(continued)

**Oral Presentations**  
**Theme Area: Insulin Action/Molecular Metabolism**  
**Session Number: IA-OR03-1.5**  
**Metabolic Control of Insulin Action and Secretion (Includes Livestream)**  
**Room: W414**  
**Chair: Young-Bum Kim, PhD**

1:30 p.m.-1:45 p.m.  
279-OR  
**FBLN7 in Pre-adipocytes Promotes Adipose Tissue Fibrosis and Disrupts Metabolic Homeostasis in Obesity**  
Presenting Author: Hairong Yu, PhD

1:45 p.m.-2:00 p.m.  
280-OR  
**Manganese Regulates Hepatic Insulin Sensitivity and Glucose Tolerance**  
Presenting Author: Jennifer Gamarra, MA

2:00 p.m.-2:15 p.m.  
281-OR  
**Pyruvate Carboxylase Flux Is Increased in the Type 1 Diabetic Exocrine Pancreas**  
Presenting Author: Anna Rushin, BS

2:15 p.m.-2:30 p.m.  
282-OR  
**Nod1 Plays a Causal Role in Western-Diet–Induced Insulin Resistance and Glucose Intolerance in Microbiota-Deficient Conditions**  
Presenting Author: S. M. Niazur Rahman, MD, MSc

2:30 p.m.-2:45 p.m.  
283-OR  
**Adipose Stromal Cells Increase Insulin Sensitivity and Decrease Liver Gluconeogenesis in a Type 1 DM Mouse Model**  
Presenting Author: Lee-Wei Chen, MD

2:45 p.m.-3:00 p.m.  
284-OR  
**Androgen-Dependent Tissue Factor Pathway Inhibitor–Regulating Protein (ADTRP) Regulates Macrophage Polarization and Migration to Adipocytes**  
Presenting Author: Sze Min Ong, Bachelor's Degree
1:30 p.m.-3:00 p.m. (continued)

**Oral Presentations**

*Theme Area: Islet Biology/Insulin Secretion*

**Session Number: IB-OR02-1.5**

**Islet Signal Transduction**

Room: W206  
Chair: Jeffrey S. Tessem, PhD

1:30 p.m.-1:45 p.m.

**285-OR**  
**m^6A carRNA Methylation Regulates Chromatin State and Transcription in Islets from Humans with Type 2 Diabetes**  
Presenting Author: Namrata Shukla, MSc, PhD

1:45 p.m.-2:00 p.m.

**286-OR**  
**JNK3—A Key Downstream Target of Incretin Responses in β-Cells**  
Presenting Author: Ruy Andrade Louzada Neto, PhD

2:00 p.m.-2:15 p.m.

**287-OR**  
**Traf6 Directs a Noncanonical Role for Innate Immune Signaling in Pancreatic β-Cells**  
Presenting Author: Elena Levi D. Ancona, BS

2:15 p.m.-2:30 p.m.

**288-OR**  
**Inflammation-Induced Repression of Insulin Production by Targeting Its mRNA to Stress Granules via ADP-Ribosylation Machinery**  
Presenting Author: Soumyadeep Sarkar, MS, PhD

2:30 p.m.-2:45 p.m.

**289-OR**  
**Autophagy Promotes Islet α-Cell Function by Maintaining ER Proteostasis and Glucagon Production**  
Presenting Author: Wenzhen Zhu, PhD

2:45 p.m.-3:00 p.m.

**290-OR**  
**Acetylation Induces a SUMOylation–Phosphorylation Switch to Enhance MafA Transactivation**  
Presenting Author: Margot Chirikjian, BS
SUNDAY, JUNE 23, 2024

1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR02-1.5
Research Advances in Metabolic Liver Disease
Room: W308
Chair: Michael R. Rickels, MD, MS

1:30 p.m.-1:45 p.m.
291-OR A Noninvasive Index for Significant Liver Fibrosis and Stratifying Risk of Cirrhosis in Patients with Type 2 Diabetes Mellitus in Primary Care
Presenting Author: Xiaolong Qi, MD

1:45 p.m.-2:00 p.m.
292-OR Coenzyme A Synthase Knockdown Alleviates Metabolic Dysfunction–Associated Steatohepatitis via Decreasing Cholesterol in Liver Lipid Droplets
Presenting Author: Ikki Sakuma, MD, PhD

2:00 p.m.-2:15 p.m.
293-OR Improvement of Tissue-Specific Insulin Sensitivity after Bariatric Surgery Does Not Restore Hepatic OXPHOS Capacity
Presenting Author: Sabine Kahl, MD

2:15 p.m.-2:30 p.m.
294-OR The Role of Inositol Polyphosphate Multikinase in Progression of Nonalcoholic Steatohepatitis
Presenting Author: Ikrak Jung, PhD

2:30 p.m.-2:45 p.m.
295-OR The PNPLA3 G-allele Reduces the Beneficial Effects of a Healthy Diet on Hepatic Lipid Content in Type 2 Diabetes
Presenting Author: Kalliopi Pafili, Doctor

2:45 p.m.-3:00 p.m.
296-OR Glucagon and Insulin Cross Talk Regulates Hepatic Glycogen Metabolism
Presenting Author: Megan Capozzi, PhD
SUNDAY, JUNE 23, 2024

1:30 p.m.-3:00 p.m. (continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR04-1.5
New Insights into Therapeutic Strategies for Obesity and Diabetes
Room: W304 E-H
Chair: TBD

1:30 p.m.-1:45 p.m.
297-OR A Novel GLP-1/FGF21 Dual Agonist ZT003 Has Therapeutic Potential for Obesity, Diabetes, and Nonalcoholic Steatohepatitis
Presenting Author: Yuanyuan Zhang, PhD

1:45 p.m.-2:00 p.m.
298-OR Precision-Engineered Activin and GDF Ligand Trap HS235—A Novel Lean Mass-Preserving Treatment for Obesity
Presenting Author: Gauthier Schang, PhD

2:00 p.m.-2:15 p.m.
299-OR Discovery of Long-Acting Unimolecular Peptide Tetra-agonists Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors for Enhanced Metabolic Benefits in Animal Models of Obesity
Presenting Author: Cristina M. Rondinone, PhD

2:15 p.m.-2:30 p.m.
300-OR Beneficial Effect of the Combination Therapy of Cagrilintide, a Dual Amylin/Calcitonin Agonist, and Tirzepatide, a Dual GLP-1/GIP Agonist, on Body Weight Loss in Obese Rats
Presenting Author: Pilar Valdecantos, PhD

2:30 p.m.-2:45 p.m.
301-OR Synergistic Effects of Dapagliflozin and Tirzepatide Combination Treatment on Weight Loss and Glucose Regulation in Diet-Induced Obese Animals
Presenting Author: Mohamed Abu-Farha, PhD

2:45 p.m.-3:00 p.m.
302-OR The Anti-myostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity
Presenting Author: Melissa A. Fulham, PhD
SUNDAY, JUNE 23, 2024

1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR07-1.5
Novel Modulators of Adipose Tissue Function and Adiposity
Room: W304 A-D
Chair: Kevin Y. Lee, PhD

1:30 p.m.-1:45 p.m.
303-OR Notch Signaling Inhibitor ADPO-002 Promotes Browning in Human Adipose Tissue Explants
Presenting Author: Muhammad Raisul Abedin, PhD

1:45 p.m.-2:00 p.m.
304-OR The Obesity-Related Natriuretic Handicap Involves the Coordinated Regulation of Multiple Genes in Adipose Tissue to Blunt Natriuretic Peptide Signaling
Presenting Author: Ryan P. Ceddia, PhD

2:00 p.m.-2:15 p.m.
305-OR Adipose Tissue Perilipin 1 Insulin Responsiveness in Obesity
Presenting Author: Kelli Lytle, PhD

2:15 p.m.-2:30 p.m.
306-OR Diet-Induced Hyperlipidation of Adiponectin Contributes to Adiponectin Dysfunction
Presenting Author: Maia Smith, BS

2:30 p.m.-2:45 p.m.
307-OR Defective G-CSF in the Secretome of Epicardial Adipose Cells Favors Apoptosis and Cellular Stress of Cardiac Progenitor Cells in Human Obesity
Presenting Author: Giuseppe Palma, PhD

308-OR WITHDRAWN
1:30 p.m.-3:00 p.m.  
(continued)

ePoster Theater  
Theme Area: Clinical Diabetes/Therapeutics  
Session Number: ePoster11  
(*) Type 2 Diabetes—Prevention, Treatment, and Technology  
Room: Exhibit Hall (West A1-A3) ePoster Theater A  
Moderator: Sara Stafford, BSc, MDCM  

(*) Continuing Education Credit Is Not Awarded for this Session.

1:30 p.m.-1:40 p.m.  
1856-LB Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)  
Presenting Author: Linong Ji, MD

1:40 p.m.-1:50 p.m.  
1862-LB Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Suicide and Self-Harm among Patients with Type 2 Diabetes  
Presenting Author: Samantha B. Shapiro, MSc

1:50 p.m.-2:00 p.m.  
1904-LB Glycemic Improvement with Use of the Omnipod 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes—Results of the SECURE-T2D Pivotal Trial  
Presenting Author: Francisco J. Pasquel, MD, MPH

2:00 p.m.-2:10 p.m.  
1907-LB Estimating Optimal CGM Wear Time for Individuals with Type 2 Diabetes Not on Insulin  
Presenting Author: Souptik Barua, PhD

2:10 p.m.-2:20 p.m.  
1927-LB Impact of Continuous Glucose Monitoring Use on Hospitalizations in People with Type 2 Diabetes—Real-World Analysis  
Presenting Author: Satish K. Garg, MD

2:20 p.m.-2:30 p.m.  
1930-LB A Randomized Trial of Real-Time Continuous Glucose Monitoring (RT-CGM) with Culturally Tailored Education for Latino Patients with Type 2 Diabetes (DM)  
Presenting Author: Nicole Marie Ehrhardt, MD

(continued on next page)
2:30 p.m.-2:40 p.m.
1932-LB Cost-Effectiveness of the National Diabetes Prevention Program—A Real-World, Two-Year Prospective Study
Presenting Author: Shihchen Kuo, RPh, PhD

2:40 p.m.-2:50 p.m.
2071-LB Reduced Risk of Obesity-Related Cancers with Real-World Weight Loss
Presenting Author: Kenda Alkwatli, MD
1:30 p.m.-3:00 p.m. (continued)

**ePoster Theater**  
*Theme Area: Epidemiology/Genetics*  
*Session Number: ePoster12*  
(*) Growing Older with Diabetes  
*Room: Exhibit Hall (West A1-A3) ePoster Theater B*  
*Moderator: Naveed Sattar, MD, PhD*

(*) Continuing Education Credit Is Not Awarded for this Session.

1:30 p.m.-1:40 p.m.  
**1252-P** Markers of Alzheimer's Disease (AD) in Young Adults with Type 1 Diabetes, With and Without Diabetic Retinopathy (DR)  
*Presenting Author: Meghan E. Pauley, DO*

1:40 p.m.-1:50 p.m.  
**1253-P** Differential Risk of Dementia in Older Adults with Diabetes by Race/Ethnicity, Gender, and Age—Health and Retirement Study 1992–2020  
*Presenting Author: Aprill Z. Dawson, PhD*

1:50 p.m.-2:00 p.m.  
**1254-P** Association between Hemoglobin A1c, Time in Range, and Dementia in Veterans with Diabetes Mellitus  
*Presenting Author: Patricia C. Underwood, PhD, NP*

2:00 p.m.-2:10 p.m.  
**1255-P** Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real World Data in Japan  
*Presenting Author: Masaya Sakamoto, MD, PhD*

2:10 p.m.-2:20 p.m.  
**1256-P** Studying Mortality in Patients with Diabetes over 75 Years  
*Presenting Author: Sakiho Koide*

2:20 p.m.-2:30 p.m.  
**1367-P** Cognitive Assessment in Type 2 Diabetes—A Pilot Study in an Outpatient Clinic  
*Presenting Author: Roger Chen, MB BS, FRACP, PhD*

2:30 p.m.-2:40 p.m.  
**1368-P** Early-Life Adversity, Indicated by Difference between Observed and Genetically Predicted Height, and Risks of Diabetes and 48 Related Diseases  
*Presenting Author: Yanbo Zhang, PhD*

2:40 p.m.-2:50 p.m.  
**1378-P** The Association between Baseline Hemoglobin A1c (A1C) and Risk of Progression from Prediabetes to Diabetes across Adult Age Groups  
*Presenting Author: Ghazal S. Fazli, MPH, PhD*
SUNDAY, JUNE 23, 2024

3:15 p.m.–4:00 p.m.

Kelly West Award for Outstanding Achievement in Epidemiology Lecture *(Includes Livestream)*

*Lessons Learnt from Epidemiology of Diabetes in South Asians—The Kelly West Lecture 2024*

Viswanathan Mohan, MD, PhD, DSc, FRCP, FNA, FACE, MACP, FRSE

Room: W320 (Chapin Theater)

3:15 p.m.–4:15 p.m.

**Symposium**

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Session Number: BM-SY16-1**

**The Future of Diabetes Nutrition Interventions—Innovation in Practice (Includes Livestream)**

Room: W415B (Valencia Ballroom)

Chair: Barbara Eichorst, MS, RD, CDCES

3:15 p.m.–3:35 p.m. *Nutrition Education and Food Security Resource for American Indians and Alaska Natives—A Multilevel Intervention to Improve Type 2 Diabetes Outcomes*

Sarah A. Stotz, PhD, MS, RDN, CDCES

3:35 p.m.–3:55 p.m. *Produce Prescription as Intervention Method for Achieving Sustainable Impact on Individual and Community*

Elise Mitchell, MS, MPH

3:55 p.m.–4:15 p.m. *Gamification of Nutrition Interventions throughout the Lifespan*

Grace E. Shearrer, PhD

3:15 p.m.–3:35 p.m. *The United Kingdom Perspective*

Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD

3:35 p.m.–3:55 p.m. *The United States Perspective*

Rodolfo J. Galindo, MD

3:55 p.m.–4:15 p.m. *Question and Discussion Period*

Panel

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Session Number: BM-PN10-1**

**Educating Clinicians in the Latest Inpatient Management Strategies from Both Sides of the Pond**

Room: W311

Chair: Jane Jeffrie Seley, DNP, MPH, MSN, GNP, BC-ADM, CDCES, FADCES

3:15 p.m.–3:35 p.m. *The United Kingdom Perspective*

Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD

3:35 p.m.–3:55 p.m. *The United States Perspective*

Rodolfo J. Galindo, MD

3:55 p.m.–4:15 p.m. *Question and Discussion Period*
Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR01-1
Lower Extremity Complications with Systemic Effects
Room: W206
Chair: Ryan T. Crews, PhD, CCRP

309-OR WITHDRAWN

3:15 p.m.-3:30 p.m.
310-OR Bacteremia and Endocarditis Complicating Moderate and Severe Diabetic Foot Infections
Presenting Author: Mario C. Reyes, DPM

3:30 p.m.-3:45 p.m.
311-OR High Transepidermal Water Loss (TEWL) Associates with Failure to Maintain Wound Closure in Diabetic Foot Ulcers
Presenting Author: Brian M. Schmidt, DPM

3:45 p.m.-4:00 p.m.
312-OR OPAT is Protective of Major Amputation following Hospitalization for Diabetic Foot Infection
Presenting Author: Arthur Tarricone, DPM, MPH
3:15 p.m.-4:15 p.m.
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR05-1
Physiologic Responses to Hypoglycemia—New Insights
Room: W207
Chair: David A. Baidal, MD

3:15 p.m.-3:30 p.m.
313-OR Metoclopramide Improves Hypoglycemic Counterregulation in Diabetic Rats
Presenting Author: Micah H. Devore, BSc

3:30 p.m.-3:45 p.m.
314-OR A Randomized Study of a GPR119 Agonist on Glucagon Counterregulation
during Hypoglycemia in Type 1 Diabetes Mellitus (T1DM)
Presenting Author: Richard E. Pratley, MD

3:45 p.m.-4:00 p.m.
315-OR Task-Induced Alterations in the Salience Network amongst Patients with Type
1 Diabetes
Presenting Author: Elizabeth Sanchez Rangel, MD

4:00 p.m.-4:15 p.m.
316-OR Interoception Predicts Impaired Awareness of Hypoglycemia (IAH) in Adults
with Type 1 Diabetes (T1D)
Presenting Author: Austin M. Matus, PhD
3:15 p.m.-4:15 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Acute and Chronic Complications*  
*Session Number: AC-OR12-1*  
**Diabetic Kidney Disease** (Includes Livestream)  
Room: W307  
Chair: Jennifer A. Schaub, MD

3:15 p.m.-3:30 p.m.

317-OR  
**Identification of Genetic Regulators of Circulating Biomarkers of Kidney Decline in Diabetes**  
Presenting Author: Marcus G. Pezzolesi, PhD, MPH

3:30 p.m.-3:45 p.m.

318-OR  
**Podocyte-Specific Expression of REDD1 Promotes Altered Glomerular Pathology and Renal Function Deficits in a Rodent Model of Diabetic Nephropathy**  
Presenting Author: Siddarth Sunilkumar, PhD

3:45 p.m.-4:00 p.m.

319-OR  
**Renoprotective Effects of Glucagon and Incretin Agonist Combinations Mediated by Macula Densa Cells**  
Presenting Author: Georgina Gyarmati, MD, PhD, MPH

4:00 p.m.-4:15 p.m.

320-OR  
**Pyruvate Kinase M2 (PKM2) Activation in the Podocyte Prevented Subset Differentiation of Glomerular Cells Induced by Diabetes**  
Presenting Author: Jialin Fu, MD, PhD
3:15 p.m.–3:30 p.m.
**321-OR** Haptoglobin (Hp) Levels and Phenotype Are Unrelated to Severe Retinopathy in Type 2 Diabetes, but Lower Hp Reductions by Fenofibrate Are Associated with Greater Retinopathy Benefit—A FIELD Trial Study
Presenting Author: Kwok Leung Ong, PhD

3:30 p.m.–3:45 p.m.
**322-OR** Delaying Progression of Diabetic Retinopathy Worsens the Risk for Age-Related Macular Degeneration
Presenting Author: Ward Fickweiler, MD, PhD

3:45 p.m.–4:00 p.m.
**323-OR** Genetic Basis of Diabetic Macular Edema and Proliferative Diabetic Retinopathy—Insights from Next Generation Sequencing in the DRGen Study
Presenting Author: Sampath Rangasamy, PhD

4:00 p.m.–4:15 p.m.
**324-OR** Characterization of Aqueous Retinol Binding Protein 3 Concentrations and Diabetic Retinopathy Progression in Type 1 and Type 2 Diabetes
Presenting Author: Tanvi Choksi, BS
3:15 p.m.-4:15 p.m.  
(continued)

Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR09-1
Clinical Contributions in Type 1 Diabetes and Exercise
Room: W314
Chair: Jane E. Yardley, PhD

3:15 p.m.-3:30 p.m.
325-OR Enhancing Physical Activity Engagement among Individuals with Type 1 Diabetes—Exploring Perceived Barriers in the Era of New Technologies
Presenting Author: Capucine Guédet, MSc

3:30 p.m.-3:45 p.m.
326-OR Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System
Presenting Author: Lauren V. Turner, MSc

3:45 p.m.-4:00 p.m.
327-OR Does Exercise in Cool Water Result in a Greater Decrease in Blood Glucose Concentration than Exercise in Thermoneutral Water or on Land in People with Type 1 Diabetes?
Presenting Author: Kristina Abramoff, BS (Hons), PhD Candidate

4:00 p.m.-4:15 p.m.
328-OR Hypoglycemia Associated with Physical Activity in Automated Insulin Delivery Users—Frequency and Prevention Strategies
Presenting Author: Valerie Boudreau, RD, PhD
Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR19-1

New Insights and Treatments in Management of Youth with Type 1 Diabetes Mellitus
Room: W315
Chair: Laura M. Nally, MD

3:15 p.m.-3:30 p.m.
329-OR Dynamics of Treatment Regimens and Glycemic Outcomes in >100,000 Children from International Pediatric Diabetes Registries
Presenting Author: Anthony Zimmermann, MBBS, FRACP

3:30 p.m.-3:45 p.m.
330-OR Narrow Variation of Glucose Inflection Points (IPs) during Progression to Type 1 Diabetes (T1D) Stratified by Demographic and Genetic Differences in Autoantibody-Positive (Ab+) Individuals
Presenting Author: Heba M. Ismail, MB, BCh, PhD

3:45 p.m.-4:00 p.m.
331-OR Clinical and Immunologic Features Differ in Children at Type 1 Diabetes Onset by Ethnicity
Presenting Author: Kagan E. Karakus, MD

4:00 p.m.-4:15 p.m.
332-OR Multiomic Profiling of Extended Honeymoon Unveils New Therapeutic Targets
Presenting Author: Cristian Loretelli, PhD
Oral Presentations

Theme Area: Immunology/Beta-Cell Replacement

Session Number: IBC-OR06-1

Preclinical/Clinical Efforts for Beta-Cell Replacement Therapy

Room: W304 A-D

Chair: David M. Harlan, MD

3:15 p.m.-3:30 p.m.

333-OR Hypoimmune Islet Cells Mediate Insulin Independence after Allogeneic Transplantation in a Fully Immunocompetent Nonhuman Primate without Immunosuppression

Presenting Author: Xiaomeng Hu, PhD

3:30 p.m.-3:45 p.m.

334-OR Allogeneic Neo-Islets Reduce Insulin Need by up to 1.2 U/kg bw in Autoimmune Type 1 Diabetes Dogs over Three Years without Requiring Antirejection Drugs, Enough to Meet Human Type 1 Diabetes Mellitus Needs

Presenting Author: Anna Gooch, PhD

3:45 p.m.-4:00 p.m.

335-OR Preliminary Results of Islet Survival in a Novel Biovascular Pancreas Implanted in Primates

Presenting Author: Mehmet H. Kural, PhD

4:00 p.m.-4:15 p.m.

336-OR Females Undergoing Islet Transplantation with CNI-Based Immunosuppression May Be at Higher Risk of Renal Function Decline

Presenting Author: Alice L.J. Carr, PhD, MSci
3:15 p.m.–4:15 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Islet Biology/Insulin Secretion*  
Session Number: IB-OR04-1  
Endgame—Oral Abstracts on Beta-Cell Apoptosis (With ADA Presidents’ Select Abstract Presentation) *(Includes Livestream)*  
Room: W414  
Chair: Danielle Dean, PhD

3:15 p.m.–3:30 p.m.

**337-OR**  
**ADA Presidents’ Select Abstract: The LonP1 Protease Maintains Pancreatic B-Cell Survival by Governing Mitochondrial Protein Folding**  
Presenting Author: Jin Li, PhD

3:30 p.m.–3:45 p.m.

**338-OR**  
**Regulation of Pancreatic Beta-Cell Survival and Function during Aging**  
Presenting Author: Jimin Park, PhD

3:45 p.m.–4:00 p.m.

**339-OR**  
**Enhanced Expression of Zinc Finger Protein 385D Leads to Type 2 Diabetes Phenotype in Human Beta Cells**  
Presenting Author: Geming Lu, MD

4:00 p.m.–4:15 p.m.

**340-OR**  
**Transcriptional Activation in Beta Cells during ER Stress Linking iPLA2beta with NFkB**  
Presenting Author: Sasanka Ramanadham, PhD
SUNDAY, JUNE 23, 2024

3:15 p.m.~4:15 p.m.
(continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR03-1
Novel Pathways in Metabolic Regulation
Room: W304 E-H
Chair: Mark A. Herman, MD

341-OR WITHDRAWN

3:15 p.m.-3:30 p.m.
342-OR Systemic Identification of Functionally Conserved IncRNA Metabolic Regulators between Humans and Mice
Presenting Author: Chengfei Jiang, PhD

3:30 p.m.-3:45 p.m.
343-OR Identifying Nogo-B Receptor as a Resilience Factor in Preventing Obesity Associated Type 2 Diabetes
Presenting Author: Qing Miao, PhD

3:45 p.m.-4:00 p.m.
344-OR The MOTS-c/CK2 Pathway Is a Novel Molecular Target for Type 2 Diabetes in East Asians
Presenting Author: Hiroshi Kumagai, PhD
3:15 p.m.-4:15 p.m.
(continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR09-1
Risk Factors Reimagined—Beyond Obesity in Metabolic Risk
Room: W308
Chair: Mary-Elizabeth Patti, MD

3:15 p.m.-3:30 p.m.
345-OR Beyond Size Matters—The Impact of Pancreatic Volume and Pancreatic Fat on Type 2 Diabetes
Presenting Author: Hajime Yamazaki, MD, PhD

3:30 p.m.-3:45 p.m.
346-OR Hypothalamic Gliosis Is Associated with CVD Risk Factors in the Framingham Heart Study (FHS)
Presenting Author: Justin Lo, MS

3:45 p.m.-4:00 p.m.
347-OR Plasma Lipidome in People with Insulin-Sensitive and Insulin-Resistant Obesity
Presenting Author: Max C. Petersen, MD, PhD

4:00 p.m.-4:15 p.m.
348-OR Multiancestry Whole Genome Sequencing (WGS) Meta-analysis to Identify Loci Associated with Imaging-Measured Hepatic Steatosis
Presenting Author: Nicholette Allred, PhD
SUNDAY, JUNE 23, 2024

4:30 p.m.-6:00 p.m.

Panel
Theme Area: Acute and Chronic Complications
Session Number: AC-PN04-1.5
Diabetic Foot Disparities—Treatment With and Without a Multidisciplinary Team
Room: W208
Chair: Amanda L. Killeen, DPM, FACPM, CWSP, FFPM RCPS (Glasg)
4:30 p.m.-4:50 p.m. How It Looks When It Works—Multidisciplinary Team Approach to Diabetic Foot Infection
Peter A. Crisologo, DPM, FFPM, RCPS (Glasg)
4:50 p.m.-5:10 p.m. Practicing as an Island—When a Multidisciplinary Team Isn’t Available
Vilayvanh Saysoukha, DPM
5:10 p.m.-5:30 p.m. From Home to Hospital—A Paramedic’s Perspective on the Diabetic Foot
Andrew J. Torres, NRP, CP
5:30 p.m.-6:00 p.m. Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY03-1.5
Survey Says—Psychosocial Screening Tools and Their Psychometric Properties for Youth and Adults with Diabetes
Room: W314
Chair: Marisa E. Hilliard, PhD
4:30 p.m.-5:00 p.m. Screening Tools for Executive Function
Jessie J. Wong, PhD
5:00 p.m.-5:30 p.m. Screening Tools for Depression
Jeffrey S. Gonzalez, PhD
5:30 p.m.-6:00 p.m. Screening Tools for Anxiety Disorders
Holly K. O’Donnell, PhD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY12-1.5
Mind the Gap—Health Benefits of Exercise in Women With or at Risk for Diabetes (Includes Livestream)
Room: W307
Chair: Lia Bally, MD, PhD
4:30 p.m.-4:55 p.m. Exercise and Health in Women with Diabetes through the Lifespan
Cuilin Zhang, MD, PhD
4:55 p.m.-5:20 p.m. Exercise for the Prevention/Management of Type 2 Diabetes in Breast Cancer Survivors
Sam Orange, PhD
5:20 p.m.-5:45 p.m. Mechanism Underlying the Benefits of Maternal Exercise on Offspring Health
Laurie Goodyear, PhD
5:45 p.m.-6:00 p.m. Question and Discussion Period
Debate
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-DB05-1.5
Keeping Up with Hollywood—Who Should Be Prioritized for New Antiobesity Medications?
Room: W308
Co-Chairs: Caroline K. Kramer, MD, PhD and W. Timothy Garvey, MD, MACE
4:30 p.m.-4:40 p.m. The Person Who Has Already Benefited from the Medication
Deborah Horn, DO, MPH, MFOMA
4:40 p.m.-4:50 p.m. The Person with Overweight and Cardiovascular Disease
Pam R. Taub, MD, FACC, FASPC
4:50 p.m.-5:00 p.m. The Person with Class 3 Obesity and No Comorbidities
Neda Rasouli, MD
5:00 p.m.-5:05 p.m. Rebuttal
Deborah Horn, DO, MPH, MFOMA
5:05 p.m.-5:10 p.m. Rebuttal
Pam R. Taub, MD, FACC, FASPC
5:10 p.m.-5:15 p.m. Rebuttal
Neda Rasouli, MD
5:15 p.m.-5:30 p.m. The Health Economics Perspective
William H. Herman, MD, MPH
5:30 p.m.-6:00 p.m. Question and Discussion Period

Panel
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-PN17-1.5
Prioritizing Diversity in Clinical Trials
Room: W315
Chair: Viral N. Shah, MD
4:30 p.m.-4:50 p.m. Lack of Equitable Representation in Clinical Trials Compounds Disparities
Nana-Hawa Yayah Jones, MD
4:50 p.m.-5:10 p.m. The Importance of Diversity from the Regulatory Perspective
Dolly Misra, MD
5:10 p.m.-5:30 p.m. Equitable Science Is Good Science—The Importance of Diversity from the PI’s Perspective
Ananta Addala, DO, MPH
5:30 p.m.-5:50 p.m. The Importance of Diversity from the Advocacy Perspective
Kyle Banks
5:50 p.m.-6:00 p.m. Question and Discussion Period
4:30 p.m.–6:00 p.m.  (continued)

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY02-1.5*

**Controversies in Continuous Glucose Monitoring (CGM) Use during Pregnancy—Time in Range and Beyond Time in Range**  
*Room: W415C (Valencia Ballroom)*  
*Chair: Emily D. Szmuilowicz, MD, MS*

4:30 p.m.–4:50 p.m.  *Time in Range vs. Conventional Fasting/Postprandial Targets—Which Should Take Precedence?*  
Sarit Polsky, MD, MPH

4:50 p.m.–5:10 p.m.  *Confronting A1C in the Era of Continuous Glucose Monitoring (CGM)*  
Claire L. Meek, MB, ChB, MRCP, FRCPath, PhD

5:10 p.m.–5:30 p.m.  *Time in Range and Beyond Time in Range—Which Continuous Glucose Monitoring Metrics to Follow during Pregnancy, and What Should the Targets Be?*  
Ashley Battarbee, MD, MSCR

5:30 p.m.–5:50 p.m.  *Glycemic Targets in Early vs. Late Gestation as a Predictor of Fetal Overgrowth*  
Eleanor M. Scott, BM, BS, MD, FRCP

5:50 p.m.–6:00 p.m.  *Question and Discussion Period*

---

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY31-1.5*

**Multiple Faces of Therapeutic Inertia in Diabetes**  
*Room: W311*  
*Chair: Alexander Turchin, MD, MS*

4:30 p.m.–4:50 p.m.  *Therapeutic Inertia in Treatment of Diabetes—Are We Making Progress?*  
Steven Edelman, MD

4:50 p.m.–5:10 p.m.  *The Other End of the Spectrum—Therapeutic Inertia in Treatment of Hypoglycemia*  
Stewart B. Harris, CM, MD, MPH, FCFP, FACPM

5:10 p.m.–5:30 p.m.  *Therapeutic Inertia Is Not Just About Medications—Lifestyle Counseling in Diabetes*  
Huabing Zhang, MD

5:30 p.m.–5:50 p.m.  *When Patients Decline Diabetes Treatment Recommendations*  
William H. Polonsky, PhD, CDCES

5:50 p.m.–6:00 p.m.  *Question and Discussion Period*
SUNDAY, JUNE 23, 2024

4:30 p.m.-6:00 p.m. (continued)

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY38-1.5*  
**Joint ADA/PAHO Symposium—Latin America and the Caribbean Regional Approach to Prevent and Control Diabetes**  
*Room: W304 E-H*  
*Chair: Anselm Hennis, MD, PhD, FRCP, FACP*

4:30 p.m.-4:50 p.m. *The Growing Burden of Diabetes in Latin America and the Caribbean*  
Anselm Hennis, MD, PhD, FRCP, FACP

4:50 p.m.-5:10 p.m. *Mexico’s Experience to Address Obesity and Improve Diabetes Control*  
Ruy López Ridaura, MD, PhD

5:10 p.m.-5:30 p.m. *Improving Diabetes Care in Jamaica*  
Tamu Davidson, MD, MPH

5:30 p.m.-6:00 p.m. *Question and Discussion Period*

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY42-1.5*  
**THE STEP-HFpEF and STEP-HFpEF-DM Trials—Targeting Obesity to Treat Heart Failure**  
*(Includes Livestream)*  
*Room: W320 (Chapin Theater)*  
*Chair: Naveed Sattar, MD, PhD*

4:30 p.m.-4:45 p.m. *STEP-HFpEF and STEP-HFpEF-DM Trials—Why and What?*  
Mikhail N. Kosiborod, MD

4:45 p.m.-5:00 p.m. *STEP-HFpEF-DM—A Deep Dive into the Metabolic Outcomes*  
Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP, FMedSci

5:00 p.m.-5:15 p.m. *Does Weight Reduction Modulate Heart Failure Benefit? Insights from STEP-HFpEF*  
Javed Butler, MD

5:15 p.m.-5:30 p.m. *Clinical Implications of the STEP-HFpEF Program and Defining the Next Steps Forward*  
Subodh Verma, MD, PhD, FRCSC

5:30 p.m.-5:45 p.m. *Discussant*  
Vanita R. Aroda, MD

5:45 p.m.-6:00 p.m. *Question and Discussion Period*
Symposium
Theme Area: Epidemiology/Genetics
Session Number: EG-SY03-1.5
Big P, Little P—Diabetes Policies for Public Health
Room: W207
Chair: Gabriel Q. Shaibi, PhD
4:30 p.m.-4:50 p.m. Global Policies for Diabetes Prevention—Successful Policies and Proposed Action Plans
Jennifer Manne-Goehler, MD, ScD
4:50 p.m.-5:10 p.m. Medicaid Expansion (or Lack Thereof) and Diabetes Health Outcomes
Meng-Yun Lin, PhD, MPH
5:10 p.m.-5:30 p.m. State-Level Policies That Promote Diabetes Prevention and Successful Disease Management
Matthew J. O'Brien, MD, MSc
5:30 p.m.-5:50 p.m. Working to Prevent Diabetes—Workplace Policies in Canada That Promote Health
Diana Sherifali, PhD, RN, CDE
5:50 p.m.-6:00 p.m. Question and Discussion Period

Symposium
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-SY07-1.5
Long-Term Goals and Challenges for Beta-Cell Replacement Therapy (Includes Livestream)
Room: W414
Chair: Edward Phelps, PhD
4:30 p.m.-4:50 p.m. Sites for Delivery
Melanie L. Graham, PhD, MPH
4:50 p.m.-5:10 p.m. Porcine/Xeno Approaches
David K.C. Cooper, MB, MD, PhD
5:10 p.m.-5:30 p.m. Induction of Long-Term Tolerance
Norma Sue Kenyon, PhD
5:30 p.m.-5:50 p.m. Role for Basic Science/Animal Models
Eckhard Wolf, PhD
5:50 p.m.-6:00 p.m. Question and Discussion Period
Symposium
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-SY05-1.5
Lipid Regulation of Mitochondrial Metabolism
Room: W304 A-D
Chair: Meilian Liu, PhD
4:30 p.m.-4:45 p.m. Mitochondrial Phospholipid Metabolism
Katsu Funai, PhD
4:45 p.m.-5:00 p.m. Structure/Function of Regulators of Lipid Droplet Formation
Michael Airola, PhD
5:00 p.m.-5:15 p.m. Mitochondrial Dynamics and Function
Erin Seifert, PhD
5:15 p.m.-5:30 p.m. Mitochondria Association with Lipid Droplets—Regulation and Function
Orian Shirihai, MD, PhD
5:30 p.m.-6:00 p.m. Question and Discussion Period

Symposium
Theme Area: Obesity/Integrated Physiology
Session Number: IP-SY02-1.5
Weight-Reducing Mechanisms of GLP-1-Based Therapies—New Insights from Animal Studies (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Zhiping Pang, PhD
4:30 p.m.-4:50 p.m. Novel Insights into Regulation of Energy Metabolism by GIPR Agonism and GIPR—GLP-1R Coagonism
Timo D. Müller, PhD
4:50 p.m.-5:10 p.m. Systemically-Administered GLP-1 Receptor Agonists vs. Brain-Derived GLP-1—Does It Matter for Weight-Reducing Therapy?
Stefan Trapp, PhD
5:10 p.m.-5:30 p.m. Unraveling the Distributed Neural Circuits Underlying Food Intake and Body Weight Effects of GLP-1 and Its Analogues
Karolina P. Skibicka, PhD
5:30 p.m.-5:50 p.m. Strategies for Mitigating Nausea and Emesis Side Effects of GLP-1R Agonism
Tito Borner, PhD
5:50 p.m.-6:00 p.m. Question and Discussion Period
SUNDAY, JUNE 23, 2024

4:30 p.m.–6:00 p.m.  
(continued)

Oral Presentations  
Theme Area: Islet Biology/Insulin Secretion  
Session Number: IB-OR03-1.5  
Beta-Cell Blueprints—Oral Abstracts on Islet Development and Postnatal Growth  
Room: W206  
Chair: Ronadip R. Banerjee, MD, PhD

4:30 p.m.–4:45 p.m.  
349-OR  Reduction of RNA-Editing Enzyme ADAR1 in Human Islets Triggers an Interferon Response and Impairs Beta-Cell Function  
Presenting Author: Chunhua Dai, MD

4:45 p.m.–5:00 p.m.  
350-OR  Parturition Event Regulates Endocrine Genesis during Pancreas Differentiation  
Presenting Author: Agena Suzuki, Master's Degree

5:00 p.m.–5:15 p.m.  
351-OR  Role of Mef2a in Beta-Cell Differentiation and Function during ER Stress  
Presenting Author: Rohit B. Sharma, PhD

5:15 p.m.–5:30 p.m.  
352-OR  Selective Loss of the Spliced Form of Xbp1 Causes Early-Onset Diabetes in Male but Not Female Mice  
Presenting Author: Yingfeng Deng, PhD

5:30 p.m.–5:45 p.m.  
353-OR  Chd3 Helicase Modulates Pancreatic β-Cell Function in Absence of Chd4  
Presenting Author: Sukrati Kanojia, MS

5:45 p.m.–6:00 p.m.  
354-OR  The Role of Clic-Like Chloride Channel 1 in the Pancreatic Beta Cell  
Presenting Author: Yaohuan Zhang, Bachelor's Degree
MONDAY, JUNE 24, 2024

Scientific Sessions
8:00 a.m.-9:30 a.m.

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY15-1.5
A Means to an Endpoint—Establishing Meaningful Outcomes in Clinical Neuropathy Trials
Room: W206
Chair: Lynn Ang, MD
8:00 a.m.-8:20 a.m. Epidemiology Overview of Diabetic Neuropathy
   Barbara H. Braffett, PhD, MS
8:20 a.m.-8:40 a.m. Meaningful Endpoints in Clinical Trials—Lessons Learned
   Rodica Busui, MD, PhD
8:40 a.m.-9:00 a.m. Perspectives on Small-Fiber Endpoints
   Bruce A. Perkins, MD, MPH, FRCP(C)
9:00 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY08-1.5
Innovative Programs That Take on the Challenge of Hard-to-Reach Populations (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Veronica J. Brady, PhD, MSN, BSN
8:00 a.m.-8:30 a.m. Delivering Diabetes Self-Management Education in the Wild West
   Deb Bjorsness, MPH, BC-ADM, RD, CDCES
8:30 a.m.-9:00 a.m. Delivering Diabetes Self-Management Support in the Diabetes Belt
   Windsor W. Sherrill, PhD, MHA, MBA
9:00 a.m.-9:30 a.m. Delivering Diabetes Prevention and Self-Management Support in Latino Communities in the Rockies
   Rocio I. Pereira, MD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY03-1.5
Myth Busters on “Category X” Drugs in Pregnancy—Evidence for Stopping Commonly Used Medications during Pregnancy, Preconception, and Lactation (Includes Livestream)
Room: W414
Chair: Carol J. Levy, MD, CDCES
8:00 a.m.-8:20 a.m. Pharmacology Overview—Which Types of Medications Are Most Likely to Cause Problems in Pregnancy?
   Jason G. Umans, MD, PhD
8:20 a.m.-8:40 a.m. Lipid-Lowering Drugs—The Good, The Bad, and The Not That Ugly
   Ira J. Goldberg, MD
8:40 a.m.-9:00 a.m. GLP-1 Receptor Agonists—How Should We Counsel Our Patients?
   Maisa N. Feghali, MD, MSCR
9:00 a.m.-9:20 a.m. ACE Inhibitors and ARBs—Timing Is Everything
   Jessica S. Tangren, MD
9:20 a.m.-9:30 a.m. Question and Discussion Period
Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY21-1.5
Cost and Quality—Improving Diabetes Care and the Cost of Ongoing Inequities
Room: W311
Chair: Celeste Thomas, MD

8:00 a.m.-8:20 a.m. Virtual Peer Groups in Adolescents and Young Adults with Type 1 Diabetes
Jennifer Raymond, MD, MCR

8:20 a.m.-8:40 a.m. Improving Diabetes Outcomes and Reducing Inequities through Collaboration—Perspective from the T1D Exchange
Osagie Ebekozien, MD, MPH, CPHQ

8:40 a.m.-9:00 a.m. Insurance Coverage, Medical Costs and Productivity Loss among Working Age Adults with Diabetes
Primary Speaker: TBD

9:00 a.m.-9:20 a.m. Disparities in Diabetes Prevalence and Management
Saria Hassan, MD, MPH

9:20 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY22-1.5
Towards Innovative and Equitable Care in Youth-Onset Type 2 Diabetes
Room: W315
Chair: Sheela N. Magge, MD, MSCE

8:00 a.m.-8:20 a.m. Advances in Pathophysiology and Novel Treatments in Youth-Onset Type 2 Diabetes
Stephanie T. Chung, MBBS

8:20 a.m.-8:40 a.m. Diabetes Care Technology Use and Barriers in Youth-Onset Type 2 Diabetes
Laya Ekhlaspour, MD

8:40 a.m.-9:00 a.m. The Genetics of Youth-Onset Type 2 Diabetes—Where Are We and What Lies Ahead?
Jennifer N. Todd, MD

9:00 a.m.-9:20 a.m. New Insights into Pathophysiology and Screening of Early Microvascular Complications in Youth-Onset Type 2 Diabetes
Risa M. Wolf, MD

9:20 a.m.-9:30 a.m. Question and Discussion Period
MONDAY, JUNE 24, 2024

8:00 a.m.-9:30 a.m. (continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY39-1.5
ADA Symposium—Major Advances and Discoveries in Diabetes—The Year in Review
Room: W415C (Valencia Ballroom)
Chair: Alice Y.Y. Cheng, MD, FRCPC
8:00 a.m.-8:20 a.m. Clinical
     Vanita R. Aroda, MD
8:20 a.m.-8:40 a.m. Translational
     Mary-Elizabeth Patti, MD
8:40 a.m.-9:00 a.m. Basic
     Bruce Verchere, PhD
9:00 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Epidemiology/Genetics
Session Number: EG-SY07-1.5
Omics to Understand Genome-Wide Association Study—What’s the Mechanism?
Room: W207
Chair: H. Efsun Arda, PhD
8:00 a.m.-8:30 a.m. Genome-Wide Association Study—From Variant to Function
     Debora Sobreira, PhD
8:30 a.m.-9:00 a.m. Genome-Wide Association Study Functional Follow-up at a Single Locus
     Nicole Krentz, PhD
9:00 a.m.-9:30 a.m. Leveraging Omics in the Study of Type 2 Diabetes in Underrepresented Populations
     Ayo P. Doumatey, PhD

Symposium
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-SY01-1.5
Cross Talk between Beta Cells and Immune Cells
Room: W304 A-D
Chair: Laura M. Jacobsen, MD
8:00 a.m.-8:20 a.m. Mining Spatial Transcriptomics for Beta-Cell—Immune-Cell Cross Talk
     Miguel Medina-Serpas, BS
8:20 a.m.-8:40 a.m. Profiling Islet—Immune Cell Interactions in the Human Pancreas
     Klaus H. Kaestner, PhD, MS
8:40 a.m.-9:00 a.m. Imaging Beta-Cell—Immune-Cell Interactions
     Dirk Homann, MD
9:00 a.m.-9:20 a.m. What Do Immune Cells See in the Pancreas?
     Eddie A. James, PhD
9:20 a.m.-9:30 a.m. Question and Discussion Period
8:00 a.m.-9:30 a.m. (continued)

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-SY06-1.5
Molecular Integration of Amino Acid and Fat Metabolism in Health and Metabolic Disease
Room: W304 E-H
Chair: Richard Kibbey, IV, MD, PhD
8:00 a.m.-8:15 a.m. Amino Acid Metabolism and Brown Fat Activation
Shingo Kajimura, PhD
8:15 a.m.-8:30 a.m. Amino Acid Signaling and Glucose Regulation
Phillip J. White, PhD
8:30 a.m.-8:45 a.m. Mitochondrial Branched-Chain Amino Acid Oxidation and Metabolism
Kelsey Fisher-Wellman, PhD
8:45 a.m.-9:00 a.m. Pleotropic Effects of Exercise on Amino Acid and Fat Metabolism in Metabolic Disease
Kristin I. Stanford, PhD
9:00 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Obesity/Integrated Physiology
Session Number: IP-SY03-1.5
Metabolism and Aging-Related Diseases
Room: W308
Chair: Liangyou Rui, PhD
8:00 a.m.-8:20 a.m. LRP1 Is a Major Link between Obesity, Memory, and Neurodegenerative Disease
Young-Bum Kim, PhD
8:20 a.m.-8:40 a.m. Caloric Restriction and Aging in Nonhuman Primates
Ricki Colman, PhD
8:40 a.m.-9:00 a.m. Skeletal Aging, the Role of Cellular Senescence in Aging and Endocrine Disease
Joshua N. Farr, PhD
9:00 a.m.-9:20 a.m. Aging-Dependent Regulatory Cells Emerge in Subcutaneous Fat to Inhibit Adipogenesis
Hei Sook Sul, PhD
9:20 a.m.-9:30 a.m. Question and Discussion Period
8:00 a.m.-9:30 a.m. (continued)

**Symposium**

*Theme Area: Obesity/Integrated Physiology*

*Session Number: IP-SY04-1.5*

**Beyond the Scale—Exploring Causes and Consequences of Weight Fluctuation** *(Includes Livestream)*

*Room: W307*

*Chair: Siegfried Ussar, PhD*

8:00 a.m.-8:30 a.m.  *Immune Cell Memory and Weight Cycling*

  Heather Caslin, PhD

8:30 a.m.-9:00 a.m.  *Signs of Antiaging in Lifestyle Interventions*

  Iris Shai, PhD

9:00 a.m.-9:30 a.m.  *Nutrient Uptake and Metabolism during Weight Loss*

  Marcus DaSilva Goncalves, MD, PhD

**Symposium**

*Theme Area: Clinical Diabetes/Therapeutics*

*Session Number: CT-SY50-1.5*

**Consensus Monitoring Guidance in Early-Stage Type 1 Diabetes** *(Includes Livestream)*

*Room: W320 (Chapin Theater)*

*Co-Chairs: Anastasia Albanese-O’Neill, PhD, APRN, CDCES and Chantal Mathieu, MD, PhD*

8:00 a.m.-8:10 a.m.  *Why Do We Need Monitoring Guidance?*

  Moshe Phillip, MD

8:10 a.m.-8:20 a.m.  *Coming to Consensus*

  Linda DiMeglio, MPH, MD

8:20 a.m.-8:35 a.m.  *Overview of Pediatric Advice*

  Kurt J. Griffin, PhD, MD

8:35 a.m.-8:50 a.m.  *Overview of Adult Advice*

  Rifka C. Schulman-Rosenbaum, MD, FACE, FACP

8:50 a.m.-9:10 a.m.  *Psychosocial and Educational Considerations*

  Brigitte Frohnert, MD, PhD

9:10 a.m.-9:20 a.m.  *Next Steps and Real World Applications*

  Sanjoy Dutta, PhD

9:20 a.m.-9:30 a.m.  *Panel Discussion*
MONDAY, JUNE 24, 2024

8:00 a.m.-9:30 a.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR15-1.5
New Technology—Continuous Glucose Monitoring
Room: W314
Chair: Ebne Rafi, PharmD

8:00 a.m.-8:15 a.m.
355-OR Glycemic Outcomes with CGM Use in Patients with Type 2 Diabetes—Real World Analysis
Presenting Author: Satish K. Garg, MD

8:15 a.m.-8:30 a.m.
356-OR A Randomized Controlled Trial Using Continuous Glucose Monitoring (CGM) to Guide Food Choices and Diabetes Self-Care in People with Type 2 Diabetes Not Taking Insulin
Presenting Author: Thomas W. Martens, MD

8:30 a.m.-8:45 a.m.
357-OR Association between Continuous Glucose Monitoring and Diabetes-Related Complications in Children with Type 1 Diabetes—Nationwide Cohort Study
Presenting Author: Ji Yoon Kim, MD, MS

8:45 a.m.-9:00 a.m.
358-OR Remote CGM Monitoring in People with Type 2 Diabetes (T2D) in an Underresourced Setting
Presenting Author: Valerie F. Ruelas, MSW

9:00 a.m.-9:15 a.m.
359-OR CGM in Primary Care—Practice Characteristics and Choice of CGM Implementation Strategy in PREPARE 4 CGM
Presenting Author: Sean Oser, MD, MPH

9:15 a.m.-9:30 a.m.
360-OR Defining New Targets for Interventions to Increase Continuous Glucose Monitoring (CGM) Use in Primary Care
Presenting Author: Jovan Milosavljevic, MD
MONDAY, JUNE 24, 2024

9:45 a.m.-11:15 a.m.

Special Lectures and Addresses
Session Number: OSAA-01
Outstanding Scientific Achievement Award Lecture and Banting Medal for Scientific Achievement Award Lecture (Includes Livestream)
Room: West Hall B3-4 (General Session)
9:45 a.m.-9:50 a.m. Introduction of Outstanding Scientific Achievement Awardee
Mandeep Bajaj, MD
9:50 a.m.-10:20 a.m. Insulin and Instructions—How the Epigenome Directs Diabetes
Stephen C.J. Parker, PhD
10:20 a.m.-10:25 a.m. Introduction of Banting Award Winner
Mandeep Bajaj, MD
10:25 a.m.-10:55 a.m. The Science of Diabetes and A Life of Trials
Rury R. Holman MBChB, FRCP(Lond.), FMedSci
10:55 a.m.-11:15 a.m. Conclude

11:30 a.m.-12:30 p.m.

Professional Interest Group
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-IG01-1
Discussion on Diabetes Technology—Enhancing Clinic Efficiency through the Integration of Diabetes Technologies
Room: W304 A-D
Chair: Viral N. Shah, MD
11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-11:45 a.m. Overview of Currently Available Technologies and Downloading Platforms
Laya Ekhlaspour, MD
11:45 a.m.-11:55 a.m. Outpatient Clinic Flow for Efficient Work Order
Halis K. Akturk, MD
11:55 a.m.-12:05 p.m. Efficient Workflow for Inpatient Technology Use
Estelle M. Everett, MD, MHS
12:05 p.m.-12:30 p.m. Question and Discussion Period

Professional Interest Group
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-IG04-1
Discussion on Health Care Delivery and Quality Improvement
Room: W304 E-H
Chair: Francisco J. Pasquel, MD, MPH
11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-11:55 a.m. An Algorithm for Preoperative Management of Diabetes in Elective Surgery Patients
Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD
11:55 a.m.-12:15 p.m. Designing a Program for Preoperative Management of Diabetes
Rajesh K. Garg, MD
12:15 p.m.-12:30 p.m. Question and Discussion
MONDAY, JUNE 24, 2024

11:30 a.m.-12:30 p.m.  (continued)

**Professional Interest Group**
*Theme Area: Epidemiology/Genetics*
*Session Number: EG-IG01-1*
**Discussion on Public Health and Epidemiology—Kids Are Not Little Adults—Challenges and Opportunities in the Use of Pharmacotherapy for Youth With and at Risk for Type 2 Diabetes**
*Room: W207*
*Chair: Noël C. Barengo, MD, PhD, MPH*
11:30 a.m.-11:35 a.m.  *Introduction*
11:35 a.m.-11:55 a.m.  *Role of Antiobesity Pharmacotherapy in Youth With and At Risk for Type 2 Diabetes*
  Megan Oberle Bensignor, MD, MSHP
11:55 a.m.-12:15 p.m.  *Moving Beyond Insulin and Metformin—Learning from Adult Experience to Improve Care for Youth with Type 2 Diabetes*
  Mary Ellen Vajravelu, MD, MSHP
12:15 p.m.-12:30 p.m.  *Question and Discussion Period*

**Professional Interest Group**
*Theme Area: Immunology/Beta-Cell Replacement*
*Session Number: IBC-IG01-1*
**Discussion on Immunology/Beta-Cell Replacement—Beta-Cell Stressors, Autoantigen Targets, and How This Provokes Immune Attack**
*Room: W206*
*Chair: Meaghan Stumpf, MD*
11:30 a.m.-11:35 a.m.  *Introduction*
11:35 a.m.-11:50 a.m.  *Dissecting the Autoimmune T-Cell Repertoires in Type 1 Diabetes*
  Alok Joglekar, PhD
11:50 a.m.-12:05 p.m.  *Beta-Cell Adaptive Stress Response and Immune System Cross Talk in Diabetes*
  Amelia K. Linnemann, PhD
12:05 p.m.-12:20 p.m.  *Stress-Induced Pathways in Beta Cells Increase Immune Perception of Pancreatic Islets—Implications for Type 1 Diabetes*
  Aisha Callebut, PhD
12:20 p.m.-12:30 p.m.  *Question and Discussion Period*

**Professional Development**
*Theme Area: Professional Development*
*Session Number: PD-03-1*
**Getting The Career You Envision—How To Negotiate For What You Need (And Want) (Includes Livestream)**
*Room: W307*
*Chair: Jane E.B. Reusch, MD*
11:30 a.m.-12:10 p.m.  *Getting The Career You Envision—How To Negotiate For What You Need (And Want)*
  Judith G. Regensteiner, PhD
12:10 p.m.-12:30 p.m.  *Question and Discussion Period*
**ePoster Theater**  
Theme Area: *Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
Session Number: ePoster13  
(*) Tailoring Diabetes Self-Management Education to Improve Success  
Room: Exhibit Hall (West A1-A3) ePoster Theater A  
Moderator: Helen A. Habib, PharmD, BCACP, CDCES  

(*) *Continuing Education Credit Is Not Awarded for this Session.*

11:30 a.m.-11:40 a.m.  
**533-P** Geospatial Analysis of a Diabetes Management Program—Program Participation and Social Determinants of Health  
Presenting Author: Samantha Kanny, MS

11:40 a.m.-11:50 a.m.  
**534-P** Structured CGM Education Delivered via Mobile Phone Is Associated with Increased Time in Range—Proof-of-Concept Study Results  
Presenting Author: Melissa P. Holloway, BA, MSt

11:50 a.m.-12:00 p.m.  
**535-P** Success of Interactive, Online, Case-Based Education Related to Use of CGM for Type 2 Diabetes  
Presenting Author: Amy Larkin, PharmD

12:00 p.m.-12:10 p.m.  
**536-P** Characteristics of People with Type 2 Diabetes Based on the Extended Parallel Processing Model (EPPM)  
Presenting Author: Daniel J. Rubin, MD, MSc, FACE

12:10 p.m.-12:20 p.m.  
**537-P** Community-Based Diabetes Management—Evaluating the Efficacy of Do Right! Diabetes Challenge  
Presenting Author: Nithya S. Trichy, BS
MONDAY, JUNE 24, 2024

11:30 a.m.-12:30 p.m.
(continued)

ePoster Theater
Theme Area: Obesity/Integrated Physiology
Session Number: ePoster14
(*) Research Advances in Metabolic Regulation
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Daisy Duan, MD

(*) Continuing Education Credit Is Not Awarded for this Session.

11:30 a.m.-11:40 a.m.
1523-P Anorexia Induced by the Central Action of Fibroblast Growth Factor 1 (FGF1) Is Dependent on Activation of Parabrachial CGRP Neurons
Presenting Author: Jarrad M. Scarlett, MD, PhD

11:40 a.m.-11:50 a.m.
1524-P UNABLE TO ATTEND

11:50 a.m.-12:00 p.m.
1601-P Regulation of Circadian Rhythmicity of Human Adipose Tissue in Obesity
Presenting Author: Kelli Lytle, PhD

12:00 p.m.-12:10 p.m.
1602-P Exercise Training Reverses Skeletal Muscle DRP1 Hyperactivation and Improves Respiratory Capacity in Patients with Type 2 Diabetes
Presenting Author: Elizabeth C. Heintz, MS, BS

12:10 a.m.-12:20 p.m.
1603-P The Cardiovascular Impact of Appropriately-Timed Prandial Insulin in Type 1 Diabetes—A Randomized Crossover Study
Presenting Author: William B. Horton, MD, MSc, FACP
MONDAY, JUNE 24, 2024

12:30 p.m.-1:30 p.m.

**ePoster Theater**

Theme Area: *Clinical Diabetes/Therapeutics*
Session Number: ePoster15

(*) Creative Strategies for Care Improvement
Room: Exhibit Hall (West A1-A3) ePoster Theater A
Moderator: Jessica L. Harding, PhD

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.

1060-P  MOMs—Improved Glycemic Control and Diabetes Self-Management for Underserved Pregnant Patients
Presenting Author: Courtney U. Cart, MSW, MPH

12:40 p.m.-12:50 p.m.

1061-P  Interdisciplinary Approach to Outpatient Diabetes Management with Pharmacist-Led Interventions
Presenting Author: John Woodley, DO

12:50 p.m.-1:00 p.m.

1062-P  UNABLE TO ATTEND

1:00 p.m.-1:10 p.m.

1063-P  A Carbohydrate-Restricted Intervention and Continuous Remote Care Improves Health Outcomes across All Socioeconomic Groups at Two Years
Presenting Author: Brittanie M. Volk, PhD, RD

1:10 p.m.-1:20 p.m.

1064-P  Order Set Design and "Nudges" to Change Care in Diabetes—Towards a Novel Pragmatic Clinical Trial Design
Presenting Author: James Flory, MD, MSCE
MONDAY, JUNE 24, 2024

12:30 p.m.-1:30 p.m.

ePoster Theater
Theme Area: Islet Biology/Insulin Secretion
Session Number: ePoster16
(*) Hepatocytes, Adipocytes, Beta cells, Oh My!
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Erin E. Mulvihill, PhD

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.
1796-LB Adipocyte-Derived Extracellular Vesicles (AdEVs) Contribute to Insulin Resistance and Atherosclerosis in Obesity
Presenting Author: Xilal Y. Rima, PhD

12:40 p.m.-12:50 p.m.
1960-LB A 3D Analysis of CD8+ Leukocytic Infiltration in Human Endocrine and Exocrine Pancreas at Type 1 Diabetes Onset
Presenting Author: Alexandra Rippa, PhD

12:50 p.m.-1:00 p.m.
2036-LB Identification of a Hepatocyte Subpopulation That Simultaneously Expresses Gluconeogenic and Lipogenic Genes in the Fed State
Presenting Author: Junichi Okada, MD, PhD

1:00 p.m.-1:10 p.m.
2087-LB Novel Human Islet Spheroid Models of Type 1 Diabetes
Presenting Author: Burcak Yesildag, PhD

1:10 a.m.-1:20 p.m.
2089-LB An Adult Clock Component Links Circadian Rhythms to Pancreatic β-Cell Maturation
Presenting Author: Juan R. Alvarez, PhD
MONDAY, JUNE 24, 2024

12:30 p.m.-1:30 p.m.

Session Break
(Take this opportunity to visit the Exhibit and Poster Halls)

1:30 p.m.-3:00 p.m.

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY06-1.5
Demystifying Impaired Awareness of Hypoglycemia—Diagnosis, Experience, and Treatment in the Real World
Room: W207
Chair: Alexandria Ratzki-Leewing, PhD
1:30 p.m.-2:00 p.m. Impaired Awareness of Hypoglycemia—Screening and Diagnosis in Clinical Practice
   Scott J. Pilla, MD, MHS
2:00 p.m.-2:30 p.m. Evidence-Based Interventions to Restore Awareness of Hypoglycemia
   Jeremy Pettus, MD
2:30 p.m.-3:00 p.m. Living with Impaired Awareness of Hypoglycemia—What People Living with Diabetes Wish You Knew
   Eva Kathmann, PhD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY09-1.5
How Diabetes Technology Is Changing Diabetes Care in the Real World
Room: W311
Chair: Michelle D. Stancil, MS, BSN, RN, CDCES
1:30 p.m.-2:00 p.m. Don’t Say No to Continuous Glucose Monitors in Primary Care
   Caitlin Nass, MSN, CRNP
2:00 p.m.-2:30 p.m. Implementation of Remote Patient Monitoring in Rural Settings—Barriers and Facilitators
   Emily E. Johnson, PhD
2:30 p.m.-3:00 p.m. How Connected Insulin Pens and Caps Are Facilitating Precision Insulin Management
   Janice MacLeod, MA, RD, CDCES, FADCES
1:30 p.m.-3:00 p.m. (continued)

Symposium
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*
*Session Number: BM-SY17-1.5*
**Nutrition and Diabetes Self-Management Education and Support (DSMES)**
Room: W415C (Valencia Ballroom)
Chair: Barbara Eichorst, MS, RD, CDCES

1:30 p.m.-2:00 p.m. *Collaborations between Providers and DCES's—Bringing Standards of Care Alive*
   Louis H. Philipson, MD, PhD, FACP
   Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES

2:00 p.m.-2:15 p.m. *Integrating Therapeutic Education into Obesity Interventions*
   Zoltan Pataky, MD

2:15 p.m.-2:30 p.m. *Culturally Sensitive Conversations When Approaching Nutrition Changes*
   Victoria Bouhairie, MD, DipACLM

2:30 p.m.-2:45 p.m. *Integrating Multidisciplinary Team in Diabetes Management—Germany Perspective*
   Peter E.H. Schwarz, PhD

2:45 p.m.-3:00 p.m. *Question and Discussion Period*

Symposium
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY07-1.5*
**Impact of Precision Medicine on Diabetes**
Room: W314
Chair: Anna L. Gloyn, DPhil

1:30 p.m.-2:00 p.m. *How Is Precision Medicine Changing the Paradigm in Type 1 Diabetes?*
   Chantal Mathieu, MD, PhD

2:00 p.m.-2:30 p.m. *How Is Precision Medicine Changing the Paradigm in Type 2 Diabetes?*
   Jose C. Florez, MD, PhD

2:30 p.m.-3:00 p.m. *How Is Precision Medicine Changing the Paradigm in Monogenic Diabetes?*
   Rochelle N. Naylor, MD
MONDAY, JUNE 24, 2024

1:30 p.m.-3:00 p.m.
(continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY20-1.5
Just Do It—Incorporating What We Know into What We Do
Room: W315
Chair: Amisha Wallia, MD, MS
1:30 p.m.-1:50 p.m. EHR-Based Tools to Overcome Therapeutic Inertia and Improve Health Equity in Diabetes Technology Prescriptions
Brittany S. Bruggeman, MD
1:50 p.m.-2:10 p.m. REALITY Check—Preventing Diabetes in the “Real World”—Early Findings of the Real-World Effectiveness of Interventions of the Type 2 Diabetes Mellitus Prevention Network
Tannaz Moin, MD, MBA, MSHS
2:10 p.m.-2:30 p.m. The Michigan Collaborative for Type 2 Diabetes
Lauren Oshman, MD, MPH
2:30 p.m.-2:50 p.m. Screening for Type 1 Diabetes—From Evidence
Laura M. Jacobsen, MD
2:50 p.m.-3:00 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY26-1.5
ADA Diabetes Care/Diabetes/Diabetologia Symposium—The Heterogeneity of Type 1 Diabetes—Pathogenesis, Treatment, and Prevention (Includes Livestream)
Room: W320 (Chapin Theater)
Co-Chairs: Hindrik Mulder, MD, PhD and David A. D’Alessio, MD
1:30 p.m.-1:45 p.m. Beta-Cell Pathology in Type 1 Diabetes—Immune, Inflammatory, Functional
Primary Speaker: TBD
1:45 p.m.-2:00 p.m. Insulin Replacement in Type 1 Diabetes—Needles, Pumps, and Islets
Primary Speaker: TBD
2:00 p.m.-2:15 p.m. The Emerging Spectrum of Strategies to Prevent Type 1 Diabetes
Primary Speaker: TBD
2:15 p.m.-3:00 p.m. Question and Discussion Period
1:30 p.m.–3:00 p.m.  
(continued)

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY28-1.5*

**Lancet Journal Symposium—Time for a Paradigm Shift? Should We Treat Early Gestational Diabetes Mellitus?**

Room: W304 E-H  
Co-Chairs: Jessamy Bagenal, MBBS and David Simmons, MA, MBBS, FRACP, FRCP, MD (Cantab)

1:30 p.m.-1:50 p.m.  
*Epidemiology of Early Gestational Diabetes Mellitus*  
Hannah Wesley, BDS, MPH, PhD

1:50 p.m.-2:10 p.m.  
*Pathophysiology of Early Gestational Diabetes Mellitus*  
Marie-France Hivert, MD, MMSc

2:10 p.m.-2:30 p.m.  
*How Should We Diagnose Early Gestational Diabetes Mellitus?*  
Arianne Sweeting, MBBS, PhD

2:30 p.m.-2:50 p.m.  
*Further Considerations for the Early Diagnosis of Gestational Diabetes Mellitus*  
Patrick Catalano, MD

2:50 p.m.-3:00 p.m.  
Question and Discussion Period

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY41-1.5*

**The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist—Once-Weekly Semaglutide and the FLOW Trial Results (Includes Livestream)**

Room: W415B (Valencia Ballroom)

Co-Chairs: Richard E. Pratley, MD and Vlado Perkovic, MBBS, PhD, FRACP, FASN, FAHMS

1:30 p.m.-1:40 p.m.  
*Current Treatment Strategies, Unmet Medical Need, FLOW Rationale*  
Peter Rossing, MD, DMSc

1:40 p.m.-2:00 p.m.  
*FLOW Trial Design and Baseline Characteristics, Glycemic Control, and Body Weight*  
Richard E. Pratley, MD

2:00 p.m.-2:10 p.m.  
*FLOW Kidney Outcomes*  
Vlado Perkovic, MBBS, PhD, FRACP, FASN, FAHMS

2:10 p.m.-2:20 p.m.  
*FLOW CV Outcomes*  
Kenneth W. Mahaffey, MD, PhD

2:20 p.m.-2:30 p.m.  
*FLOW Results by Baseline Use of SGLT2i*  
Johannes F.E. Mann, MD

2:30 p.m.-2:40 p.m.  
*FLOW Results—Summary and Clinical Implication*  
Katherine R. Tuttle, MD, FACP, FASN, FNKF

2:40 p.m.-3:00 p.m.  
*FLOW Results—Independent Commentary*  
Sylvia Rosas, MD, MSCE
1:30 p.m.-3:00 p.m.  
(continued)

Panel  
*Theme Area: Immunology/Beta-Cell Replacement*  
*Session Number: IBC-PN03-1.5*  
*Modulating Cytokines—Mechanisms Underlying Type 1 Diabetes Treatment* *(Includes Livestream)*  
*Room: W414*  
*Chair: Cate Speake, PhD*  
1:30 p.m.-1:55 p.m.  *How Does Baricitinib Block Type 1 Diabetes Progression?*  
Michaela Waibel, PhD  
1:55 p.m.-2:20 p.m.  *How Does IL-2 Treatment Prevent Type 1 Diabetes Progression?*  
Ricardo Ferreira, PhD  
2:20 p.m.-2:45 p.m.  *How Does Ustekinumab Prevent Type 1 Diabetes Progression?*  
Stephanie Hanna, PhD  
2:45 p.m.-3:00 p.m.  *Question and Discussion Period*  

Symposium  
*Theme Area: Obesity/Integrated Physiology*  
*Session Number: IP-SY05-1.5*  
*Mitochondria as a Therapeutic Target for Diabetes*  
*Room: W308*  
*Chair: Irena A. Rebalka, PhD*  
1:30 p.m.-2:00 p.m.  *Harnessing Amino Acid Metabolism for Diabetic Therapy*  
Esther Phielix, PhD  
2:00 p.m.-2:30 p.m.  *Targeting Mitochondria via Probiotics to Restore Microbiota Health in Type 2 Diabetes*  
Natalia Shulzhenko, MD, PhD  
2:30 p.m.-3:00 p.m.  *Exercise and Skeletal Muscle Mitochondrial Adaptations in Type 1 Diabetes*  
Dean Minnock, PhD  

Symposium  
*Theme Area: Obesity/Integrated Physiology*  
*Session Number: IP-SY10-1.5*  
*Food Noise Explained—Satiety Responsiveness and Motivation Processing in the Brain* *(Includes Livestream)*  
*Room: W307*  
*Chair: Alyssa Huang, MD*  
1:30 p.m.-2:00 p.m.  *Genetic and Environmental Influences on Satiety and Food Motivation in Obesity*  
Susan Carnell, PhD  
2:00 p.m.-2:30 p.m.  *Gut–Brain Signaling Underlying Motivational Behavior*  
Ivan de Araujo, DPhil  
2:30 p.m.-3:00 p.m.  *Effect of Behavioral Weight Loss on Satiety and Food Motivation*  
Ellen Schur, MD, MS
Panel
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-PN04-1.5
Are We Using the Right Tools to Establish Causality in Islet Function and Dysfunction?
Room: W206
Chair: Alejandro Caicedo, PhD
1:30 p.m.-1:45 p.m. Transgenic Mouse Models Can Be Used to Study In Vivo Beta-Cell Biology
Jennifer L. Estall, PhD
1:45 p.m.-2:00 p.m. Of Mice and Mankind—Why Human Samples are Necessary to Advance Understanding of Pancreatic Islet (Patho)Physiology
Katie C. Coate, PhD
2:00 p.m.-2:15 p.m. Large Omics Data Sets Allow for Key Insights into Beta-Cell Biology
Kyle J. Gaulton, PhD
2:15 p.m.-2:30 p.m. A New Open Resource for the Islet Community—Towards Causality by Connecting -Omics and Function
Patrick MacDonald, PhD
2:30 p.m.-2:45 p.m. New Models Are Needed for Optimal Testing of Beta-Cell Biology
Rayner Rodriguez Diaz, PhD
2:45 p.m.-3:00 p.m. Question and Discussion Period
MONDAY, JUNE 24, 2024

1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-OR04-1.5
Revving Up the Adipose to Impact Insulin Sensitivity and Glucose Homeostasis
Room: W304 A-D
Chair: Mary Teruel, PhD

1:30 p.m.-1:45 p.m.
361-OR A Multiomics Approach to Identify Genes Important for the Regulation of Antidiabetic and Anti-inflammatory Lipids
Presenting Author: Anna Santoro, PharmD, PhD

1:45 p.m.-2:00 p.m.
362-OR Divergent Roles of METTL14-Mediated m6A in Regulating Brown and White Adipose Tissue Transcriptomes and Systemic Metabolism
Presenting Author: Ling Xiao, PhD

2:00 p.m.-2:15 p.m.
363-OR Matrix Metalloprotease-2 as a Novel Regulator of Glucose Utilization by Adipocytes and High-Fat Diet-Induced Glucose Intolerance
Presenting Author: Melissa D. Lempicki, BS

2:15 p.m.-2:30 p.m.
364-OR Beta-Cell SF1 as a Thermogenic Regulator against Diet-Induced Obesity in Mice—Elucidating Its Role in Islet–Adipose Cross Talk
Presenting Author: Yan Guo, Doctor

2:30 p.m.-2:45 p.m.
365-OR Maladaptive Sensory Plasticity via α2δ1-subunit Promotes Adipose Tissue Lipolysis after Spinal Cord Injury
Presenting Author: Debasish Roy, PhD
MONDAY, JUNE 24, 2024

3:15 p.m.–4:15 p.m.

**Symposium**  
*Theme Area: Acute and Chronic Complications*  
*Session Number: AC-SY11-1*

**Cardiovascular Disease Risk Prediction in Obesity and Type 2 Diabetes—Emerging Tools for the Clinician**  
*Room: W206*  
*Chair: Darren K. McGuire, MD, MHSc, FAHA, FACC, FESC*

3:15 p.m.-3:35 p.m. **High-Risk Cardiovascular Disease Phenotypes in Obesity—Beyond Body Mass Index**  
Marie-Eve Piché, MD, PhD, FRCPC, FAHA

3:35 p.m.-3:55 p.m. **Predicting Risk for Heart Failure in Type 2 Diabetes—Insights from the TRS-HFDM and WATCH-DM Risk Scores**  
Ambarish Pandey, MD, MSCS

3:55 p.m.-4:15 p.m. **Predicting Risk for Atherosclerotic Cardiovascular Disease in Type 2 Diabetes—Insights from SCORE2-Diabetes Risk Score**  
Caroline J. Magri, MD, MRCP(UK), FEFIM, MPhil, MSc(Brighton), PhD

**Ask the Expert**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
*Session Number: BM-AE04-1*

**The Highs and Lows of Cannabis Use in Diabetes—Behavioral and Psychosocial Considerations**  
*Room: W314*  
*Chair: Elizabeth A. Beverly, PhD*

3:15 p.m.-3:35 p.m. **The Highs and Lows of Cannabis Use in Diabetes—Overview and Landscape of Use**  
Jay H. Shubrook, DO

3:35 p.m.-3:55 p.m. **The Highs and Lows of Cannabis Use in Diabetes—Associations between CBD, THC, or CBD+THC Use vs. Nonuse on Insulin Sensitivity, Inflammation, and Behavior**  
Angela Bryan, PhD

3:55 p.m.-4:15 p.m. **The Highs and Lows of Cannabis Use in Diabetes—Behavioral and Psychosocial Considerations**  
Halis K. Akturk, MD

**Panel**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
*Session Number: BM-PN11-1*

**Are We Close to Closing the Loop? Automated Insulin Delivery during Exercise**  
*Room: W415C (Valencia Ballroom)*  
*Chair: Michael C. Riddell, PhD*

3:15 p.m.-4:15 p.m. **Are We Close to Closing the Loop? Automated Insulin Delivery during Exercise**  
Rémi Rabasa-Lhoret, MD, PhD  
Aude Bandini, PhD  
Chiara Dalla Man, PhD  
Dale Morrison, PhD
3:15 p.m.-4:15 p.m.
(continued)

Debate
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-DB04-1
Early Abnormal Glucose Metabolism in Pregnancy—To Treat or Not to Treat
Room: W311
Chair: Erin S. LeBlanc, MD, MPH
3:15 p.m.-3:35 p.m. PRO—Early Abnormal Glucose Metabolism in Pregnancy SHOULD Be Treated
   David Simmons, MA, MBBS, FRACP, FRCP, MD (Cantab)
3:35 p.m.-3:55 p.m. CON—Early Abnormal Glucose Metabolism in Pregnancy SHOULD NOT Be Treated
   Lorie M. Harper, MD, MSCI
3:55 p.m.-4:00 p.m. Rebuttal
   David Simmons, MA, MBBS, FRACP, FRCP, MD (Cantab)
4:00 p.m.-4:05 p.m. Rebuttal
   Lorie M. Harper, MD, MSCI
4:05 p.m.-4:15 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY25-1
Improving Culture of Quality in Pediatric Centers—Lessons from the Type 1 Diabetes Exchange Quality Improvement Collaborative
Room: W315
Chair: Eda Cengiz, MD, MHS
3:15 p.m.-3:35 p.m. Increasing Insulin Pump Utilization in Public-Insured Patients
   Anna Cymbaluk, MD
3:35 p.m.-3:55 p.m. Current Approaches to Addressing Racial Equity—Insights from the T1D Exchange Q1 Collaborative
   Trevon Wright, MHA
3:55 p.m.-4:15 p.m. Data-Driven Predictions to Determine High-Risk Patients with Type 1 Diabetes
   Mark A. Clements, MD, PhD
3:15 p.m.-4:15 p.m.
(continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY47-1
Use of SGLT2i in Youth with Type 1 Diabetes—Results from ATTEMPT (The Adolescent Type 1 Diabetes Treatment with SGLT2i for hyperglycEMia & hyPerfilTration Trial)
Room: W414
Chair: Peter A. Senior, MBBS, PhD
3:15 p.m.-3:30 p.m. Rationale for SGLT2i Adjunctive Therapy in Youth with Type 1 Diabetes
   Petter Bjornstad, MD
3:30 p.m.-3:50 p.m. ATTEMPT Study—Renal and Glycemic Outcomes
   Farid H. Mahmud, MD
3:50 p.m.-4:00 p.m. ATTEMPT Study—Patient Perspectives of SGLT2i For Diabetes Management
   Samantha Anthony, PhD, MSW, RSW
4:00 p.m.-4:10 p.m. ATTEMPT Study Commentary—SGLT2i in Youth with Type 1 Diabetes
   Jennifer L. Sherr, MD, PhD
4:10 p.m.-4:15 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY48-1
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Rodica Busui, MD, PhD
3:15 p.m.-3:25 p.m. The Spectrum of Hypercortisolism—An Evolution of Understanding
   Richard Auchus, MD, PhD
3:25 p.m.-3:35 p.m. Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes
   Ralph A. DeFronzo, MD
3:35 p.m.-3:45 p.m. Rationale for and Design of the CATALYST Trial
   Athena Philis-Tsimikas, MD
3:45 p.m.-3:55 p.m. Results of the CATALYST Trial Part 1
   Vivian Fonseca, MD
3:55 p.m.-4:05 p.m. Clinical Implications of the CATALYST Trial Part 1
   John B. Buse, MD, PhD
4:05 p.m.-4:15 p.m. Question and Discussion Period
Symposium
Theme Area: Epidemiology/Genetics
Session Number: EG-SY06-1
Diabetes Genetic Convergence—Shared Networks of Rare and Common Variants
Room: W207
Chair: Melina Claussnitzer, PhD
3:15 p.m.-3:35 p.m.  Diabetes Genetic Convergence—Rare to Common Variants in Networks
   Kashyap A. Patel, MRCP, PhD
3:35 p.m.-3:55 p.m.  Single Cell Transcriptomics, Networks, Genetic Convergence, HNF1A
   Yan Li, PhD
3:55 p.m.-4:15 p.m.  Genetic Convergence in Rare and Common Diabetes (HNF1A and RFX6), MPRA
   Adelaide Tovar, PhD

Debate
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-DB02-1
Do Immune or Beta Cells Drive Transition from Stage 1 to Stage 3 Type 1 Diabetes?
Room: W304 A-D
Chair: Alberto Pugliese, MD
3:15 p.m.-3:30 p.m.  Type 1 Diabetes Progression Is Precipitated by Immune Cells
   Jamie L. Felton, MD
3:30 p.m.-3:45 p.m.  Type 1 Diabetes Progression Is Precipitated by Beta Cells
   Edward Phelps, PhD
3:45 p.m.-3:50 p.m.  Rebuttal
   Jamie L. Felton, MD
3:50 p.m.-3:55 p.m.  Rebuttal
   Edward Phelps, PhD
3:55 p.m.-4:15 p.m.  Question and Discussion Period

Symposium
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-SY08-1
The Future of Diabetes Care as Cell Replacement or Regeneration Therapies (Includes Livestream)
Room: W307
Chair: Mark A. Atkinson, PhD
3:15 p.m.-3:40 p.m.  Designing the Next Generation of Beta Cells for Stem Cell Rx
   Matthias Hebrok, PhD
3:40 p.m.-4:05 p.m.  Beta-Cell Regeneration Strategies
   Andrew F. Stewart, MD
4:05 p.m.-4:15 p.m.  Question and Discussion Period
Panel
Theme Area: Obesity/Integrated Physiology
Session Number: IP-PN01-1
Leptin, 30 Years Later
Room: W304 E-H
Chair: Jeffrey S. Flier, MD
3:15 p.m.-4:15 p.m. Leptin, 30 Years Later
Martin G. Myers, Jr., MD, PhD
Stephanie Fulton, PhD
Philipp E. Scherer, PhD
Rudolph L. Leibel, MD

Panel
Theme Area: Obesity/Integrated Physiology
Session Number: IP-PN09-1
Ripple Effects after the Advent of Highly Effective Antiobesity Pharmacotherapy—Pharmacoequity in the United States
Room: W308
Chair: Jessica Schwartz, MD, MHS
3:15 p.m.-3:35 p.m. Principles of Pharmacoequity
Utibe Essien, MD, MPH
3:35 p.m.-3:55 p.m. Antiobesity Medication Access on the Clinical Frontlines
Kristina H. Lewis, MD, MPH, SM
3:55 p.m.-4:15 p.m. Economic and Public Policy Considerations in the United States
Alison Ward, PhD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY46-1
Results from a Randomized Trial of Intensive Glucose Management Using Continuous Glucose Monitoring (CGM) Versus Usual Care in Hospitalized Adults with Type 2 Diabetes—The TIGHT Study (Includes Livestream)
Room: W320 (Chapin Theater)
Chair: Celia C. Low Wang, MD
3:15 p.m.-3:26 p.m. Study Background and Rationale
Boris Draznin, MD, PhD
3:26 p.m.-3:37 p.m. Study Methods
Jagdeesh Ullal, MD, MS, FACE, FACP, ECNU
3:37 p.m.-3:48 p.m. Study Results
Guillermo Umpierrez, MD, CDCES, MACP, FACE
3:48 p.m.-3:59 p.m. Discussion of Results and Conclusions
Irl B. Hirsch, MD
3:59 p.m.-4:15 p.m. Question and Discussion Period
Product Theaters

Product Theaters are informative sessions focusing on products or a single facet of diabetes. These sessions will not provide any continuing education credit. They are for health care professionals only with practices relevant to the presented information.

SATURDAY, JUNE 22, 2024
10:15 a.m. - 11:00 a.m.

Meet Tandem Mobi: Tiny Pump, Big Control. The Future of AID.
Presented by Tandem Diabetes Care

In this product theater, Jordan Pinsker, Chief Medical Officer for Tandem Diabetes Care, will discuss the latest automated insulin delivery innovation, the Tandem Mobi system. Tandem Mobi, the world’s smallest, durable automated insulin delivery system, became commercially available in the United States in February of 2024. This product theater will feature Dr. Halis Kaan Akturk, Associate Professor of Medicine and Pediatrics at the Barbara Davis Center for Diabetes, University of Colorado, who will offer valuable insights about the early, real-world experience with Tandem Mobi. Additionally, Cari Berget, MPH, RN, CDE, Director of the PANTHER Program and Research Instructor in, Pediatrics at the Barbara Davis Center, will discuss how the unique wearability features of Tandem Mobi, combined with the Control-IQ technology algorithm, usher in a new generation for AID systems. The speakers will also discuss the benefits of a small-sized insulin system that can be disconnected for sports, swimming, and real-life scenarios, and how optimizing algorithm settings can help improve patient outcomes. Tandem will also share details about the future of its AID and the pursuit of fully closed-loop systems. Reference: 1. As of June, 2024. Data on file, Tandem Diabetes Care.

Presenters:
Jordan Pinsker, MD
Tandem Diabetes Care, Inc.
Santa Barbara, CA

Halis Khan Akturk, MD
Associate Professor of Pediatrics and Medicine
Barbara Davis Center for Diabetes, University of Colorado
Aurora, CO

Cari Berget, RN, MPH, CDCES
Instructor
Barbara Davis Center for Diabetes, University of Colorado
Aurora, CO

Location: Product Theater 1
10:15 a.m.-11:00 a.m.

Revolutionizing CGM Technology: A Journey Through Mindful Innovation
*Presented by Abbott*

Join us for an enlightening session that will explore the latest advancements in FreeStyle Libre systems and their transformative impact on diabetes management. Our expert presenters will discuss how real-time CGM data personalizes care, enhances patient engagement, and improves clinical outcomes. We will unveil FreeStyle Libre partnerships and innovative developments in sensor technology that will empower both patients and healthcare providers. Don't miss this opportunity to gain valuable insights into the future of diabetes management and how our pioneering approaches can make a difference in patient care.

**Moderator:** Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP
Endocrinology & Metabolism Institute
Cleveland Clinic Diabetes Center
Cleveland, OH

**Presenters:**
- David T. Ahn, MD
  Mary & Dick Allen Diabetes Center
  Newport Beach, CA

- Scott Harper
  Division Vice President R&D
  Abbott
  Alameda, CA

**Location:** Product Theater 2

10:15 a.m.-11:00 a.m.

Championing LDL-C Lowering in Diabetes Care
*Presented by Amgen*

This is a comprehensive presentation dedicated to prioritizing LDL-C lowering for diabetic patients with hyperlipidemia and ASCVD. We will also discuss a treatment option during this presentation.

**Presenter:** Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP
Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences (MCPHS)
Clinical Instructor
Tufts University
Clinical Pharmacist, Clinical Director, Cardiometabolic Program
Well Life
Boston, MA

**Location:** Product Theater 3
12:30 p.m.-1:30 p.m.

Empowering People with Type 2 Diabetes: Early Utilization of Dexcom CGM to Support Behavior Change and Improve Health Outcomes

*Presented by Dexcom*

Dexcom leads the development of evidence to support the use of real-time CGM (RT-CGM) in people living with type 2 diabetes (T2D), emphasizing the opportunity for early glycemic goal achievement for effective T2D management. Join this session and share in a dynamic conversation, moderated by Dr. Thomas Grace, MD, CDCES, as experts dive into the transformative impact of Dexcom CGM in T2D. Discover a dual perspective, examining both the attainment of clinical goals as well as improvement in patient-reported outcomes. We'll highlight how individuals leverage Dexcom CGM to successfully understand the impact of lifestyle choices on diabetes management goals. You'll realize the multifaceted role Dexcom CGM has in early intervention in T2D. Dexcom personalizes diabetes management and empowers people to take control of their health.

**Moderator:** Thomas Grace, MD, CDCES, ABOM
Director, Blanchard Valley Diabetes Center
Head, Clinical Advocacy and Outcomes
Dexcom
Findlay, OH

**Presenters:** Rachel Sood, RN, MSN, NP-C
Diabetes Nurse Practitioner, Primary Care & Population Health Owner
The Diabetes Collective & Faculty LSU School of Nursing
Metairie, LA

Daniel Katselnik, MD
Adult Endocrinologist
Diabetes and Metabolism Specialists
San Antonio, TX

**Location:** Product Theater 1
12:30 p.m.-1:30 p.m.

How Soon Should AID Be Offered? Success in Typically Hard-to-Manage Populations with the MiniMed™ 780G System

Presented by Medtronic

Despite the increase in CGM utilization in the U.S., people with T1D are not reaching goals. The latest data and trends support the use of AID in achieving outcomes and decreasing burden. Hear from leading experts as they share case studies and publications showing how the MiniMed™ 780G system is closing the gap between youth and adults when it comes to glycemic management.

**Moderator:** Jennifer McVean, MD  
Sr. Medical Affairs Director  
Medtronic  
Northridge, CA

**Presenters:** Richard Bergenstal, MD  
Executive Director  
International Diabetes Center, University of Minnesota  
Minneapolis, MN

Laya Ekhlaspour, MD  
Assistant Professor  
University of California, San Francisco  
San Francisco, CA

Gregory Forlenza, MD, MS  
Associate Professor of Medicine  
Barbara Davis Center, University of Colorado Anschutz Medical Campus  
Aurora, CO

Benjamin Wheeler, MD, PhD  
Professor  
University of Otago  
Dunedin, New Zealand

**Location:** Product Theater 2
Jardiance® (empagliflozin) Tablets: A Review of Multiple Clinical Trials and Approved Indications

Presented by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA LLC

This program will review multiple clinical trials and approved indications for JARDIANCE. The presentation will cover efficacy and safety data. As well as the dosing information for JARDIANCE. Attendees will also have the opportunity to ask the presenter questions about the data presented.

Moderator:  
Kari Haynie  
Associate Director, Brand Marketing  
Eli Lilly and Company

Presenters:  
Christian W. Mende, MD, FACP, FACN, FASN, FAHA  
Clinical Professor  
Department of Medicine  
University of California at San Diego  
San Diego, CA

Rosemarie Lajara, MD, FACE  
Staff Endocrinologist  
Southern Endocrinology Associates  
Clinical Associate Professor of Medicine  
UT Southwestern Medical Center  
Dallas, TX

Location:  
Product Theater 3
3:00 p.m.-3:45 p.m.

Creating the Next Chapter in Diabetes Management by Leveraging Interoperability and Dynamic Collaboration - Introducing the twiist™ AID System for Personalized, Flexible Control.

Presented by Sequel

The next chapter in diabetes management is here - introducing the twiist™ Automated Insulin Delivery (AID) System powered by Tidepool. During this panel session moderated by Jenn LeBlanc, you will hear from Sequel colleagues Alan Lotvin and Kate Farnsworth, alongside esteemed endocrinology experts Rayhan Lal and David Ahn. The session starts with a quick trip back to the 1970s when the first wearable insulin pump therapy from Dean Kamen (Sequel Med Tech Co-Founder and President of DEKA Research & Development Corp.) was introduced to the world, paving the way for DEKA's development of a new insulin delivery technology that fundamentally changes the way we think about AID systems. Learn how the twiist AID system takes advantage of the FDA’s medical device interoperability standards which will help patients personalize their diabetes management to their individual preferences - a result of dynamic collaboration between Sequel and Tidepool driven by a common mission to make life easier for people with diabetes. You’ll hear from this panel of experts on how the twisst AID system is the first to integrate the Tidepool Loop algorithm, while expanding patient access to consumer-friendly technology and powerful data. The twiist AID system is brought to you by Sequel(tm).

Presenters:  
Jenn LeBlanc, MBA, BSN, RN, CDCES  
Vice President, Clinical Strategy  
Sequel

Alan Lotvin, MD  
CEO/Co-Founder & Director  
Sequel

Kate Farnsworth  
Associate Director of Marketing  
Sequel

Rayhan Lal, MD  
Adult and Pediatric Endocrinologist  
Standard

Chief Medical Advisor  
Tidepool

David Ahn, MD  
Chief of Diabetes Services  
Mary & Dick Allen Diabetes Center at Hoag

Location:  Product Theater 1
3:00 p.m.-3:45 p.m.

Product Theater for ZepboundTM (tirzepatide) Injection

Presented by Lilly USA LLC

Join a presentation from one of your peers on the efficacy and safety of once-weekly Zepbound, and learn about how to get appropriate patients started on this treatment. Attendees will have the opportunity to pose questions to the speaker at the end of the session. Refreshments will be provided. Please see the Important Safety Information for Zepbound, including Boxed Warning about possible thyroid tumors, including thyroid cancer, the full Prescribing Information, and Medication Guide provided at the Product Theater. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Presenter: Jesse Richards, DO
Department of Internal Medicine, School of Community Medicine
University of Oklahoma
Tulsa, OK

Location: Product Theater 2
SUNDAY, JUNE 23, 2024
10:15 a.m.-11:00 a.m.

Omnipod® 5: Advancing Automated Insulin Delivery for All
Presented by Insulet

Learn how Omnipod 5, the #1 prescribed1 and patient-preferred AID system, delivers strong glycemic results across various patient populations. Hear from Omnipod clinical trial investigators Dr. Greg Forlenza and Dr. Francisco Pasquel (Chair of SECURE-T2D), who will unveil clinical outcomes and share how Omnipod is a proven therapy for many patients beyond traditional pump candidates. Get a sneak peek at what’s to come for Insulet from Dr. Trang Ly, Insulet’s Senior Vice President and Medical Director, who will provide an update on Omnipod’s exciting clinical and innovation pipeline. USA 2023, Data on file.2. The Omnipod 5 System was named 2023 Patient Choice Award Winner for preferred pump in the United States; Seagrove Patient Perspectives Survey Report (413 Total Responses, 260 T1D, 153 T2D - 245 pumpers, 98 MDI, 70 non-MDI). Seagrove Partners, LLC Patient Perspectives Report, December 2023. Insulet data on file.3. Forlenza G, et al. Diabetes Technol Ther (2024). Real-world evidence of Omnipod 5 Automated Insulin Delivery System use in 69,902 people with type 1 diabetes.

Presenters:  
Trang Ly, MBBS, FRACP, PhD  
Senior Vice President & Medical Director  
Insulet  
Acton, MA

Gregory Forlenza, MD  
Associate Professor of Pediatrics & Director of Pediatric Diabetes Technology Research  
Barbara Davis Center at the University of Colorado Anschutz Medical Campus  
Aurora, CO

Francisco Pasquel, MD, MPH  
Associate Professor of Medicine  
Emory School of Medicine  
Medical Director of Endocrinology  
Grady Health System  
Atlanta, GA

Location:  
Product Theater 1

10:15 a.m.-11:00 a.m.

From Awareness to Action: The Importance of Screening for Type 1 Diabetes
Presented by Sanofi

Type 1 diabetes (T1D) is a life-altering condition. Learn more about the epidemiology, burden of disease, and unmet need for patients with T1D. Join us for a discussion on the progressive nature of T1D and review best practices for identifying who to screen, when to screen, and how to screen, including managing the patient and/or caregiver after screening.

Presenters:  
Kimber Summons, MD, MPH/MSPH  
Barbara Davis Center for Diabetes  
Aurora, CO

Holly O’Donnell, PhD  
Barbara Davis Center for Diabetes  
Aurora, CO

Location:  
Product Theater 2
Discover a New Treatment Option that is Available for Patients with NASH with Liver Fibrosis
Presented by Madrigal Pharmaceuticals, Inc.

Please join us for an engaging and highly anticipated educational presentation focusing on this new option for patients with NASH, including the clinical data.

**Presenter:** Mazen Noureddin, MD, MHSc
Professor of Medicine
Houston Methodist Hospital
Director
Houston Research Institute
Houston, TX

**Location:** Product Theater 3

---

Explore Advancements in Type 1 Diabetes Management
Presented by Sanofi

Type 1 diabetes (T1D) can have a devastating impact on both patients and their loved ones. Explore advancements in T1D management and the importance of proactive screening, particularly among individuals at increased risk for T1D. Join us to learn more about the paradigm shift in caring for patients with T1D.

**Moderator:** Steven Edelman, MD
University of California San Diego
San Diego, CA

**Presenters:**
Anita Swamy, MD
Chicago Children's Diabetes Center
Chicago, IL

Jason Baker, MD
Weill Cornell Medicine
New York, NY

**Location:** Product Theater 1
12:30 p.m.-1:30 p.m.

Perspectives in Hyperglycemia Secondary to Hypercortisolism – A Path to Diagnosis
*Presented by Corcept Therapeutics*

Case-based panel discussion on evolving perspectives in endogenous Cushing Syndrome.

**Presenters:**
- John Anderson, MD  
  Internal Medicine and Diabetes  
  The First Clinic  
  Nashville, TN
- Ralph DeFronzo, MD  
  Professor of Medicine  
  Chief, Diabetes Division  
  University of Texas Health  
  San Antonio, TX
- James Suliburk, MD, FACS  
  Associate Professor and Chief, Endocrine Surgery  
  Division of Surgical Oncology  
  Baylor College of Medicine  
  Houston, TX

**Location:** Product Theater 2

12:30 p.m.-1:30 p.m.

Hepatitis B: You Hold the Key to Prevention. The Importance of Hepatitis B Vaccination Among Adults with Diabetes
*Presented by GSK*

Do you vaccinate your patients against hepatitis B? Do you know the CDC and ADA guidelines for hepatitis B vaccination? Why is it important for adults with diabetes to be vaccinated against hepatitis B? Learn the answers to these questions and more by joining our symposium highlighting the critical importance of hepatitis B prevention among adults with diabetes. Our experts will review the recent hepatitis B vaccination recommendations, examine current disease incidence and vaccination coverage, and discuss barriers to vaccination and consider how these could be overcome – all with a focus on the specific implications for adults with diabetes. Attendees will leave with an enhanced understanding of why this population needs to be vaccinated against hepatitis B, and will bring hepatitis B vaccine knowledge and know-how back to the clinic for implementation.

**Moderators:**
- Dorothy Brown, PharmD, MBA  
  Medical Science Liaison, US  
  Vaccines Clinical and Medical Affairs, GSK  
  Philadelphia, PA
- Anna M. Acosta, MD  
  Medical Director, Hepatitis Vaccines US  
  Vaccines Clinical and Medical Affairs, GSK  
  Philadelphia, PA

**Presenter:** Michael Valitutto, DO  
Medical Director, Ascension Borgess Diabetes & Endocrine Center  
Kalamazoo, MI

**Location:** Product Theater 3
3:00 p.m.-3:45 p.m.

Attention on MASH: The Hepatic Manifestation of the Metabolic Syndrome
Presented by Novo Nordisk

Join us as we discuss MASH (metabolic dysfunction-associated steatohepatitis) and the impact of the underlying metabolic dysfunction on disease progression. We will also discuss the importance of early identification and screening for at-risk patients and review current management considerations.

**Presenter:**  Nadege Gunn, MD, CPI  
Gastroenterology, Hepatology, and Obesity Medicine  
Medical Director and Senior Scientific Advisor, Velocity Clinical Research  
Hepatology Clinical Director, Coryell Health  
Adjunct Faculty, Baylor University and Texas A&M College of Medicine  
Waco, TX

**Location:**  Product Theater 1

3:00 p.m.-3:45 p.m.

Discover the Tempo™ Personalized Diabetes Management Platform  
Presented by Lilly USA LLC

Join our product theater to learn about Tempo, a personalized diabetes management platform that combines the Tempo prefilled insulin pen, diabetes management devices, and app-driven support to deliver individualized guidance for adults with diabetes. This presentation will review the challenges to effective diabetes self management, how Tempo may support healthcare professionals and people with diabetes, and how to start patients with diabetes on Tempo. Please see the Important Safety Information and Intended Uses for the Tempo Personalized Diabetes Management Platform provided at the product theater. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with U.S. Food and Drug Administration guidelines and is not approved for continuing education credit.

**Presenter:**  Nitrin Trivedi, MD, DM, FACE, FACP  
Division Director, Endocrine and Metabolic Medicine  
Saint Vincent Hospital  
Worcester, MA

**Location:**  Product Theater 2
3:00 p.m.-3:45 p.m.

Eversense Long-Term CGM: Addressing Traditional CGM Usage Barriers
Presented by Ascensia Diabetes Care

CGM continues to revolutionize diabetes care, but some patients experience barriers to the usage of traditional short-term CGMs. Our multidisciplinary panel of experts and a person living with diabetes will discuss the common issues patients face with traditional CGMs, including disruptions leading to adverse glycemic events, alarm fatigue, compression lows, and many more. They will show how Eversense E3, the only long-term CGM available, helps overcome these challenges and offers patients a truly differentiated CGM experience. You will also learn about the Eversense Roadmap — including the iCGM designation and pending FDA clearance of a CGM system lasting as long as 365 days.

 Moderator: Francine R. Kaufman, MD
Chief Medical Officer of Senseonics, Inc.
Distinguished Professor Emerita of Pediatrics and Communications
Keck School of Medicine
Annenberg School of Communications, University of Southern California
Beverly Hills, CA

 Presenters: David T. Ahn, MD
Chief of Diabetes Services
Mary & Dick Allen Diabetes Center
Hoag Memorial Hospital Presbyterian
Newport Beach, CA

William H. Polonsky, PhD, CDCES
President and Co-Founder of the Behavioral Diabetes Institute
Associate Clinical Professor in Medicine
University of California
San Diego, CA

Chris Ruden
Fort Lauderdale, FL

 Location: Product Theater 3
Diabetes Learning Bytes

Diabetes Learning Bytes are an opportunity for companies to highlight their newest innovations in an informal setting with a 20-minute presentation window.

SATURDAY, JUNE 22, 2024
11:00 a.m.-11:20 a.m.

Omnipod 5: Unusual Suspects for AID
Presented by Insulet

Join Dr. DeSalvo for a bite-sized case review on challenging traditional norms of AID candidacy and practical tips on:
- How Omnipod 5 can facilitate AID use for diverse patient populations
- How to incorporate technology to improve clinical results while simplifying diabetes management for you and simplifying life for your patients

**Presenter:** Daniel DeSalvo, MD  
Assistant Professor Pediatric Endocrinology  
Baylor College of Medicine  
Houston, TX

**Location:** Diabetes Learning Bytes (Booth 430)

2:20 p.m.-2:40 p.m.

Early Incorporation of a Noninvasive, In-Office Treatment for Painful Diabetic Peripheral Neuropathy of the Feet
Presented by Averitas

Averitas Pharma, Inc. invites you to join our session to learn more about the mechanism of action, efficacy and safety data, and a demonstration of a 30-minute in-office procedure for painful diabetic peripheral neuropathy of the feet.

**Presenter:** Gary Graf, APRN  
Topeka, KS, US

**Location:** Diabetes Learning Bytes (Booth 430)
SUNDAY, JUNE 23, 2024
11:00 a.m.-11:20 a.m.

The MiniMed™ 780G System Algorithm Explained
Presented by Medtronic

Learn about the MiniMed™ 780G algorithm and answers to the most frequently asked questions so you can better speak to your patients about the system.

Presenter: Louis Lintereur, MS
Medtronic
Northridge, CA

Location: Diabetes Learning Bytes (Booth 430)
1:30 p.m.-1:50 p.m.

Revolutionizing Diabetic Eye Screening: Introducing the Optomed Aurora AEYE. Empowering Early Detection with AI.

Presented by Optomed USA

The Optomed Aurora AEYE is a groundbreaking handheld fundus camera combined with advanced artificial intelligence (AI) designed to revolutionize diabetic retinopathy (DR) screening. As the first FDA-approved handheld fundus camera with integrated AI, it offers primary care physicians (PCPs) an effective tool for early detection and management of DR, significantly enhancing patient care.

The device's portability and ease of use make it a versatile addition to any primary care setting. Its handheld design allows for convenient retinal imaging without the need for extensive equipment or specialized training. This seamless integration into existing workflows ensures minimal disruption to routine patient visits while expanding the scope of services offered by PCPs.

The AI-powered AEYE-DS system within the Optomed Aurora analyzes retinal images with remarkable accuracy, boasting a sensitivity of 92-93% and specificity of 89-94%. These metrics indicate the device's ability to correctly identify both positive and negative cases of DR, ensuring reliable screening results. This high level of performance matches or exceeds many tabletop models, positioning the Optomed Aurora AEYE as a preferred choice due to its affordability and portability.

Beyond its technical capabilities, the Optomed Aurora AEYE addresses significant barriers in DR screening—affordability and accessibility. Traditional screening methods often require expensive equipment and specialized personnel, limiting their availability in many primary care settings. In contrast, the Optomed Aurora AEYE offers a cost-effective solution that can be easily deployed, making routine DR screening more accessible to a broader patient population.

The device supports comprehensive patient management by providing detailed reports that can be sent to eye care providers for referrals, stored in electronic medical records (EMR), or shared with patients for educational purposes. This promotes a collaborative approach to patient care, ensuring timely follow-ups and interventions.

The Optomed Aurora AEYE is a transformative tool for primary care practices, combining cutting-edge AI technology with practical design to enhance DR screening, improve patient outcomes, and make high-quality eye care more accessible.

**Presenter:** Blake Cooper, MD, MPH
Managing Partner
Retina Associates
Kansas City, MO

**Location:** Diabetes Learning Bytes (Booth 430)